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Abstract 
Chronic wounds represent a major health problem primarily affecting patients with 
underlying pathologies including diabetes and vasculopathy. These wounds are 
characterized by an impaired transition from the inflammatory to the proliferative phase 
of healing. In this thesis, the complex relationship between cells and their 
microenvironment was explored in the context of wound healing by investigating how 
intrinsic differences in fibroblasts affect their response to external stimuli, and how 
extracellular matrix (ECM) proteins modify cellular responses during acute wound repair. 
First, it was hypothesized that different subpopulations of fibroblasts could be identified 
in cutaneous tissue based on divergent embryonic expression patterns of the transcription 
factor Foxd1, and that these subpopulations would play varying roles during wound 
repair. Next, it was hypothesized that wound repair could be modulated in animal models 
by altering components of the ECM. To explore cell-intrinsic differences in the skin, a 
lineage tracing approach was applied to observe a population of cells derived from 
embryonic Foxd1-expressing progenitors during embryonic development and into 
adulthood. These cells contributed to a subpopulation of fibroblasts in adult dorsal skin 
that were enriched with transcripts for matrix modifying genes during homeostasis and 
following wounding relative to fibroblasts not of this origin. Next, Galectin-3, a 
multifunctional matricellular protein with pro-angiogenic, pro-fibrotic, and 
immunomodulatory properties in models outside of skin, was investigated to assess the 
role of this cell-extrinsic factor during cutaneous healing in mice and in human chronic 
wounds. Using a genetic deletion strategy, it was determined that galectin-3 was 
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dispensable during acute repair in mice. Finally, pilot studies were performed to 
investigate an acute wound model in juvenile pigs for assessing foam biomaterials 
derived from the ECM as a strategy to modulate wound healing by targeting the cellular 
microenvironment. While modifying the matrix composition of the biomaterials did not 
alter healing in this model, the findings support that further exploration into relevant 
models of impaired healing is warranted. Overall, the studies in this thesis have helped to 
elucidate complex interactions between cells and their environment during wound repair, 
providing relevant information for the design of future therapeutics for chronic wounds. 
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Chapter 1: Rationale, Literature Review and 
Thesis Overview 
1.1 Rationale, Hypothesis and Objectives 
Full thickness wound repair in skin is a complex and multifaceted process which, at best, 
results in the formation of scar tissue. In more severe cases such as in wounds of patients 
with underlying comorbidities, including vascular disease or diabetes, chronic wounds 
can develop. A major difference between these two disparate outcomes is a transition 
from an inflammatory state into the proliferative phase of healing. Thus, a better 
understanding of the factors that mediate this transition in acute wounds may enable 
novel therapeutic approaches for the treatment of impaired healing. Transition from the 
inflammatory to the proliferative phase of healing is dependent on appropriate cell 
recruitment, differentiation, and function, which are themselves dependent on cell 
intrinsic properties and the properties of their microenvironment.  In the present thesis, 
previous work from the Hamilton and Flynn laboratories was expanded upon to further 
the understanding of these cell intrinsic and extrinsic properties required for healing, with 
a focus on fibroblast activation and differentiation into myofibroblasts, for the purpose of 
guiding the development of future biomaterials. 
This thesis explored the hypothesis that fibroblast activation and differentiation into 
myofibroblasts during an acute healing response rely on cell-intrinsic differences 
stemming from a population’s embryonic lineage, and cell-extrinsic factors present 
within the extracellular matrix (ECM). Specifically, it was first hypothesized that 
2 
 
 
 
embryonic progenitors that express Foxd1 would contribute to myofibroblast progenitors 
within the skin, and that binary expression of Foxd1 could be used to stratify dermal 
fibroblasts to identify unexplored embryonic lineages of myofibroblast progenitors 
present within the adult dorsal dermis (Aim 1). Second, it was hypothesized that 
modifying the ECM by deletion of genes coding for ECM proteins normally expressed 
during wound healing would impair granulation tissue formation, while adding 
exogenous pro-fibrotic and pro-angiogenic ECM components would enhance granulation 
tissue formation and angiogenesis in models of acute cutaneous wound healing (Aims 2 
and 3). 
These were explored through the following three aims: 
1. To assess Foxd1 expression in cutaneous myofibroblast progenitor populations 
during development, and to determine how cells derived from Foxd1-expressing 
progenitors contribute to wound repair. 
2. To identify the expression profile of Galectin-3 in murine skin during homeostasis 
and cutaneous wound healing and investigate the effect of genetic deletion of 
Galectin-3 on cutaneous wound repair. Further, to characterize the expression of 
Galectin-3 in human chronic wound tissue. 
3. To investigate a porcine acute wound healing model for assessing the effects of 
ECM-based foam biomaterials, as well as exploring the potential of the 
biomaterials as platforms for the delivery of exogenous porcine ASCs. 
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1.2 Wound healing 
In healthy adults, wound healing is a multifaceted process that elicits a rapid repair 
response, culminating in a fibrotic scar that lacks both form and function (Eming et al. 
2014; Martin and Nunan 2015). Wound healing is a temporal process that develops 
through a series of overlapping phases characterized by specific cell and molecular events 
within each phase (Singer and Clark 1999; Velnar et al. 2009). Initially, hemostasis 
occurs to limit blood loss and reduce the risk of systemic infection, with blood clotting 
also providing molecular signals that initiate tissue repair (Velnar et al. 2009). The 
inflammatory phase is characterized first by neutrophil infiltration, with a primary role in 
targeting infection through their innate immune function (Martin and Leibovich 2005; 
Velnar et al. 2009). Temporally, macrophages migrate into the wound, debriding 
damaged tissue, phagocytosing neutrophils, and stimulating transition into the 
proliferative phase through the release of growth factors such as transforming growth 
factor-β1 (TGFβ1), platelet derived growth factor (PDGF), and vascular endothelial 
growth factor (VEGF) (Barrientos et al. 2008). During the proliferative phase, fibroblasts, 
which are the primary effectors of tissue repair, migrate into the wound, proliferate, and 
begin producing a temporary matrix called granulation tissue (Martin and Leibovich 
2005; Velnar et al. 2009). Finally, in the remodeling phase, fibroblasts turn over the 
granulation tissue into a type I collagen rich scar (Velnar et al. 2009). Each of these 
phases will be discussed in more detail below. 
Hemostasis is a rapid process, critical to limit blood loss, and at the same time necessary 
to initiate the wound repair response (Martin and Leibovich 2005; Velnar et al. 2009). 
Upon disruption of the endothelial barrier, platelets are exposed to the underlying matrix, 
4 
 
 
 
binding to collagens through α2β1 integrin- and von Willebrand factor (vWF)-mediated 
recognition, inducing their activation (Tomokiyo et al. 2005; Ruggeri 2009). Initially, this 
results in the aggregation of platelets, forming a physical barrier, which is then 
strengthened by a fibrin matrix, formed through the coagulation cascade (Golebiewska 
and Poole 2015). In addition to initiating the coagulation cascade, platelets also release 
factors which inhibit angiogenesis, including angiostatin, and platelets are themselves 
capable of sequestering growth factors including VEGF (Klement et al. 2009; Bodnar 
2015). While this response is imperative to regain homeostasis, platelet activation and 
degranulation further supports activation of circulating neutrophils and monocytes 
through cytokine and growth factor release, inducing their presentation of adhesion 
molecules to promote cellular homing to the site of injury (Bodnar 2015; Golebiewska 
and Poole 2015; Kral et al. 2016). Moreover, many of the factors released by platelets 
have been reported to have direct antimicrobial effects (Tang et al. 2002).  
The inflammatory response is further supported by resident macrophages and dendritic 
cells (Yates et al. 2012). In response to tissue damage and platelet degranulation, 
neutrophils are next to populate the wound bed, followed by the recruitment of 
circulating monocytes, which differentiate into macrophages (Velnar et al. 2009). 
Together, neutrophils and macrophages make up the bulk of the innate immune response 
through their release of inflammatory mediators and bactericidal factors, including 
reactive oxygen species (Yates et al. 2012). Moreover, neutrophils and macrophages are 
important for the debridement of the inflamed tissue through the release of proteases and 
through phagocytosis, removing bacteria and cellular debris from the damaged tissue 
(Singer and Clark 1999; Barrientos et al. 2008; Yates et al. 2012). Finally, neutrophils 
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and macrophages are a major source of growth factors that initiate and regulate 
angiogenesis, as well as fibroblast recruitment and activation, advancing the wound 
beyond the inflammatory phase (Barrientos et al. 2008). Although it is evident that 
neutrophils have a role in pathogen defense and growth factor secretion, it should be 
noted that they are not necessary for an effective wound healing response in wounds 
inflicted using sterile instruments and kept within a clean experimental environment 
(Dovi et al. 2003). In fact, using an excisional wound model in neutrophil depleted-wild 
type and -diabetic mice, Dovi et al. showed an increased rate of wound re-
epithelialization in neutrophil depleted animals compared to controls. Conversely, 
temporal depletion of macrophages using a diphtheria toxin (DT)/ DT receptor (DTR) 
approach, suggested that they play important roles in both the inflammatory and 
proliferative phases of healing, but not in the remodeling phase (Lucas et al. 2010). 
Notably, Lucas et al. showed a decreased rate of closure, associated with decreased 
αSMA and CD31 content within the wounds, following early depletion of macrophages, 
suggesting impaired myofibroblast differentiation and reduced angiogenesis, 
respectively.  
Throughout the healing process, keratinocytes play an active role beyond restoring the 
skin’s barrier function through re-epithlialization. Upon injury, keratinocytes release 
antimicrobial peptides and other members of the alarmin family of proteins (including 
IL1α), which act as damage associated molecular patterns (DAMPs), to further stimulate 
local inflammation through toll like receptor (TLR) signaling (Juráňová et al. 2017). 
Furthermore, activated keratinocytes are a source of matrix metalloproteinases (MMPs), 
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which play critical roles in migration, remodeling and signaling during the wound repair 
process (Caley et al. 2015). 
Following the inflammatory response, the proliferative phase begins, characterized by the 
infiltration of myofibroblasts and neovasculature (Singer and Clark 1999; Velnar et al. 
2009; Reinke and Sorg 2012). Generally, fibroblasts migrate into the wound bed in 
response to chemotactic stimuli including PDGF and basic fibroblast growth factor 
(bFGF) and differentiate into myofibroblasts, primarily in response to TGFβ1 (Hinz 
2007, 2016; Barrientos et al. 2008). Myofibroblasts are a contractile cell type often 
characterized by their incorporation of αSMA into stress fibers, enabling strong force 
generation (Hinz et al. 2001; Hinz 2007). Moreover, this population is the primary 
contributor of ECM during wound repair (Hinz 2016). Wound contraction initiates a 
positive feedback mechanism through which increased matrix stiffness enhances 
myofibroblast differentiation through both mechano-sensing and activation of latent 
TGFβ1 (Hinz 2015). Myofibroblasts are responsible for the production of type I and type 
III collagen, which further increases the stiffness of the ECM. However, the processes 
described in this simplified system are now known to be far more complex, with recent 
observations highlighting differential roles of fibroblast subsets during tissue repair 
(Dulauroy et al. 2012; Driskell et al. 2013; Rinkevich et al. 2015). Several studies have 
described fibroblasts as a heterogeneous population of cells that contribute differentially 
to tissue repair (Driskell and Watt 2015). This topic will be discussed further in section 
1.4.  
In conjunction with the proliferation and differentiation of fibroblasts, endothelial cells 
migrate into the wound in response to the release of pro-angiogenic stimuli, such as 
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VEGF and bFGF, released by keratinocytes, fibroblasts, and inflammatory cells 
(Barrientos et al. 2008). This response results in a rapid and extensive revascularization 
of the wound; however, the resultant vascular network is leaky, unstable, and poorly 
perfused (Bluff et al. 2006; Kim et al. 2009; Bolitho et al. 2010; Wietecha et al. 2013).  
The remodeling phase of wound repair takes place from months to years following the 
initial injury (Velnar et al. 2009). During this phase, fibroblasts reorganize the randomly 
arranged collagen fibrils into parallel bundles, and many of the blood vessels and 
fibroblasts present in the wound undergo apoptosis (Xue and Jackson 2015). While the 
processes that lead to the expansion of endothelial cells and fibroblasts during earlier 
stages have been extensively studied, those which result in a regressive phenotype are 
less well characterized (Wietecha et al. 2013). There are several mechanisms that have 
been proposed to mediate vascular regression in wound healing, including changes in 
ECM composition, decreased pericyte coverage, low shear stress in poorly perfused 
vessels, and reduced availability of pro-angiogenic growth factors concomitant with an 
increase in anti-angiogenic proteins and peptide fragments (Wietecha et al. 2013). 
Similarly, myofibroblasts have been shown to undergo apoptosis following wound 
resolution (Desmoulière et al. 1995). The mechanisms through which this occurs are still 
under investigation, although potential contributing factors include: decreased growth 
factor stimulation, which decreases resistance to apoptosis; decreased mechanical stress 
on cells following ECM regeneration; and increased cell-cell contact (Hinz 2007; Hinz 
and Gabbiani 2010). Interestingly, recent data have highlighted an alternate pathway for 
fibroblast deactivation, in which they differentiate into subcutaneous adipocytes during 
wound resolution (Plikus et al. 2017). 
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In this manner, successful wound repair results in effective recovery of the skin’s barrier 
function; however, the resultant scar does not completely recapitulate native skin (Eming 
et al. 2014; Martin and Nunan 2015). In humans, scar tissue lacks functional elements, 
including hair follicles and sweat glands (Li et al. 2017). Moreover, in a rat model, 
cutaneous scars recovered only about 80% of the tensile strength of unwounded skin 
(Levenson et al. 1965). While not perfect regeneration, formation of normal scar tissue 
has evolved as the mechanism of healing. Alternatively, an impaired healing response 
manifests as a reduction in ECM production, as in chronic wounds, or an excess of ECM 
production, as in hypertrophic and keloid scars (Martin and Nunan 2015). 
1.3 Chronic wounds 
Although the studies within this thesis focused primarily on understanding the 
mechanisms involved during acute wound healing, the long-term goal of this work is to 
apply these findings to chronic wounds to identify novel therapeutic strategies. As such, 
an overview of repair in a chronic wound setting follows, with an emphasis on the 
discrepancies between acute and chronic healing. 
Chronic skin wounds are a complex clinical issue most prevalent in patients with 
underlying comorbidities, including diabetes, vasculopathy, impaired mobility and 
increased age (Demidova-Rice et al. 2012). Although the underlying susceptibility of 
patients to impaired healing might differ, chronic wounds of diverse etiology are 
similarly impaired, and are all characterized by excessive and prolonged inflammation 
(Demidova-Rice et al. 2012; Frykberg and Banks 2015). Despite remaining in an 
inflammatory state, chronic wounds are also characterized by persistent infections 
(Frykberg and Banks 2015). Prolonged inflammation is especially problematic for wound 
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repair due to the release of reactive oxygen species and proteolytic enzymes, which 
contribute to destruction of ECM, growth factors, and signaling molecules, creating a 
non-permissive microenvironment for tissue repair (Barrientos et al. 2008; Moor et al. 
2009; Frykberg and Banks 2015). For example, levels of VEGF mRNA were found to be 
upregulated in human chronic wound tissue compared to uninjured tissue, but correlated 
with low protein content (Lauer et al. 2000). Moreover, in this study, chronic wound 
fluid, but not acute wound fluid, resulted in the proteolytic degradation of VEGF.  
In addition to these extrinsic factors affecting closure, the cells themselves may have 
intrinsic differences that affect how they respond to available growth factors. For 
example, the surface receptor for TGFβ1, TGFβ receptor II (TGFβRII), was found to be 
decreased in fibroblasts isolated from chronic wound tissue, which also displayed 
impaired TGFβ1-induced proliferation in comparison to fibroblasts isolated from 
unwounded tissue from the same patient (Kim et al. 2003). However, our group has 
previously observed no change in proliferative capacity of chronic wound edge 
fibroblasts compared to fibroblasts sourced from non-wounded tissue from the same 
patient (Elliott et al. 2015). Further, chronic wound fibroblasts displayed enhanced 
expression of Acta2 (αSMA) mRNA in response to TGFβ1 relative to those from non-
wounded tissue (Elliott et al. 2015). Thus, there is a possibility that, given a suitable 
environment, resident fibroblasts may be able to respond appropriately through activation 
and matrix deposition to contribute to tissue repair.  
The relationship between cells and their microenvironment has also been investigated in 
chronic wounds (Peppa et al. 2009; Schultz and Wysocki 2009; Widgerow 2011). The 
dynamic reciprocity between cells and the ECM is critical for normal wound repair; 
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however, it is also evident that a modified ECM or altered cell phenotype, as described in 
chronic wounds, can disrupt this relationship (Schultz et al. 2011). As an example, 
impaired TGFβ1 signaling in chronic wounds is evident, alongside high expression of 
MMPs and reduced expression of tissue inhibitors of metalloproteinases (TIMPs). These 
altered signals all result in impaired matrix deposition. Additionally, it is established that 
activation of TGFβ1 from latent TGF binding protein (LTBP-1) requires force generation 
by the cell to the matrix-bound LTBP-1, a process mediated by integrin binding (Hinz 
2015). However, without a sufficiently rigid matrix, such activation is impaired, 
increasing TGFβ1 deficiency, which results in impaired matrix production.  
The pathophysiology of chronic wounds is further exacerbated, particularly in diabetes, 
by accumulation of advanced glycation end-products (AGEs) (Singh et al. 2014; Van 
Putte et al. 2016). AGEs are a heterogeneous group of compounds formed from non-
enzymatic reactions between reducing sugars and free amino groups on proteins, which 
form at a rate limited by the concentration of the reducing sugar (Ahmed and Thornalley 
2007). While diabetic patients can produce higher levels of endogenous AGEs due to 
higher levels of reducing sugars in tissues for prolonged periods of time, humans without 
diabetes are also susceptible to accumulation through diet, with both endogenous and 
exogenous sources accumulating over time (Luevano-Contreras and Chapman-
Novakofski 2010; Singh et al. 2014). Importantly, data from our group has identified high 
levels of AGEs within chronic wounds, compared to uninjured tissue from the same 
patient (Pepe et al. 2014). In addition to roles in cell signaling pathways through AGE-
receptors, AGE formation on proteins inhibits function and the ability to interact 
effectively with other molecules, and may make them more difficult to degrade (Ahmed 
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and Thornalley 2007; Peppa et al. 2009). Importantly, it has been shown in multiple 
studies that AGEs inhibit wound healing. Both ingestion (Zhu et al. 2011) and injection 
(Berlanga et al. 2005) of AGEs have led to altered, diabetes-like wound healing in 
rodents. Furthermore, a study performed by Liao et al. (2009) identified that placing a 
glycated, lyophilized collagen matrix into a pre-existing wound of healthy mice was 
sufficient to cause deleterious effects to the wound healing process similar to that seen 
with diabetes, including impaired rate of healing, reduced cell infiltration, and reduced 
fibroblast contractility (Liao et al. 2009).  
Relative to acute wounds, chronic wounds are associated with a range of deficient 
signaling mechanisms (Demidova-Rice et al. 2012; Frykberg and Banks 2015). This is 
manifest in changes in both intercellular signaling and the interactions between cells and 
their environment (Barrientos et al. 2008; Schultz and Wysocki 2009; Demidova-Rice et 
al. 2012; Frykberg and Banks 2015). Although advances have been made to chronic 
wound therapies, many patients still do not respond to treatment (Santema et al. 2016; 
Norman et al. 2017), suggesting a need for novel therapeutics targeting specific 
pathological features. 
 
1.4 Wound healing from a cell intrinsic perspective 
In acute wounds, the bulk functionality of myofibroblast progenitors, including any cell 
that can differentiate into myofibroblasts, requires proliferation and migration into the 
granulation tissue, and differentiation into contractile myofibroblasts that secrete ECM 
proteins, especially collagens (Hinz 2007). The factors that induce myofibroblast 
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activation are cell extrinsic in nature, including matrix stiffness, signaling molecules such 
as TGFβ1, or ECM components such as matricellular proteins or the ED-A splice variant 
of fibronectin (Serini et al. 1998; Hinz 2007). In contrast to these extrinsic factors, recent 
observations have supported a more nuanced system in which myofibroblast progenitor-
specific intrinsic differences alter how they respond to extrinsic stimuli (Driskell and 
Watt 2015; Hu et al. 2018). Thus, whereas extrinsic factors stimulate myofibroblast 
differentiation, intrinsic factors control the degree to which a myofibroblast progenitor 
responds and the downstream effect of that response. These differences reside within the 
cells themselves and can be tracked using lineage tracing strategies to monitor 
subpopulations that have or are derived from progenitors that had unique gene expression 
patterns. The findings from these studies support a level of role specification based on the 
intrinsic nature of the myofibroblast progenitor and will be the focus of this section. A 
better understanding of the specific roles of fibroblast subsets, and how these subsets 
interact, may be useful in the identification of novel therapeutic targets or strategies for 
the treatment of chronic wounds. 
Lineage tracing technology has been used to identify several distinct myofibroblast 
progenitor populations that play a role in skin repair and fibrosis, including fibroblasts, 
perivascular cells, adipogenic lineages, and bone-marrow derived populations (Dulauroy 
et al. 2012; Driskell et al. 2013; Suga et al. 2014; Marangoni et al. 2015; Rinkevich et al. 
2015). Of particular interest from these findings, fibroblasts, as described through 
positive selection using PDGFRα within dermal isolates, or by negative selection as 
dermal cells lacking epithelial, endothelial and circulating cell markers, have been 
described as having subsets with different functional roles during wound healing 
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(Driskell et al. 2013; Rinkevich et al. 2015). Specifically, the fibrogenic potential, the 
propensity to produce ECM, has been suggested to vary between fibroblast subsets. Thus, 
not only are multiple cell types capable of contributing to the myofibroblast population, 
but there may be further levels of specialization within those cell types. Importantly, 
these intrinsic differences within fibroblast populations have been reported to arise during 
embryonic development (Driskell et al. 2013; Rinkevich et al. 2015; Jiang et al. 2018). 
Therefore, in order to appreciate the heterogeneity in fibroblasts, skin development will 
be discussed, highlighting both when and where dermal fibroblast populations arise. This 
will be followed by a discussion of the current understanding of the contributions of 
diverse myofibroblast progenitor populations to tissue repair in the skin and other organs. 
1.4.1 Skin development 
In mice, gastrulation initiates around embryonic day 5(E5)-E6, and is complete around 
E7.5 (Tam and Behringer 1997). At this time the mesoderm has split into three regions, 
known as the paraxial mesoderm, intermediate mesoderm, and lateral plate mesoderm. 
The paraxial mesoderm divides into somites, creating a segmented body plan in a rostral 
to caudal direction (Gilbert 2000). These somites then undergo differentiation into the 
sclerotome and the dermatomyotome, which itself splits into the dermatomes and 
myotomes. Importantly, the somite-derived dermatomes are the source of dorsal 
fibroblasts, whereas the lateral plate mesoderm gives rise to the dermal cells in both 
lateral and ventral dermis (Gilbert 2000). However, it is noteworthy that the lateral and 
ventral populations are less studied in animal models, in which the investigation of dorsal 
skin and dorsal wound tissue are most common.  
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Within the dorsal region, a recently described myofibroblast precursor population with 
strong fibrogenic potential, defined as being derived from engrailed-1-positive 
progenitors, arises from two parallel tracks ventral to the developing neural tube, and 
migrates dorsally around E10.5 (Jiang et al. 2018). Interestingly, this population began 
migrating from the rostral regions first followed by the caudal regions, fitting with the 
sequence of somite differentiation. These cells were then described to move laterally 
from the medial dorsal skin, replacing the lineage-negative fibroblast population, 
characterized by a lesser fibrogenic potential, by maintaining a clonal advantage (Jiang et 
al. 2018). Currently, it is unknown where the original population of lineage-negative 
fibroblasts arises, whether it is coming from an earlier wave of migration from the 
somites, or another population altogether. Once the fibroblast progenitor cells migrate to 
the dermis, the initial multipotent progenitors undergo further specification (Driskell et 
al. 2013). One distinct population makes up the upper papillary dermis, including the 
papillary fibroblasts, dermal sheath and dermal papilla, as well as the arrector pili 
muscles, whereas another population derives the reticular dermis and both the 
preadipocytes and adipocytes of the subcutaneous adipose tissue (Driskell et al. 2013). To 
appreciate the structures of the skin, histological sections of adult murine, porcine, and 
human skin are shown in Figure 1.1. 
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Figure 1.1: Structures within skin from murine, porcine, and human sources. 
Masson’s trichrome stained sections of adult female mouse dorsal skin (A), juvenile male 
pig dorsal skin (B), and adult female human skin isolated from the lower limb (C). Scale 
bars are 500 µm for mouse skin and 1 mm for porcine and human skin. Cutaneous 
structures are highlighted including an approximation of the divide between the reticular 
dermis and papillary dermis. All species explored in this thesis possess the epidermis, 
papillary dermis, reticular dermis, and subcutaneous adipose tissue; however, only 
murine skin contains the panniculus carnosus muscle. 
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One notable change that occurs during development in mammals is a switch from nearly 
perfect dermal regeneration following wounding at early fetal stages, to scar formation at 
later stages; in mice, this switch occurs around E17.5 (Walmsley et al. 2015). 
Interestingly, this timeframe corresponds to a rapid increase in the cellular frequency of 
the more fibrogenic engrailed-1 lineage of fibroblasts within the skin (Jiang et al. 2018), 
as well as a fate restriction between the cells of the upper papillary dermis and lower 
reticular dermis (Driskell et al. 2013). Additionally, it was recently reported that during 
this time, dermal fibroblasts undergo a critical change, switching from a proliferative 
phenotype to a synthetic phenotype (Rognoni et al. 2018). Prior to this proliferative 
switch, changes in tissue volume correlate with cell number, suggesting proliferation is 
primarily responsible for increased tissue mass. However, following this switch, ECM 
production becomes the major process, and proliferation is halted (Rognoni et al. 2018). 
It is noteworthy that these changes were described throughout the tissue, and not only in 
specific fibroblast subsets, suggesting independence of cell lineage. The ECM itself also 
undergoes a critical change during development in which an initially loose fibronectin-
rich matrix changes to one rich in collagen I, providing greater tension (Jiang et al. 2018). 
From these important studies it is evident that the skin undergoes a remarkable shift 
during development that is related to changes in both cell intrinsic and cell extrinsic 
factors.  
 
1.4.2 Origins of myofibroblasts in tissue repair 
Myofibroblasts, characterized by their expression of αSMA, are the main source of ECM 
production following tissue injury (Hinz 2007). Numerous cell types can differentiate 
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into myofibroblasts in various fibrotic events, including wound healing (Hinz 2016). 
There has been a recent push towards identifying these precursor populations, 
predominantly using two different strategies for lineage tracing. First, bone marrow 
chimera models utilize a transplantation method in which genetically tagged 
hematopoietic stem cells from one animal are implanted into a non-genetically-tagged 
recipient that has undergone non-lethal irradiation to deplete endogenous hematopoietic 
lineages (Kretzschmar and Watt 2012; Hsu 2015). In this way, tagged cells will 
reconstitute the hematopoietic cell niche, and any hematopoietic populations to which 
those cells contribute will also be genetically tagged. The second method that has been 
widely used to track both hematopoietic and non-hematopoietic lineages is Cre/Lox 
based lineage tracing adapted from bacteriophage P1 (Kretzschmar and Watt 2012). This 
system is highly versatile, but for many applications a cell-type specific promoter is used 
to control the expression of Cre-recombinase, while a reporter sequence under control of 
a ubiquitous promoter is blocked by a transcriptional stop sequence that can be excised 
by recombinase activity (Kretzschmar and Watt 2012). In this way, the reporter sequence 
(fluorescent or enzymatic) is only expressed in cells that express Cre-recombinase, as 
well as the progeny of those cells. Utilizing these methods, several myofibroblast 
progenitor populations have been explored within the skin and other organs during 
fibrotic repair and will be discussed below. Identification of these key progenitor 
populations could have important implications for therapeutic strategies. For human 
chronic wounds, where matrix deposition is reduced, these findings could help to identify 
pro-fibrotic pathways for therapeutic activation or could identify specific surface markers 
to allow sourcing of pro-fibrotic cells from other sites for delivery into affected tissues. 
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1.4.3 Sources of myofibroblasts in wound repair and fibrosis 
Due to the potential therapeutic benefits of identifying pro-fibrotic populations within the 
skin and other organs, several studies have employed lineage tracing strategies to 
investigate myofibroblast precursor populations. Within the dermis, it has long been 
assumed that resident fibroblasts in the neighboring tissue are the major source of 
myofibroblasts during dermal wound healing (Singer and Clark 1999). As an organ that is 
prone to injury from external sources, and one which maintains a large reservoir of 
potential myofibroblast progenitors, this seems intuitive; however, strong evidence for 
resident stromal cells as the major myofibroblast progenitor population has only been 
described more recently (Driskell et al. 2013; Marangoni et al. 2015; Rinkevich et al. 
2015). Driskell et al. (2013) first documented different lineages of fibroblast populations 
in the dorsal dermis, which arise during development. During wound repair they showed 
that the lower lineage, consisting of fibroblasts in the reticular dermis and adipocyte 
precursors within the hypodermis, were the major contributors to granulation tissue 
synthesis. In contrast, the upper lineage of fibroblasts within the papillary dermis were 
recruited later, contributing only to the newly forming papillary dermis and required for 
regrowth of hair follicles (Driskell et al. 2013).  
The idea that adipocyte precursors are sources of myofibroblasts was further supported 
by Marangoni et al. (2015) who made the observation that in human patients with skin 
fibrosis, and in animal models of induced skin fibrosis, the amount of adipose tissue in 
the hypodermis is decreased. To expand upon this initial observation, they demonstrated 
through lineage tracing that adiponectin-positive adipocytes differentiated into 
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myofibroblasts following bleomycin induced skin fibrosis in mice. More recently, Plikus 
et al. (2017), strengthened the relationship between adipocytes and myofibroblasts, 
showing that following wound repair, some of the myofibroblasts will differentiate into 
adipocytes (Plikus et al. 2017). A similar pattern of differentiation can also be seen 
during lung fibrosis in which lipogenic fibroblasts differentiate into myofibroblasts 
following a fibrogenic insult, and then dedifferentiate back into lipogenic fibroblasts 
during resolution (El Agha et al. 2017). Taken together, these findings suggest that there 
might be homology in the myofibroblast precursors of diverse tissues.  
In another study, Rinkevich et al. (2015) used lineage tracing of engrailed-1, a protein 
expressed solely during development in a specific subset of dermal fibroblast precursors 
(Rinkevich et al. 2015). Engrailed-1 lineage-derived fibroblasts begin to appear in the 
papillary dermis around embryonic day 12.5 (E12.5) and constitute only ~1% of the total 
fibroblast population. After this time, this population of cells expands into the reticular 
dermis, contributing to ~75% of dermal fibroblasts in adult mice. These cells are shown 
to be responsible for most of the ECM deposition during wound healing. Ablation of 
these cells resulted in an increase in the time required for healing, concomitant with a 
reduction in the amount of collagen deposition. These results would be expected given 
the high percentage of dermal fibroblasts that are derived from the engrailed-1 lineage. 
As such, it is logical that matrix deposition and the rate of closure would be impaired 
when this population is ablated or inhibited. However, surprisingly, the overall tensile 
strength of healed wounds was similar for both control wounds and wounds in which the 
engrailed-1 lineage was ablated (Rinkevich et al. 2015). Expanding on these findings, 
evidence was provided to show that the engrailed-1 lineage fibroblasts were enriched for 
21 
 
 
 
CD26, a serine exopeptidase. Importantly, when wounds were treated with a small 
molecule inhibitor for CD26, scarring was reduced. Thus, using a relatively broad lineage 
tracing method, the authors identified a specific targetable and functionally relevant 
marker of myofibroblast progenitors within the skin.  
Another population identified to have fibrogenic potential is perivascular cells. Dulauroy 
et al. (2012) showed that a population of perivascular cells within mouse ear dermis 
upregulated a disintegrin and metalloproteinase 12 (ADAM12) following chemically 
induced fibrosis (Dulauroy et al. 2012).  Tracking of ADAM12 lineage-positive 
populations showed that through proliferation and differentiation into myofibroblasts, 
these cells were responsible for excessive matrix production, which could be decreased 
through their ablation (Dulauroy et al. 2012). It should be noted, however, that the stroma 
of the head and neck is derived from both the neural crest as well as the mesoderm 
(Santagati and Rijli 2003; Bhattacherjee et al. 2007). As such, the progenitor populations 
giving rise to myofibroblasts within the ear may not be the same as those within the 
dermis of more caudal regions, including the dorsum, where the stroma is derived 
primarily from the mesoderm (Ben-Yair 2003). 
It has been shown that pericytes contribute to fibrotic repair in areas beyond those 
derived from the neural crest, including the tibialis anterior muscle (Dulauroy et al. 
2012), kidney (Humphreys et al. 2010; Kramann et al. 2015), lung (Hung et al. 2013; 
Kramann et al. 2015), bone marrow (Schneider et al. 2017), heart (Kramann et al. 2015), 
and liver  (Mederacke et al. 2013; Kramann et al. 2015). In contrast to these studies, other 
groups have provided evidence that pericytes are not a source of myofibroblasts. In a 
murine renal fibrosis model, LeBleu et al. (2013) used lineage tracing of the commonly 
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accepted pericyte markers PDGFRβ and NG2 (LeBleu et al. 2013). Following injury, 
these cells expanded but contributed to only a small fraction of αSMA positive 
myofibroblasts. Moreover, ablation of proliferating PDGFRβ+ or NG2+ cells using a 
thymidine kinase/ ganciclovir strategy, did not alter matrix deposition following 
unilateral ureteral obstruction induced kidney fibrosis (LeBleu et al. 2013). In another 
study, a lineage tracing strategy using expression of the T-box 18 (Tbx18) transcription 
factor to label smooth muscle cells and pericytes throughout the mouse provided strong 
evidence that these cell types are not progenitors of myofibroblasts during muscle or 
cardiac fibrosis (Guimarães-Camboa et al. 2017).  
The differences in these findings could potentially stem from the inherent heterogeneity 
in the perivascular cell population (Bodnar et al. 2016; Dias Moura Prazeres et al. 2017). 
Genetic lineage tracing strategies rely on differentiation via binary expression of single 
genes. However, finding a target that uniquely defines the entire population of interest 
during both homeostasis and following injury, may not be possible for many 
subpopulations. This may be true for pericytes, which originate from diverse embryonic 
precursor populations including the neural crest, mesoderm, and mesothelium (Dias 
Moura Prazeres et al. 2017). Additionally, a recent study identified that about one-quarter 
of pericytes within the rostral dorsal skin arise from a hematopoietic lineage, as defined 
by expression of the Vav-1 promoter (Yamazaki et al. 2017). 
Another potential source of myofibroblasts that has been investigated is the circulating 
fibrocyte, a bone marrow derived cell that homes to injured tissues to aid in repair. 
However, the contribution of these cells to the myofibroblast population is often debated. 
Using both bone marrow chimera and parabiosis models, groups have shown that 
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circulating cells do not give rise to collagen-producing cells in injured skin (Higashiyama 
et al. 2011; Dulauroy et al. 2012; Rinkevich et al. 2015).  However, using the same 
models, others have shown that circulating populations may give rise to a small subset of 
α-SMA negative, collagen-expressing circulating cells, which the authors attribute to 
collagen-producing macrophages based on morphology, co-labelling with Mac-3, and 
their temporal association with the inflammatory infiltrate (Barisic-Dujmovic et al. 2010). 
More recently, Suga et al. (2014) showed through lineage tracing that a population of 
hematopoietic-derived cells (based on expression of the Vav-1 promoter) contributed to 
the collagen and αSMA expressing myofibroblast population in a murine wound model 
(Suga et al. 2014). Although these cells represented approximately 10% of the cells 
within healthy dorsal dermis, following injury, these cells made up approximately 30% of 
cells within the granulation tissue, peaking in number at day 7 post wounding (Suga et al. 
2014). Importantly, at this time point, 43% of these labelled cells expressed collagen I 
mRNA, and many also expressed αSMA, with the authors suggesting that these were 
hematopoietic-derived fibrocytes and that they contributed to the myofibroblast 
population. Tracking of vav-1 lineage cells over time indicated that they decreased after 
day 7 post wounding, down to basal levels by day 28 (Suga et al. 2014). Alternatively, it 
is possible that the Vav-1 lineage gives rise to mesenchymal populations during 
development, and it is these populations from which the myofibroblasts are derived upon 
wounding, not the circulating cells. This interpretation is supported by the findings of 
Yamazaki et al. (2017), who showed that Vav-1 derived populations could contribute to 
pericytes within the rostral dorsal dermis during embryonic development. Due to the 
different locations studied by Yamazaki et al. and Suga et al. (rostral dorsal dermis vs. 
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dorsal dermis, respectively) this alternative interpretation may not be accurate, yet it 
warrants further investigation. In combination, the evidence for the contribution of 
circulating cells is not strong, while several studies have provided evidence supporting 
the null hypothesis. 
Overall, these studies suggest that resident cells are likely the major contributors of 
collagen producing cells within the wound healing response. Whether the populations 
that have been tracked to date overlap with each other, or whether they can be further 
divided into more specific populations is not currently known. While marker expression 
has, in the past, been used to stratify subpopulations of fibroblasts (Phipps et al. 1989), 
these more recent lineage tracing studies highlight that some of the heterogeneity 
exhibited by adult fibroblast populations arises from disparate embryonic lineages. The 
extent of fibroblast heterogeneity has recently been assessed in human dermal fibroblasts 
using single cell PCR (Philippeos et al. 2018; Tabib et al. 2018). However, whether the 
diversity characterized by single cell RNA-Sequencing studies results from different cell 
lineages, from different temporary states within a cell lineage, or combinations of these, 
is unknown. These findings support the need for additional lineage tracing models to 
identify different subsets of these fibroblast populations, which may help to identify 
distinct roles of varying subpopulations during tissue repair. Such findings would have 
important implications for therapies in the context of both impaired healing and fibrosis. 
 
1.4.4 Foxd1 as a marker for myofibroblast progenitors 
Foxd1 is a transcription factor of the forkhead box family (Quintero-Ronderos and 
Laissue 2018). The protein itself is coded by a single exon, and shares a high level of 
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homology within the DNA binding domain between mice and humans (Quintero-
Ronderos and Laissue 2018). During development, Foxd1 expression has been shown to 
be critical for development of the retina, optic chiasm, and kidney (Quintero-Ronderos 
and Laissue 2018). Within the kidneys, Foxd1 was found to be expressed exclusively by 
the stromal populations, and not within the epithelium (Hatini et al. 1996). Global Foxd1 
knockout resulted in reduced kidney volume, fewer developed nephrons, and lethality 
shortly after birth (Hatini et al. 1996; Levinson 2005).  
A recent study by Fetting et al. (2014) identified Foxd1 as an important regulator of 
several ECM proteins including decorin and collagen IV (Fetting et al. 2014). 
Importantly, decorin has been shown to be a potent inhibitor of receptor tyrosine kinases 
(RTKs) and the TGFβ superfamily pathways (Neill et al. 2012, 2015). In fact, during 
development, genetic deletion of Foxd1 led to increased decorin expression resulting in 
impaired BMP7 signaling via the inhibition of SMAD signal transduction by decorin 
(Fetting et al. 2014). The authors showed that this results in an inability of stromal 
progenitor cells to differentiate, impairing proper kidney development. Thus, Foxd1 
expression is required for stromal progenitor populations to exhibit appropriate 
differentiation.  
In addition to its critical roles during kidney development, cells derived from Foxd1-
expressing progenitors have been shown to be myofibroblast precursors following tissue 
injury. Using a Foxd1-Cre knock-in mouse crossed with a Rosa26-loxp-stop-loxp(lsl)-
lacZ reporter mouse, Humphreys et al. (2010) were able to provide strong evidence for a 
mesenchymal source of myofibroblasts during kidney fibrosis (Humphreys et al. 2010). 
Along with lineage tracing data showing that no renal epithelial cells contributed to the 
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myofibroblast population, this study provided strong evidence to refute the hypothesis 
that epithelial to mesenchymal transition (EMT) is a source of myofibroblasts in this 
process. Moreover, this group used this same model to support a resident mesenchymal 
contribution to myofibroblasts in bleomycin induced lung fibrosis (Hung et al. 2013).  
As Fetting et al. (2014) describe, Foxd1 expression is required to allow progenitor cells 
to differentiate during kidney development (Fetting et al. 2014). Similar to the kidney, 
TGFβ signaling is also critical for the development of skin (Owens et al. 2008),  and the 
stromal cells in both kidney and dorsal dermis are derived from the paraxial mesoderm 
during embryogenesis (Fomenou et al. 2005; Guillaume et al. 2009). Thus, there is a 
possibility that the progenitor cells that differentiate into the stromal populations in both 
the dorsal skin and the kidney follow a similar pattern of differentiation. However, 
whether this common pattern of differentiation includes transcriptional regulation by 
Foxd1 is unknown. Moreover, if a Foxd1-positive progenitor derived population exists 
within the skin, it is unknown whether it would have similar profibrotic potential as the 
Foxd1 lineage derived populations in the renal (Humphreys et al. 2010) and pulmonary 
(Hung et al. 2013) systems. 
 
1.5 Matricellular proteins in wound repair 
The cellular component of tissue exists within an extracellular framework, which together 
determine cell function. Importantly, changes to cell function result in changes to the 
ECM, which further modifies cell function, a process termed dynamic reciprocity 
(Thorne et al. 2015). This process is exemplified by the expression of matricellular 
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proteins, and their receptors, generally integrins, on the cell surface (Schultz et al. 2011). 
First defined by Bornstein (1995), matricellular proteins are a group of modular proteins 
that localize to the ECM, but do not necessarily provide structural support (Bornstein 
1995). Instead, matricellular proteins interact with the ECM and cell surface receptors 
and have varied effects, which depend on the condition of the ECM, modifications made 
to the matricellular protein itself, and on the expression of receptors present on the cell 
membrane. In this way, matricellular proteins provide a direct link to transfer information 
on the state of the ECM to the cell. The rapid turnover and change in ECM composition 
during wound repair also involves changes in matricellular protein content, making it an 
important model to study their effects. Furthermore, as many of these proteins regulate 
processes in the inflammatory and proliferative phases of healing, modifying their 
activity may be a therapeutic strategy for impaired wound healing. In Table 1.1 below, 
the wound healing specific phenotypes observed following genetic manipulation of 
specific matricellular proteins are described, with their temporal expression patterns 
shown in Figure 1.2. The matricellular proteins focused on in this thesis, Galectin-3, 
Periostin, and CCN2, will be discussed in more detail below.  
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Table 1.1 Wound healing specific phenotypes following genetic manipulation of 
matricellular proteins. From Walker et al. Cell–matrix interactions governing skin 
repair: matricellular proteins as diverse modulators of cell function. Res Reports Biochem 
2015;5:1–16 
Matricellular 
Protein 
Influence on excisional skin healing References 
CCN2 Fibroblast-specific deletion of CCN2 does not 
affect cutaneous wound healing of 4 mm wounds 
evident by no difference in collagen content, 
myofibroblast differentiation, and proliferation in 
CCN2-null and wild-type mice.  
(Liu et al. 2014) 
Galectin-7 Galectin-7–deficient mice displayed a reduced 
re-epithelialization potential compared with wild-
type littermates during wound healing of 
superficial scratch along the length of the tail and 
this effect was attributed to a defect in cell 
migration. 
(Gendronneau et 
al. 2008) 
Hevin Closure and maturity of cutaneous excisional 5 
mm wounds were accelerated in hevin-null 
compared to wild-type mice.  
(Sullivan et al. 
2008) 
Osteopontin Osteopontin mutant mice resulted in 
disorganization of matrix and an alteration of 
collagen fibrillogenesis leading to smaller 
diameter collagen fibrils after incisional wound 
healing. 
(Liaw et al. 
1998) 
Periostin Excisional wound (3 mm) closure was delayed in 
Periostin-null mice coupled with a delay in re-
epithelialization and reduced proliferation of 
keratinocytes. 
 
During excisional wound (6 mm) healing, 
Periostin-null mice had reduced level of 
myofibroblast differentiation compared to wild-
type mice. The attenuated myofibroblast 
differentiation in Periostin-null mice was rescued 
by addition of recombinant Periostin containing 
scaffolds. 
 
Incisional wounding re-established embryonic 
pattern of Periostin deposition in adult skin. 
 
 
(Nishiyama et al. 
2011) 
 
 
 
(Elliott et al. 
2012) 
 
 
 
 
(Zhou et al. 
2010) 
29 
 
 
 
SPARC A significant delay in wound closure in 25 mm 
wounds in SPARC-null mice compared to wild 
type mice. A significant reduction in granulation 
tissue formation and ECM protein production in 
6 mm wounds in SPARC-null mice compared to 
wild-type mice.  
 
A significant increase in the rate of wound 
closure in SPARC-null compared to wild-type 
mice at 4 and 7 days post-wounding in 5 mm 
excisional wounds. 
(Basu et al. 
2001) 
 
 
 
 
 
(Bradshaw et al. 
2002) 
Tenascin-C Healing of 6 mm excisional wounds was not 
significantly altered in tenascin-C deficient mice 
compared to wild-type mice.  
 
(Forsberg et al. 
1996) 
Tenascin-X 
(TNX) 
No differences between TNX-null and wild-type 
mice were noted in the rate of wound closure, or 
in expression of fibrillar collagen during 
excisional wound healing (8 mm). 
(Egging et al. 
2007) 
Thrombospondin-
1 (TSP1) 
Delayed wound closure (by 6 days) and impaired 
granulation tissue in transgenic mice 
overexpressing TSP1 in the skin compared to 
wild-type when 6 mm excisional wounds were 
created. 
 
TSP1-null and TSP1/TSP2-null mice 
demonstrated reduced vascularization and 
impaired inflammatory phase compared to wild-
type mice while TSP2 null mice were similar to 
wild-type mice. 
(Streit et al. 
2000) 
 
 
 
 
(Agah et al. 
2002) 
Thrombospondin-
2 
(TSP2) 
At 14 days post-wounding, the vascular density 
in wild-type, TSP1-null and TSP1/TSP2 double-
null mice was the same, but TSP2-null wounds 
remained highly vascularized. 
 
At 14 days post-wounding 6 mm excisional 
wounds, TSP2-null mice showed greater 
neovascularization and MMP-2 compared to 
wild-type mice.  
 
The levels of MMP-2, MMP-9, TIMP-1, TIMP-
2, and soluble VEGF were increased in 6 mm 
excisional wounds in TSP2-null mice compared 
to wild-type mice. 
(Bornstein et al. 
2004) 
 
 
 
(Agah et al. 
2004) 
 
 
 
(MacLauchlan et 
al. 2009) 
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Figure 1.2 Temporal expression of matricellular proteins during dermal wound 
repair. From Walker et al. Cell–matrix interactions governing skin repair: matricellular 
proteins as diverse modulators of cell function. Res Reports Biochem 2015;5:1–16. 
 
1.5.1 Galectin-3 
Like all galectins, Galectin-3 contains a C-terminus carbohydrate recognition domain 
(CRD) that recognizes β-galactosides (Larsen et al. 2011); however, Galectin-3 is unique 
from the other proteins in the family in that it has an N-terminus glycine/proline rich 
tandem repeat region with similarity to collagen (Ahmad et al. 2004). The glycine/proline 
rich N-terminus was described to enable the protein to form a unique homo-pentamer 
(Ahmad et al. 2004), but can be cleaved from the carbohydrate recognition domain by 
MMP-9, which, interestingly, also increases the affinity of the carbohydrate recognition 
domain for glycans (Ochieng et al. 1998).  
Galectin-3 was shown to localize in the nucleus, cytoplasm, and the ECM. It contains a 
nuclear localization signal (Nakahara et al. 2006), however it lacks a signal for 
extracellular transport and is suspected to traverse the plasma membrane through a novel 
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mechanism (Larsen et al. 2011). Notably, it was observed to be differentially expressed 
over the course of acute wound healing in rats (Gál et al. 2011). Within the wound, 
Galectin-3 was highly expressed during the inflammatory phase but decreased into the 
proliferative phase of healing. Similarly, in the epidermis, Galectin-3 was expressed at 
high levels normally and during the initial inflammation phase, but decreased 
subsequently (Gál et al. 2011).  
Galectin-3 has been observed to play important roles in the innate immune system. 
Although Galectin-3 is not a chemoattractant for neutrophils, in models of lung and skin 
infection Galectin-3 was observed to contribute to neutrophil accumulation at the sites of 
infection (Nieminen et al. 2008; Bhaumik et al. 2013). One described mechanism for this 
is through Galectin-3-mediated cell adhesion between neutrophils and endothelial cells at 
the site of injury to promote extravasation at sites of inflammation (Sato et al. 2002). 
Furthermore, upon resolution of inflammatory processes, Galectin-3 has been described 
to participate in neutrophil clearance by mediating phagocytosis of apoptotic neutrophils 
by macrophages (Karlsson et al. 2009). Galectin-3 has also been linked to macrophage 
polarization into a pro-regenerative M2 phenotype (MacKinnon et al. 2008). Bone 
marrow derived macrophages from Galectin-3 knockout and wild-type mice showed 
similar release of pro-inflammatory cytokines in vitro, but Galectin-3 knockout animals 
displayed impaired differentiation into an M2 phenotype in response to interleukin-4 
(IL4) and IL-13 stimulation (MacKinnon et al. 2008). 
Galectin-3 has also been implicated in different roles in fibrosis, a process which, like 
cutaneous wounding, initiates with inflammation, but yields extensive matrix production, 
impairing organ function (Wynn and Ramalingam 2012). Genetic deletion of Galectin-3 
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has been explored in models of hepatic (Henderson et al. 2006; Jiang et al. 2012), renal 
(Henderson et al. 2008; Okamura et al. 2011), and pulmonary (MacKinnon et al. 2012) 
fibrosis. Importantly, in each of these studies, deletion of Galectin-3 impaired 
myofibroblast differentiation. Whether a similar result would be observed during 
cutaneous wound healing has not been previously explored. 
Galectin-3 is important for the re-epithelialization of both corneal (Cao et al. 2002) and 
skin wounds (Liu et al. 2012) in mice. During corneal wound healing, Galectin-3 was 
highly expressed at the leading edge of the migrating epithelium, and knockout mice 
were slower to re-epithelialize (Cao et al. 2002). This deficiency was shown to be 
independent of epithelial cell proliferation, leading the authors to suggest that there was a 
migratory defect. This migratory defect was replicated in Galectin-3 knockout 
keratinocytes both in vitro and in vivo in a skin wound healing model (Liu et al. 2012). In 
this system, intracellular Galectin-3 was found to regulate trafficking of epidermal 
growth factor receptor (EGFR), enabling endocytosed receptor to be recycled back to the 
plasma membrane after stimulation and preventing its degradation within the lysosome. 
This process led to enhanced EGFR presentation at the cell surface and was linked to 
increased signal transduction through phosphorylated extracellular signal-regulated 
kinase 1 (pERK) compared to Galectin-3 knockout keratinocytes (Liu et al. 2012). 
Finally, Galectin-3 has been described as an inducer of angiogenesis (Nangia-Makker et 
al. 2000, 2010, Markowska et al. 2010, 2011). Galectin-3 was determined to mediate both 
bFGF- and VEGF-induced angiogenesis in vitro and in vivo (Markowska et al. 2010). 
Chromatography using HUVEC lysates run through Galectin-3 coated columns, followed 
by matrix-assisted laser desorption ionization time of flight mass spectrometry identified 
33 
 
 
 
both αv and β3 integrin subunits as major binding partners of Galectin-3. Interestingly, 
both of these integrin subunits are known mediators of VEGF- and bFGF-induced 
angiogenesis (Brooks et al. 1994; Liu 2003). Galectin-3 was further found to induce 
clustering of αvβ3 integrins in HUVECs through a mechanism that could be inhibited 
either by adding lactose (a ligand of the CRD of Galectin-3), but not sucrose, or by 
cleaving the glycine/proline rich N-terminus domain of Galectin-3 (Markowska et al. 
2010).  
These data suggest that Galectin-3 binds to integrin subunits αV and β3 through its CRD, 
and tethers multiple integrins together through formation of homo-pentamers via its N-
terminal domain. Moreover, it was determined that knockdown of α-1,6-
mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (Mgat5), a protein 
involved in the synthesis of N-acetyllactosamine glycans (recognition sites of the CRD of 
Galectin-3), blocked Galectin-3 induced clustering of these integrins, suggesting that the 
appropriate glycan signal on αvβ3 integrins must be present for this interaction. 
Importantly, the downstream effect of αvβ3 integrin clustering was focal adhesion kinase 
(FAK) activation, which is an important downstream mediator of integrin-induced 
angiogenic signaling (Zhao and Guan 2011). Further supporting its role in angiogenesis, 
Galectin-3 was found to bind VEGFR-2 through a similar mechanism, reducing receptor 
internalization after stimulation by VEGF-A and effectively increasing surface 
expression of this important mediator of angiogenic signaling (Markowska et al. 2011). 
From the studies highlighted above, it is evident that Galectin-3 may function in a wound 
healing response beyond what has been described in re-epithelialization (Liu et al. 2012), 
which was investigated in this thesis. 
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1.5.2 Periostin 
Periostin is a matricellular protein comprised of several modular domains including an 
EMI domain with homology to the EMILIN protein family, four Fas-1 domains with 
homology to drosophila fascilin-1, and a C-terminal domain with binding sites for 
heparan sulfate proteoglycans (Kii and Ito 2017). Both the EMI and Fas-1 domains have 
been identified to interact with a range of different extracellular proteins including 
collagens, fibronectin, other matricellular proteins, integrins, and secreted enzymes 
including lysyl oxidase (LOX) (Kudo 2011; Kii and Ito 2017). The C-terminal domain 
can be alternatively spliced, potentially modifying how Periostin interacts with heparan 
sulfate proteoglycans in the ECM and on cell surfaces, although this requires further 
investigation (Hoersch and Andrade-Navarro 2010; Kii and Ito 2017). 
During skin development in mice, Periostin was most highly expressed in subcutaneous 
tissue and the dermal-epidermal junction at E13.5, with lesser expression noted 
throughout the developing dermis (Zhou et al. 2010). This pattern of expression remained 
relatively consistent within neonatal mice, but expression began to appear surrounding 
hair follicles as these structures began to develop. In healthy adult skin, Periostin 
expression was noted primarily surrounding hair follicles. Conversely, upon wounding, 
Periostin expression within the neighboring skin more closely mimicked the patterns 
during development, where it was expressed throughout the dermis and within the 
dermal-epidermal junction (Zhou et al. 2010). Within the granulation tissue, Periostin 
protein was first detected at 3 days post wounding, peaking at 7 days post wounding 
(Jackson-Boeters et al. 2009), corresponding with the peak Periostin transcript level 
(Elliott et al. 2012).  In contrast to acute wounding in mice, investigation into Periostin 
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transcript levels in human chronic wound tissue suggested that it was significantly 
downregulated within the wound tissue compared to unwounded tissue from the same 
patient (Elliott et al. 2015). 
Genetic deletion of Periostin in mouse models resulted in impaired wound closure 
manifested during the proliferative phase of healing (Nishiyama et al. 2011; Elliott et al. 
2012). As one possible mechanism for this impairment, Nishiyama et al. (2011) 
highlighted impaired keratinocyte proliferation resulting in delayed re-epithelialization. 
Further, Elliott et al. (2012) identified a role of Periostin in wound contraction, 
compounding the effects of delayed re-epithelialization on wound closure. Whereas wild-
type mice displayed a strong induction of αSMA at the mRNA and protein levels by 7 
days post wounding, this response was impaired in Periostin knockout mice (Elliott et al. 
2012). Using culture models, it was determined that dermal fibroblasts isolated from 
knockout animals displayed impaired myofibroblast differentiation on soft surfaces 
(Elliott et al. 2012). In this model, exogenous Periostin was sufficient to recover a wild-
type phenotype. Importantly, this recovery could be blocked by inhibition of FAK 
activation or through the delivery of antibodies to block β1 integrin, suggesting that 
Periostin signals through β1 integrins to promote FAK activation in order to promote 
myofibroblast differentiation (Elliott et al. 2012). Further, it was determined that the 
addition of exogenous Periostin to knockout animals following wounding was sufficient 
to recover a normal healing response (Ontsuka et al. 2012; Elliott et al. 2012).  
Based on the findings from Periostin knockout mice and the evidence of low Periostin 
transcript levels in human chronic wound tissue, exogenous Periostin was explored 
previously by the Hamilton lab as a potential therapeutic for impaired healing (Elliott et 
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al. 2018). To investigate its therapeutic potential, exogenous Periostin was delivered into 
wounds in a type II diabetic mouse model (db/db) which displays impaired wound 
healing (Elliott et al. 2018). Critically, the rate of wound healing in this model was 
significantly enhanced following delivery of Periostin compared to control wounds and 
was similar to the rate of healing observed in wild-type mice. These findings supported 
the therapeutic potential of exogenous Periostin for impaired wound healing. 
 
1.5.3 CCN2 
CCN2, originally named connective tissue growth factor (CTGF), is one of six members 
of the CCN protein family, also including CCN1 (Cyr61), CCN3 (Nov), CCN4 (Wisp1), 
CCN5 (Wisp2), and CCN6 (Wisp3) (Brigstock et al. 2003; Perbal 2013). These proteins 
are characterized by a common set of four modular domains, including an insulin-like 
growth factor binding protein domain, a von Willibrand factor type-C repeat, a 
thrombospondin type-1 repeat, and a C-terminal cystine knot motif, with the exception of 
CCN5, which lacks the cystine knot motif (Holbourn et al. 2008). These modular 
domains allow these proteins to interact with a range of different ECM and cell 
membrane proteins including collagens, fibronectin, integrins, and TGFβ family 
members. The versatility of CCN proteins is enhanced by protein cleavage, which can 
further modify their interactions (Holbourn et al. 2008). The overarching model for CCN 
proteins is one in which they alter signaling by controlling spatial relationships between 
ligands and their receptors, and create domains integrating multiple receptors to co-
ordinate cellular responses (Perbal 2013). 
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During development, CCN2 was most highly expressed within the vasculature and in 
developing bone and cartilaginous tissues of mice (Friedrichsen et al. 2003). Following 
genetic ablation of CCN2, mouse embryos displayed severe skeletal defects leading to 
perinatal lethality (Ivkovic 2003). However, knockout animals did not display altered 
skin development, as assessed through blood vessel density, skin thickness, and matrix 
deposition (Liu and Leask 2011).  
In rodent skin, CCN2 was expressed at low levels under homeostatic conditions, 
however, upon wounding or induction of fibrosis, CCN2 expression was greatly 
upregulated (Igarashi et al. 1993; Kapoor et al. 2008; Liu et al. 2010). CCN2 has been 
described to have an integral role in the development of bleomycin-induced skin fibrosis 
in mice (Liu et al. 2011). Using tamoxifen inducible Cre under the control of a Col1a2 
promoter sequence, Liu et al. targeted genetic deletion of CCN2 in collagen producing 
fibroblasts. Following deletion, myofibroblast activation via treatment with bleomycin 
was ameliorated and the level of fibrosis was reduced as measured by dermal thickness 
and matrix deposition (Liu et al. 2011). Using the same system, it was further determined 
that CCN2 was dispensable during cutaneous wound healing, with CCN2 knockout 
animals displaying no deficits in the rate of closure or the composition of the granulation 
tissue (Liu et al. 2014). However, CCN2 is also expressed by keratinocytes during wound 
re-epithelialization (Kiwanuka et al. 2013); whether this could compensate for fibroblast-
specific deletion is not known. 
Previous investigations concluded that CCN2 transcript levels were not different in 
human chronic wound tissue compared to unaffected tissues from the same patient 
(Elliott et al. 2015), contrasting its upregulation in animal models of acute wound healing 
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(Igarashi et al. 1993; Kapoor et al. 2008). Conversely, its expression is strongly 
upregulated in fibrotic conditions in humans, and the level of expression correlates with 
the severity of fibrosis across organs (Leask et al. 2009), including skin where both blood 
plasma and interstitial levels of the N-terminal domain of CCN2 positively correlated 
with disease severity (Dziadzio et al. 2005). As such, previous work in the Hamilton lab 
investigated whether exogenous CCN2 could be used therapeutically to induce fibrotic 
processes, including angiogenesis and matrix deposition, in a db/db mouse model of 
impaired wound healing (Elliott et al. 2018). Similar to the results described for Periostin, 
treatment with exogenous CCN2 was sufficient to increase the rate of healing in db/db 
mice to a level that was similar to that observed in wild-type mice (Elliott et al. 2018). 
Moreover, micro-computed tomography imaging of the vasculature within treated 
wounds supported a pro-angiogenic response following CCN2 treatment (Elliott et al. 
2018). Although genetic deletion of CCN2 within collagen I expressing cells was 
determined to be inconsequential for cutaneous wound healing (Liu et al. 2014), the 
positive effects of exogenous CCN2 on models of impaired healing warrant further 
investigation to probe its potential as a wound healing therapeutic. 
1.6 Strategies for healing chronic wounds 
The current standard of care for chronic wound patients targets the underlying 
pathophysiology and can differ depending on wound etiology. For example, in diabetic 
patients, controlling hyperglycemia and developing a nutritious diet are priorities 
(Frykberg and Banks 2015; Han and Ceilley 2017). Alternatively, in patients with 
vascular ulcers, strategies to improve blood flow are beneficial, including vascular 
surgeries and compression therapy (Frykberg and Banks 2015; Han and Ceilley 2017). 
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Hyperbaric oxygen therapy can also be included to increase oxygen tension within the 
wound if these primary strategies fail. Across wound etiologies, maintaining a moist 
wound environment that is free of infection is critical (Frykberg and Banks 2015; Han 
and Ceilley 2017). Upon detection of infection, wounds are treated aggressively with 
antimicrobial agents, including antibiotics and silver-based therapies. Debridement is also 
of particular importance across etiologies, as it allows healthier tissue to contribute to 
wound repair while removing the dead tissue, which can further aid in reducing the 
bacterial load (Frykberg and Banks 2015; Han and Ceilley 2017). Finally, negative 
pressure therapy has been widely supported as an effective strategy to enhance healing by 
stimulating granulation tissue formation and increasing wound contraction (Frykberg and 
Banks 2015; Han and Ceilley 2017). Although these different strategies constitute the 
standard of care, they are not adequate to facilitate closure in a large number of patients. 
For example, clinical studies that have investigated standard care as a control treatment in 
diabetic foot ulcers have reported approximately 30% complete closure within follow up 
periods of 6-16 weeks, and approximately 10% frequency of lower extremity amputation 
(Santema et al. 2016).  
To complement standard care, many novel therapeutics have been approved by United 
States Food and Drug Administration (FDA) for the treatment of chronic wounds. 
However, these are generally chosen based on clinician preference and personal 
experience, and are not backed by quality clinical data (Snyder et al. 2012; Frykberg and 
Banks 2015). Some of these complementary strategies, as well as more exploratory 
approaches will be discussed in more detail below. 
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1.6.1 Growth factor therapies 
Despite promise in animal models, with the exception of PDGF-BB, growth factor 
therapies have not been successfully translated to the clinic, potentially due in part to the 
proteolytic nature of chronic wounds (Barrientos et al. 2008; Han and Ceilley 2017). 
PDGF-BB has received approval from the FDA for use in chronic wounds, but has 
displayed only limited efficacy and is not widely used (Apelqvist et al. 2008; Papanas 
and Maltezos 2010). There has been speculation into the limited efficacy of growth factor 
therapies. Singer and Clark (1999) proposed that the use of single growth factors in such 
a complex, dysregulated microenvironment may not be adequate and suggested the use of 
combination therapies at specific intervals to promote wound healing (Singer and Clark 
1999). However, to date there are no growth factor combination therapies approved for 
use.  
1.6.2 MMP inhibitors 
To reduce matrix degradation, MMP inhibitors have been explored for wound healing, 
but MMPs also possess a number of necessary functions that promote healing. For 
example, both MMP-9 knockout mice (Kyriakides et al. 2009) and rats treated with the 
broad spectrum MMP inhibitor BB-94 (Mirastschijski et al. 2010) showed significantly 
delayed wound healing. However, in a chronic wound setting, inhibition of MMPs 
remains a potential clinical target to improve healing (Caley et al. 2015). A strategy 
utilizing the collagenous ECM from sheep forestomach has, in limited clinical 
assessment, shown to be effective for treatment of chronic wounds (Bohn et al. 2016). 
This strategy relies on providing a large amount of substrate to inhibit endogenous 
proteases, while simultaneously sequestering growth factors and cytokines to prevent 
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their degradation (Negron et al. 2014; Bohn et al. 2016). In fact, this mechanism of 
overwhelming endogenous MMPs is likely a major factor in the reported efficacy of 
many collagen based wound dressings (Fleck and Simman 2010). 
1.6.3 Biomaterials for wound repair 
A wide range of biomaterials have been developed for wound healing applications, 
including both wound dressings and skin substitutes (Mir et al. 2018). Skin substitutes, 
which are the focus here, will be defined as materials designed for cellular infiltration, 
acting themselves as a biodegradable scaffold. This broad definition encompasses a wide 
range of materials including those designed from biological sources and synthetic 
polymer-based materials (Shahrokhi et al. 2014; Mir et al. 2018). Furthermore, these can 
be either acellular or combined with fibroblasts and/or keratinocytes. Based on this broad 
classification, numerous skin substitutes have been developed. In 2012, Snyder et al. 
compiled a comprehensive assessment identifying 57 skin substitutes for use in treatment 
of chronic wounds that have been approved by the FDA and are commercially available 
(Snyder et al. 2012). However, a recent Cochrane review investigating the use of skin 
grafts and skin substitutes for treatment of diabetic foot ulcers showed a moderate 
improvement with current therapeutics when combined with standard care (Santema et al. 
2016). In this review, the combined data collected from clinical trials exploring the use of 
standard care plus skin grafts or skin substitutes including Dermagraft®, Apligraf®, 
OASIS®, and TheraSkin®, resulted in a frequency of complete closure of 42%, 
compared to 27% with standard care alone within a follow-up period of 6-16 weeks. The 
differences between therapeutics were inconclusive. Thus, while the current generation of 
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skin substitutes are improving the quality of life of a large number of people affected by 
chronic wounds, there is clearly a need for improved clinical outcomes. 
 
1.6.3.1 Collagen-based biomaterials for wound healing 
Collagens are the most abundant proteins in natural ECM, providing a structural network 
to support cells and a biologically active substrate that can interact directly with cell 
surface receptors and sequester secreted proteins to modulate bioavailability 
(Chattopadhyay and Raines 2014). Furthermore, collagens are naturally biodegradable 
and contain crypto sequences that are released upon degradation, which can stimulate 
angiogenic or regenerative inflammatory pathways (Postlethwaite et al. 1978; Perumal et 
al. 2008; Ames et al. 2016). Depending on the processing conditions applied to extract 
the collagens, much of the antigenicity responsible for immune rejection can be lost, 
allowing xenogeneic-derived ECM to successfully integrate into host tissues (Ruszczak 
2003; Badylak 2004). These properties have made collagens attractive structural 
components for medical applications (Chattopadhyay and Raines 2014). Type I collagen 
is the most abundant of the collagen proteins and has been widely used in the production 
of biomaterials (Chattopadhyay and Raines 2014). Several commercially available 
collagen-based materials have been developed for wound healing applications, such as 
SkinTemp®, Collatamp®, and Integra™ Matrix Wound Dressing (Ruszczak 2003). 
Collagen-based biomaterials can be synthesized from purified collagen using different 
techniques depending on the target applications (Chattopadhyay and Raines 2014). 
Specific scaffold formats investigated to date include foams (sponge), membranes, and 
injectables, all of which can be further modified physically and/or biologically 
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(Chattopadhyay and Raines 2014). Examples of physical modifications include chemical 
cross-linking or inclusion of synthetic polymers, whereas biological modifications can 
include drug or cell delivery. Based on these possible modifications, a wide range of 
collagen-based materials have been synthesized and explored in wound healing 
environments. Foam synthesis, a focus in this thesis, will be discussed in more detail 
below. 
Collagen foams can be synthesized by lyophilizing frozen solubilized collagen, with 
physical properties altered by manipulating the concentration of collagen and the rate of 
freezing (Doillon 1987; Chattopadhyay and Raines 2014). Early investigations into these 
materials highlighted their porous structure enabling cellular infiltration during a wound 
healing response (Doillon 1987). Investigating a foam made from type I collagen, 
chitosan, and chondroitin sulphate, Berthod et al. observed increased collagen synthesis 
by fibroblasts relative to tissue culture plastic or a collagen gel (Berthod et al. 1993). The 
authors attributed this to the porous nature of the foams, which allowed secreted collagen 
to be dispersed further from the cells. This is in contrast to the reduced collagen synthesis 
observed in fibroblasts cultured within collagen gels relative to tissue culture plastic, 
which the authors hypothesized relates to negative feedback by cells trapped in a 
collagen-rich environment with low porosity (Mauch et al. 1988; Berthod et al. 1993), but 
may also involve differences in matrix stiffness (Kanta 2015).  
The structural properties of collagen foams also make them suitable carriers for 
exogenous cells and proteins. Using chemically cross-linked collagen foams, Marks et al. 
delivered allogeneic guinea pig fibroblasts or exogenous bFGF to wounds in a guinea pig 
model, both of which significantly increased the final tensile strength of the wounds over 
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treatment with collagen foams alone (Marks et al. 1991). The ability to easily modify 
physical properties, shape, and biological functionality of collagen-based foams makes 
them a highly versatile platform for the development of novel wound healing strategies. 
 
1.6.3.2 Decellularized tissues for wound healing 
Several biomaterials have been developed from decellularized tissues and are 
commercially available for wound healing applications including decellularized cadaveric 
skin (Alloderm™; GraftJacket®), decellularized porcine small intestinal submucosa (SIS; 
OASIS®), decellularized porcine urinary bladder matrix (UBM; Matristem®), and 
decellularized fetal bovine skin (PriMatrix™), highlighting the utility of decellularized 
tissues (Turner and Badylak 2015).  
Decellularized tissues include a complex array of ECM proteins, including structural 
proteins, matricellular proteins, growth factors, and cytokines, more closely mimicking a 
native ECM than matrices derived from purified components (Badylak 2002). As an 
example of the complexity within decellularized tissues, a recent proteomics study from 
the Flynn lab investigated the protein composition of decellularized human adipose tissue 
and bone, identifying a total of 906 and 1478 unique proteins within the processed 
tissues, respectively (Kuljanin et al. 2017). These proteins included structural proteins, 
glycoproteins, proteoglycans, matricellular proteins, and signaling proteins (Kuljanin et 
al. 2017), all of which are important mediators of wound healing (Turner and Badylak 
2015).  
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ECM can be sourced from human adipose tissue that is commonly discarded in medical 
procedures including abdominoplasties and panniculectomies (Flynn 2010). 
Decellularized adipose tissue (DAT) is an acellular, collagen-rich, multicomponent 
material containing intact collagen fibrils, and, similar to purified collagen, can be 
processed into foam biomaterials (Flynn 2010; Yu et al. 2013; Kuljanin et al. 2017). 
Subcutaneous implantation of DAT foams into an immune competent rat model yielded 
an early angiogenic response, and eventual tissue remodeling, characterized by an initial 
inflammatory response that subsided with time (Yu et al. 2013). Recent investigation 
using a bead foam synthesis method, designed for increased cellular infiltration, further 
supported the angiogenic potential of DAT (Morissette Martin et al. 2018). Purified 
collagen- and DAT-based bead foams were seeded with chronic wound edge dermal 
fibroblasts. Interestingly, cells cultured on DAT bead foams secreted higher levels of 
angiogenic factors, including VEGF, hepatocyte growth factor, stromal cell-derived 
factor 1, angiopoietin-1, and PDGF-BB. Furthermore, following subcutaneous 
implantation into athymic mice, wound edge dermal fibroblast seeded DAT bead foams 
demonstrated greater CD31+ cell infiltration compared to seeded collagen bead foams 
(Morissette Martin et al. 2018). Using a relevant cell type, these findings support the 
potential of DAT in a chronic wound environment, warranting further investigation into 
wound healing models. 
 
1.6.4 Cell therapies for wound healing 
Current commercially-available cell therapies for wound healing come in the form of 
living skin equivalents including a neonatal foreskin fibroblast seeded matrix 
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(Dermagraft®; Organogenesis) and a neonatal foreskin keratinocyte/fibroblast seeded 
matrix (Apligraf®; Organogenesis) (Snyder et al. 2012). These materials are considered 
advanced care options and are only recommended for use if alternative therapies have 
failed within a one-month (Apligraf®) or six-week (Dermagraft®) follow-up period, and 
only in cases where the wounds are not infected (Snyder et al. 2012). A recent Cochrane 
review supported their clinical use, identifying a 50% increase in the rate of complete 
closure for both of these products compared to standard care alone (Santema et al. 2016). 
However, it is important to note that roughly half of patients treated with Apligraf® and 
Dermagraft® still fail to exhibit appropriate healing (Santema et al. 2016). Whether 
alternative cell sources might result in better outcomes is not known. 
Mesenchymal stem/stromal cells (MSCs) are multipotent progenitor populations that 
upon isolation are characterized by a set of minimal criteria outlined by the International 
Society for Cellular Therapy (ISCT). These include adherence to tissue culture plastic, 
positive surface marker expression of CD73, CD90, and CD105, negative surface marker 
expression of CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-DR, and the 
capacity to differentiate into adipogenic, chondrogenic, and osteogenic lineages in culture 
(Dominici et al. 2006). Perivascular populations characterized by in vivo expression of 
CD146 were shown to exhibit MSC characteristics upon isolation and culturing, and 
could be isolated in abundance from the stromal vascular fraction of adipose tissue 
(Crisan et al. 2008). Importantly, for allogeneic applications, these adipose-derived MSCs 
(ASCs) can be isolated from normally discarded medical waste (Hassan et al. 2014).  
The use of MSCs shows potential for wound healing applications by supporting 
endogenous fibroblast and keratinocyte activation, angiogenesis, and 
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modulation/resolution of the inflammatory phase (Lee et al. 2016). In a db/db mouse 
model of impaired healing, murine ASC treatment increased granulation thickness, 
angiogenesis and the rate of re-epithelialization (Nambu et al. 2009, 2011). Similar 
results were observed in streptozotocin-induced diabetic rats, which displayed an 
increased rate of healing associated with reduced CD45-positive cell infiltration, and 
increased cell proliferation and fibroblast activation at the wound edge (Kuo et al. 2016). 
Many of the beneficial effects of ASCs are thought to be attributed to their secretome, 
which includes angiogenic and pro-fibrotic factors, immune-modulating cytokines, as 
well as matrix modifying proteins including collagens, TIMPs, and MMPs (Park et al. 
2008; Lee et al. 2010; Salgado et al. 2010; Dubey et al. 2018). 
Limited clinical investigation of MSC delivery to patients with chronic wounds lasting 
greater than one year and not responding to conventional and advanced therapeutics, 
supported the use of MSCs in chronic wound patients (Falanga et al. 2007). These 
findings also suggested that the beneficial results are dose dependent, with greater cell 
delivery correlating with improved healing (Falanga et al. 2007). Thus, delivery strategies 
that can distribute high numbers of MSCs across the area of the granulation tissue could 
be supportive of better clinical outcomes. 
 
1.7 Thesis Overview 
With a focus on exploring intrinsic differences in the fibroblast populations during skin 
development and wound healing, the effect of embryonic lineage on fibroblast function 
was first explored in a murine model. A Cre/Lox lineage tracing method was used to 
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track Foxd1 lineage-positive cells and explore whether resident myofibroblast 
progenitors within the skin shared Foxd1 as a common developmental gene signature to 
those previously-described in lung (Hung et al. 2013) and kidneys (Humphreys et al. 
2010). Further, the expression profile of this lineage was characterized in the skin during 
homeostasis and wound repair and compared to the non-Foxd1-lineage fibroblasts. 
Within this aim, it was hypothesized that the Foxd1 lineage would contribute to skin 
development, and that these lineage-positive cells would be a major source of 
myofibroblasts during wound repair. 
In the second chapter, the role of the matricellular protein Galectin-3 was investigated as 
a potential extrinsic factor mediating cutaneous repair in an acute wound model in 
knockout mice. Previous investigation has supported a role of Galectin-3 in wound re-
epithelialization (Liu et al. 2012), however further investigation into how this protein 
functions within the granulation tissue was warranted. Furthermore, investigation into 
Galectin-3 regulation in human chronic wounds and chronic wound fibroblasts had not 
been previously performed and could provide insight into dysregulated mechanisms that 
may be targeted in future therapeutic development. Within this aim, it was hypothesized 
that genetic deletion of Galectin-3 would result in an unresolved inflammatory state, 
impaired angiogenesis, and reduced myofibroblast accumulation resulting in delayed 
wound closure relative to wild-type mice.  
In the final experimental chapter, pilot studies were performed as a first step towards the 
development of novel therapeutic approaches with the potential to modulate both cell 
infiltration and the wound microenvironment to promote healing. More specifically, a 
porcine acute wound model was explored due to the reported anatomical similarities 
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between porcine and human skin (Sullivan et al. 2001). Within this model, a variety of 
ECM-derived foam biomaterials were tested, as they offer a versatile platform to 
combine proteins of interest, as well as for cell therapy. Type I collagen foams 
incorporating Periostin and CCN2 were tested, as these matricellular proteins were 
previously shown to improve wound closure when added exogenously in a db/db model 
of impaired wound healing (Elliott et al. 2018). Further, foams derived from the more 
complex ECM of human DAT were also assessed. Preliminary testing was also 
performed to assess the potential of the foams as a platform for therapeutic delivery of 
porcine ASCs. It was hypothesized that all of the foam biomaterials would improve the 
rate of wound closure and promote wound angiogenesis and myofibroblast differentiation 
relative to untreated controls. These studies represented important first steps in applying a 
more relevant pre-clinical large animal model, which is critically needed for the design of 
more effective biomaterials-based therapies for treating chronic wounds in humans. 
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Chapter 2: Lineage tracing of Foxd1-expressing 
embryonic progenitors to assess the role of 
divergent embryonic lineages on adult dermal 
fibroblast function 
2.1 Abstract 
Recent studies have highlighted the functional diversity of dermal fibroblast populations 
in health and disease, with part of this diversity linked to fibroblast lineage and 
embryonic origin. In particular, fibroblast lineage has become an important predictor for 
determining fibroblast function during skin development, as well as during homeostasis 
and repair in adult skin. Single-cell transcriptional profiling studies have been pivotal in 
determining the extent of diversity in fibroblast populations localized in skin. However, 
whether this diversity is derived from different discrete cell states within fibroblasts of 
the same lineage, or is defined by different lineages, is not known. Additionally, it is 
unclear whether common expression signatures in disparate embryonic progenitor 
populations can lead to similar functional properties in their fibroblast progeny across 
organs. Fibroblasts derived from Foxd1-expressing progenitors contribute to the 
myofibroblast populations present in lung and kidney fibrosis in mice. Here, it was 
hypothesized that dermal fibroblast progenitors would express Foxd1, and that the 
fibroblast progeny of these cells would contribute to granulation tissue formation during 
cutaneous wound repair. Using a Cre/Lox system to genetically track populations derived 
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from Foxd1-expressing progenitors, lineage-positive fibroblasts were identified as a 
subset of the dermal fibroblast population. At embryonic day 9.5 (E9.5), lineage-positive 
cells were evident within the most dorsal embryonic tissues, contributing to the 
developing dermal fibroblast population, and remaining in this niche into adulthood. 
Using real-time PCR array analysis of fluorescence activated cell sorting (FACS)-
enriched fibroblasts isolated from adult tissues at 10 days post-wounding demonstrated 
that the Foxd1 lineage-positive dermal fibroblasts were enriched with transcripts 
associated with matrix synthesis relative to their Foxd1 lineage-negative counterparts. 
Specifically, within fibroblasts isolated from the wound tissue, transcripts for the 
extracellular matrix constituents type III collagen, decorin, CCN2, and thrombospondin 2 
were enriched in Foxd1 lineage-positive fibroblasts. Conversely, in Foxd1 lineage-
negative fibroblasts, there was an enrichment in transcripts for cell surface receptors 
including several integrins, and soluble signaling factors including tumor necrosis factor-
alpha (TNFα), platelet derived growth factor-A (PDGF-A) and PDGF-B. This work 
provides a foundation for the future assessment of functional differences between 
fibroblasts of Foxd1-positive and -negative lineages and characterization of markers of 
differentiation for translational research outside of a lineage tracing context. 
2.2 Introduction 
Within the skin, resident fibroblasts have long been proposed as the source of 
myofibroblasts during cutaneous wound repair (Singer and Clark 1999). Recent evidence 
from lineage tracing studies in mice has supported this hypothesis (Driskell et al. 2013; 
Rinkevich et al. 2015), while other research has demonstrated complementary 
myofibroblast contribution from perivascular cells, adipocytes, and bone marrow-derived 
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populations in skin fibrosis and wound healing (Dulauroy et al. 2012; Suga et al. 2014; 
Marangoni et al. 2015). Myofibroblasts, characterized by the expression of alpha smooth 
muscle actin (αSMA), are the main source of extracellular matrix (ECM) production 
during tissue injury (Gabbiani 2003; Hinz 2007). As such, investigation into the 
progenitors from which these myofibroblast populations originate within the skin during 
health and disease could provide insight into novel strategies to improve wound healing 
and treat skin fibrosis (Driskell and Watt 2015; Hu et al. 2018).  
An important finding from lineage tracing studies is that there is previously unrecognized 
heterogeneity within the fibroblast subpopulation of myofibroblast progenitors, and that 
this heterogeneity is correlated with specific gene expression signatures in embryonic 
precursor populations (Driskell et al. 2013; Driskell and Watt 2015; Rinkevich et al. 
2015; Hu et al. 2018). During development, the most dorsal fibroblast population, 
characterized by the expression of Blimp1 and Lrig1, gives rise to the papillary dermal 
fibroblasts of post-natal mice (Driskell et al. 2013). In contrast, the more ventral 
population, expressing Dlk1, contributes to the reticular dermal fibroblasts and 
underlying adipogenic population (Driskell et al. 2013). Furthermore, lineage tracing 
analysis of these populations identified unique contributions to dermal wound repair in 
adult mice. While the dlk1-traced lower dermis contributed to early granulation tissue 
formation, the upper blimp1-traced population migrated into the wound during re-
epithelialization, and contributed primarily to hair follicle regeneration (Driskell et al. 
2013).  
Further investigation of embryonic lineages identified that there are different fibroblast 
subsets with distinct specialization contributing to granulation tissue formation 
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(Rinkevich et al. 2015). Tracing a population of fibroblasts characterized by embryonic 
expression of Engrailed-1, Rinkevich et al. identified a subset of fibroblasts with greater 
fibrogenic potential relative to fibroblasts derived from precursors not expressing 
Engrailed-1. More importantly, in this study, the cell surface marker and enzyme CD26 
(Dipeptidyl peptidase-4; Dpp4) was enriched on adult mouse fibroblasts of the fibrogenic 
Engrailed-1 lineage. In adult mice, wounds treated with a chemical inhibitor of Dpp4 
healed more slowly but had a significant reduction in scar size, highlighting the 
translational potential of this research (Rinkevich et al. 2015). 
The level of heterogeneity within dermal fibroblasts has recently been assessed in human 
skin using single-cell qPCR analysis (Philippeos et al. 2018; Tabib et al. 2018). These 
studies have identified approximately five subpopulations of fibroblasts based on cluster 
analysis of gene expression profiles. Whether these populations are fixed, and 
predetermined based on developmental lineage, or if cells from one discrete sub-type can 
transition to another, are critical questions arising from these studies with important 
clinical implications. Lineage tracing studies in mice represent a promising tool to begin 
to explore these important questions. 
In fibrotic processes including dermal wound healing and organ fibrosis, myofibroblasts 
are implicated as the effector cell of uncontrolled matrix deposition across organs, 
regardless of the available pool of myofibroblast precursors in that organ (Hinz et al. 
2012; El Agha et al. 2017). Recent lineage tracing studies have also demonstrated that 
unique embryonic gene signatures within dermal fibroblast precursors are predictive of 
unique myofibroblast functions during dermal wound repair in adulthood (Driskell et al. 
2013; Rinkevich et al. 2015). Consequently, it was hypothesized that specific common 
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embryonic gene signatures between myofibroblast progenitors of different organs would 
be predictive of common myofibroblast functions. Binary expression of Foxd1 during 
embryogenesis presented a potential candidate as a common gene expression signature. 
Foxd1 is a transcription factor expressed primarily during development, and is required 
for appropriate renal stromal cell differentiation from progenitors during embryogenesis 
(Levinson 2005; Fetting et al. 2014). Additionally, as a lineage tracing marker, resident 
Foxd1 lineage-derived populations in the kidney and lung contributed to the 
myofibroblast populations in induced renal fibrosis following unilateral ureteral 
obstruction and ischemia reperfusion injury, as well as bleomycin induced lung fibrosis, 
respectively (Humphreys et al. 2010; Hung et al. 2013). In the present study, using a 
Cre/Lox lineage tracing system in mice, the Foxd1 lineage of stromal cells was 
investigated in dorsal skin development, homeostasis, and wound healing. It was 
hypothesized that binary expression of Foxd1 during embryogenesis would be a useful 
marker to identify a distinct stromal cell progenitor population and that the progeny of 
this population would contribute to dermal fibroblasts in adult skin and myofibroblasts 
upon cutaneous wounding. 
2.3 Materials and methods 
2.3.1 Mice 
All animal procedures were in compliance with protocols approved by the University 
Council on Animal Care at Western University (Animal use protocol # 2016-085). 
Foxd1GC (Foxd1tm1(GFP/Cre)Amc/J), Foxd1GCE (B6;129S4-Foxd1tm2(GFP/Cre/ERT2)Amc/J), Ai14 
(B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J), and mTmG (B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J) mice were purchased from The Jackson 
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Laboratory (Farmington, CT). Schematics and brief descriptions of each of the Cre/Lox 
models used in this study are provided in Figure 2.1. Mice were genotyped as per The 
Jackson Laboratory’s instructions. Mice that were heterozygous for the alleles of interest 
were used for all experiments. For timed pregnancy, females were monitored for vaginal 
plugs and the day following was considered embryonic day 0.5 (E0.5). Embryos were 
isolated from pregnant females at E9.5, E10.5, E11.5, E14.5, and E17.5 as specified for 
each experiment. For all time-points, at least 3 embryos were analyzed from at least 2 
independent litters.  
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Figure 2.1: Schematics of Cre/Lox strategies used to track Foxd1 lineage-positive 
populations. (A) A cross between Foxd1GC and Ai14 mice yields tdTomato positive 
populations in cells derived from Foxd1-expressing progenitors. (B) A cross between 
Foxd1GC and mTmG results in membrane-targeted tdTomato expression in all Foxd1 
lineage-negative populations and membrane-bound eGFP in all Foxd1 lineage-positive 
populations. (C) A cross between Foxd1GCE and Ai14 mice is similar to the cross in (A), 
however the modified human estrogen receptor (ER) fragment attached to the Cre-
recombinase impedes translocation into the nucleus preventing recombination in the 
absence of the synthetic ER ligand, tamoxifen (Metzger and Chambon 2001).  
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2.3.2 Tamoxifen injections 
To temporally control Cre-mediated recombination, mice carrying a tamoxifen-inducible 
Cre variant, CreERT2, were crossed to Ai14 reporter mice (Figure 2.1C) (Metzger and 
Chambon 2001; Feil et al. 2009). Using this strategy, injection of tamoxifen was used to 
determine the temporal expression of Foxd1 in both embryonic and adult tissues. Timed 
pregnancies were used for the embryo isolations as above. In these animals, tamoxifen 
was injected intraperitoneally into pregnant females twice on 2 consecutive days at a dose 
of 0.6 mg per day. For all studies, a solution of 10 mg/mL tamoxifen in 90% corn oil 
(Sigma) and 10% ethanol was administered. A minimum of 3 embryos from one or more 
litters were analyzed at all time-points. 
Tamoxifen injection in postnatal mice was performed on mice heterozygous for both 
Foxd1GCE and Ai14 alleles (Figure 2.1C). At 1 month of age, mice were injected with 1 
mg of tamoxifen each day for 3 consecutive days. At 2 months of age, wounding 
experiments were performed using a non-splinted wound model as previously described 
(Elliott et al. 2012). Briefly, the dorsal skin of mice was shaved, and hair was removed 
with depilating cream (Nair®). Two full-thickness dorsal wounds were made with a 6 
mm biopsy punch (Integra™ Miltex™). Wounds were left to heal without bandaging. 
Pain was managed using 0.05 mg/Kg buprenorphine administered intraperitoneally prior 
to surgery and again 6-8 hours following surgery. Directly following wounding, mice 
were subjected to a second tamoxifen regimen of 1 mg each day for 3 consecutive days. 
After 7 days post wounding, the animals were euthanized, and tissues were collected for 
histological analyses. Postnatal tamoxifen injection and wounding was performed on 6 
animals. Tissues from these animals were compared to unwounded adult skin, and 
80 
 
 
 
granulation tissue at 7 days post wounding (non-splinted) from constitutively active 
Foxd1GC/Ai14 mice (Figure 2.1A). 
2.3.3 Wound healing 
With the exception of mice wounded and injected with tamoxifen as described above, all 
excisional wounds were splinted and wrapped as described previously (Dunn et al. 2013). 
The dorsal skin was shaved, and the remaining hair was removed with depilating cream 
(Nair®).  The 6 mm wounds were created with a biopsy punch and wounds were splinted 
open with silicone splints (Grace Bio labs), which were held in place with a 
cyanoacrylate adhesive and 6-0 nylon sutures. Wounds were then covered with an 
adhesive contact layer (Mepitel® One; Mӧlnlycke) and a semi-occlusive dressing 
(OPSITE®; Smith & Nephew), prior to being wrapped in a self-adherent bandage and 
cloth tape. Following surgery, pain was controlled using 0.05 mg/Kg buprenorphine 
delivered intraperitoneally prior to surgery and 6-8 hours following surgery. Dressings 
were changed every 3-4 days. For the 21-day time point, bandages and splints were 
removed after 14 days. 
2.3.4 Histology and immunofluorescence microscopy analyses 
Isolated embryos, skin, and wound tissue were fixed in 10% neutral buffered formalin for 
24 hours at 4ºC. These tissue samples were then dehydrated in a sucrose gradient prior to 
embedding in frozen section compound (Leica). Samples were frozen on dry ice and were 
stored at -20ºC. Cryosections were cut to 8 µm thickness. Unstained sections to 
investigate only endogenous fluorescent proteins, were washed in phosphate buffered 
saline (PBS) and directly mounted with VectaShield mounting media with DAPI (Vector 
Labs). For antibody labelling, slides were first washed with 1% sodium dodecyl sulfate 
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for 5 minutes, rinsed three times in PBS, and incubated for 30 minutes in 10% horse 
serum in PBS for blocking. Sections were then incubated with primary antibodies as 
outlined in Table 2.1 in 10% horse serum. Following staining, slides were stained with 
VectaShield mounting media with DAPI (Vector Labs). No-primary controls were used 
for negative controls for antibody labelling (shown in Appendix Figure A1). 
Table 2.1: Antibodies used for histological assessment 
Target Tissue 
investigated 
Antibody ID Dilution 
αSMA Adult Ab5694 (Abcam) 1:100 
CD26 Adult AF954 (R&D systems) 1:50 
GFP Embryonic/Adult Ab6673 (Abcam) 1:200 
PDGFRα Adult AF1062 (R&D systems) 1:100 
PDGFRβ Adult AF1042 (R&D systems) 1:50 
CD31 Adult Ab28364 (Abcam) 1:200 
Vimentin Adult Ab92547 (Abcam) 1:500 
α2 Integrin Adult AF1740 (R&D systems) 1:50 
α3 Integrin Adult AB1920 (EMD 
Millipore) 
1:200 
αV Integrin Adult AF1219 (R&D systems) 1:50 
β1 Integrin Adult AF2405 (R&D systems) 1:50 
β6 Integrin Adult AF2389 (R&D systems) 1:50 
 
2.3.5 Dermal fibroblast isolation 
To isolate dermal fibroblasts from wounded and subject-matched healthy tissue, skin was 
excised from mice 10 days post wounding using an 8 mm biopsy punch centered on the 
middle of the wound, or excised from unwounded, depilated dorsal skin outside of the 
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wounded area. For isolation of naïve healthy fibroblasts for culture studies, unwounded 
mice were depilated, and the dorsal skin was removed immediately. In all cases, 
subcutaneous fat was mechanically removed from the skin. The full, excised dorsal skin 
was then incubated in 0.25% trypsin with 100 µg/mL dispase for 30 minutes at 37ºC. The 
epidermis was then removed mechanically by scraping the surface with a scalpel blade, 
and the remaining dermis was minced with a scalpel. The minced tissue was incubated in 
a digest solution of 4 mg/mL collagenase IV (Gibco) in DMEM/Ham’s F-12 media for 2 
hours, at 37ºC on a shaker set to 100 rpm. The resultant cell suspension was filtered 
through 100 µm and 40 µm nylon filters and prepared for FACS. Individual samples 
were processed independently from wounded and unwounded tissue. For isolation of 
naïve healthy fibroblasts, cells from 4-6 mice were pooled.  
2.3.6 Fluorescence activated cell sorting 
Cell suspensions were stained with LIVE/DEAD fixable aqua stain (Life technologies), 
as per the manufacturer’s instructions. Cells were then incubated on ice for 25 minutes 
with APC-labelled antibodies for CD31 (BD Pharmingen; 551262), CD45 (BD 
Pharmingen; 559864), and EpCAM (BD Pharmingen; 563478) each diluted 1:25 in PBS 
with 5% FBS, to negatively select for endothelial, bone marrow derived, and epithelial 
populations, respectively. Cells were then sorted on a FACSAria III cell sorter as follows. 
Forward- and side-scatter were first used to select individual cells. Using a 405 nm laser 
with a 510/50 filter, cells negative for the LIVE/DEAD fixable aqua stain were selected. 
Next, using a 633 nm laser with 660/20 filter, cells negative for APC were selected. 
Finally, the remaining fibroblast populations were sorted into the Foxd1 lineage-positive 
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(FLP) and Foxd1 lineage-negative (FLN) subpopulations based on expression of 
tdTomato using a 561 nm laser with 610/20 filter. 
2.3.7 Cell Culture 
To assess isolated cells in culture, free-floating soft collagen gels were used as a 3-
dimensional culture substrate. For these studies, 2 mg/mL collagen gels were synthesized 
by neutralizing 6 mg/mL collagen (Nutragen; Advanced Biomatrix) with HEPES (final 
concentration 0.02 M). This solution was then combined with FACS-sorted fibroblasts in 
culture media. For each 500 µL collagen gel, 70,000 cells were seeded using a 24-well 
suspension culture plate as a mold. The samples were incubated for 30 minutes at 37ºC to 
allow gelation and then detached from the well plate with a pipette tip. Samples were 
cultured in DMEM/Ham’s F-12 media supplemented with penicillin/streptomycin and 
10% FBS. To induce a myofibroblast phenotype, one set of samples was treated with 5 
ng/mL mouse TGFβ1 (R&D Systems) whereas the other was left untreated. Depending 
on the cell yield, 1-3 collagen gels were synthesized per treatment group for each cell 
lineage. After 16 hours, the cells were cultured in DMEM/Ham’s F-12 media 
supplemented with 5% FBS, with fresh TGFβ1 added daily, for a total of 7 days. On day 
7, the gels were digested in 4 mg/mL collagenase type IV (Gibco) in DMEM/Ham’s F-12 
media for RNA isolation. Multiple gels from the same group were pooled. These cell 
culture experiments were performed on isolated cells from a total of 6 independent 
digestions, each combining the pooled fibroblasts from 4-6 mice. 
2.3.8 RNA isolation  
RNA was isolated from freshly-sorted FLP and FLN fibroblast populations and from 
cells cultured in collagen gels. For all samples, RNA was isolated with TRIzol reagent 
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(Life Technologies) and purified using RNeasy micro kits (Qiagen, Valencia, CA), 
including DNase digestion. Isolated RNA was stored at -20ºC for short-term storage prior 
to quantitation. 
2.3.9 RT-qPCR array 
To assess cell intrinsic differences between FACS-sorted FLP and FLN fibroblasts during 
homeostasis and wound healing, a RT2 profiler array for genes associated with fibrosis 
(Qiagen; PAMM-120Z) was used to measure gene expression. Samples were collected 
independently from 8 mice and were divided into 4 groups each (FLP wound, FLN 
wound, FLP unwounded, FLN unwounded). Isolated RNA was converted to cDNA with 
a RT2 first strand kit (Qiagen), and pre-amplified with array specific primers. Genes that 
were not consistently amplified in any group were removed from further analysis. 
Expression was normalized to a panel of housekeeping genes. Outliers in the 2-ΔCt values 
were calculated using the ROUT method (Q = 1.0%) (Motulsky and Brown 2006) in 
GraphPad Prism. Two groups of the 32 total groups were deemed to have a high number 
of outliers and were completely removed from further analysis. In the remaining data set, 
23 data points were removed as outliers, of the 2,220 total data points remaining (~1%). 
2-ΔCt values were then compared with multiple t-tests and adjusted for multiple 
comparisons with a false discovery rate correction set to 10%.  
2.3.10 TaqMan® qPCR 
Gene expression in freshly-sorted FLP and FLN fibroblast populations from unwounded 
mouse skin, along with the two populations cultured in collagen gels for 7 days as 
described in Section 2.3.7, were assessed with TaqMan® probe sets (Thermofisher 
Scientific) using iTaq Universal 1-step master mix (Bio-rad) as per the manufacturer’s 
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instructions. Samples were run in triplicate. Threshold cycles were compared to a 
standard curve generated from serial dilutions of unsorted dermal isolates for relative 
quantitation. The resultant relative quantities were then normalized to endogenous 18S 
rRNA. The TaqMan® probe sets used in this study are listed in Table 2.2. Isolated cells 
from a total of 6 independent digestions, each combining the pooled fibroblasts from 4-6 
mice, were assessed. 
2.3.11 Statistical methods 
With the exception of the analysis performed on the array data as described above, 
statistical analyses were performed using R statistics software (R core team 2017) using 
the “nlme” package for linear and nonlinear mixed effects models (Pinheiro et al. 2014), 
and the “multcomp” package for simultaneous inference in general parametric models 
(Hothorn et al. 2008). GraphPad Prism software version 6 (GraphPad, La Jolla, CA) was 
used to produce graphs. Statistical analyses were performed using linear mixed effects 
models. Data were compared, correcting for multiple comparisons as described by 
Hothorn et al. (2008). Corrected p-values <0.05 were considered to be statistically 
significant. 
 
 
 
 
 
86 
 
 
 
Table 2.2: Taqman® probes used to assess gene expression 
Target Probe ID 
Acta2 Mm01546133_m1 
Col1a1 Mm00801666_g1 
Col3a1 Mm01254476_m1 
Ctgf Mm01192933_g1 
Itga2 Mm00434371_m1 
Itgb8 Mm00623991_m1 
Lox Mm00495386_m1 
Mmp3 Mm00440295_m1 
Dlk1 Mm00494477_m1 
Dpp4 Mm00494548_m1 
Pdgfra Mm00440701_m1 
Thy1 Mm00493681_m1 
Eukaryotic 18S 4332641 
 
 
 
2.4 Results 
2.4.1 Foxd1 was expressed during murine embryonic development 
Using a lineage tracing strategy to track Foxd1 derived populations (schematic shown in 
Figure 2.1A), contribution of this lineage to dermal populations during early development 
was observed (Figure 2.2). Foxd1 expression was assessed in embryos from embryonic 
day (E)9.5-E17.5. Within this time frame, Foxd1 was expressed from E9.5-E11.5 within 
the head and in the dorsal region of the embryo, where it was expressed in proximity to 
the neural tube, both ventrally and laterally. At E14.5, expression was primarily confined 
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to the head, with reduced expression moving posteriorly. No Foxd1 expression was 
detected at E17.5. 
Notably, at E9.5, the earliest stage examined, FLP cells that were negative for Foxd1 
were present within the dorsal tissue of the embryo, suggesting they were derived from a 
population that expressed Foxd1 prior to E9.5. By E14.5 and up to the final stage 
examined of E17.5, it was observed that FLP cells contributed to the cell populations 
within the dermis (Figure 2.2). FLP cells were also evident in several internal organs 
throughout the embryo, including, but not limited to, the kidney, lungs, and with a low 
frequency in the heart (Appendix Figure A2). Within the developing dermis, FLP cells 
were distributed primarily along the midline, dorsal to the neural tube, however, the 
frequency of these cells was decreased in the lateral dermis (Figure 2.3; shown in an 
mTmG reporter as described in Figure 2.1B). Within adult mice, the ventral dermis was 
only sparsely populated by FLP cells, although they remain abundant within the dorsal 
dermis (Figure 2.3C).   
To further define when dermal FLP progenitors express Foxd1 developmentally, a 
tamoxifen-inducible system was utilized to induce recombination at specific intervals and 
investigate down-stream evidence of recombination within the dorsal skin (Figure 2.4A). 
With the exception of tamoxifen injection from E5.5 to E6.5, injection at all other 
intervals yielded tdTomato positive FLP cells within the dorsal dermis at E14.5. A 
difference in the populations labelled between earlier (E7.5-8.5) and late (E10.5-11.5) 
tamoxifen injection was observed. More specifically, while recombined cells were 
identified throughout the developing dermis following earlier injection, later injection 
primarily labelled the most ventral cells in the developing dorsal dermis (Figure 2.4B).  
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Figure 2.2: Foxd1-positive progenitor cells in the developing embryos contributed to 
FLP cells within the developing dermis. During development, Foxd1-GFP-Cre (green) 
was most highly expressed within the head and in the dorsal region, in proximity to the 
neural tube. FLP cells (red) contribute to a range of tissues within the embryo, including 
the dermis. Scale is 1 mm (full embryos). The indicated regions of interest are shown 
below. Yellow arrows indicate examples of GFP positive cells. Scale bar is 500µm. 
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Figure 2.3: FLP cells were most abundant in the medial dorsal skin during 
development and were primarily localized to the dorsal skin of adult mice. Foxd1GC 
mice were crossed with an mTmG reporter (model in Figure 2.1B) to investigate FLP 
(Green) and FLN (Red) contributions to skin during embryonic development and 
adulthood. (A) Sections taken along the sagittal plane were imaged, and those that 
contained the neural tube were stratified as sagittal sections, whereas those that did not 
were considered parasagittal. Scale bars are 200 µm. (B) Axial sections at E14.5 and 
E17.5 showing the dorsolateral quarter of the embryos highlight the contribution of FLP 
cells to the medial dorsal skin, with fewer cells dispersed laterally. The dorsal midline of 
the axial images is indicated by the arrow. Scale bar is 1 mm. (C) Isolated skin from adult 
mice shows minimal contribution of FLP cells to the ventral skin, although they remain 
abundant in dorsal skin. Scale is 1 mm. Representative images from 5 embryos are shown 
for sagittal sections, from 3 embryos for axial sections, and from 3 adult mice for the 
dorsal and ventral sections. 
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Figure 2.4: Dermal FLP progenitors expressed Foxd1 from E7.5 to E11.5. (A) Using 
a Foxd1GCE/Ai14 cross (Figure 2.1C), tamoxifen was injected at different intervals to 
determine when dermal FLP progenitors expressed Foxd1 during development. (B) 
Injection at intervals ranging from E7.5 to E11.5 resulted in recombination, evident by 
the tdTomato positive cells present at E14.5. Scale bars are 500 µm. A minimum of 3 
embryos were observed for each injection regimen. 
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2.4.2 Foxd1-expressing cells are rare in postnatal tissue during homeostasis and 
following wounding 
In adult skin, FLP cells were present throughout the dermis and hypodermis, and 
following wounding were observed in the granulation tissue (Figure 2.5A). To determine 
if postnatal expression of Foxd1 was contributing to the FLP populations observed in 
these tissues, recombination in a tamoxifen inducible Cre model was investigated by 
crossing the Foxd1GCE line with the Ai14 reporter (Figure 2.1C). Using this system, 
tamoxifen was delivered to postnatal mice before and after wounding and a histological 
assessment of recombination was performed (Figure 2.5B).  Low numbers of cells in the 
skin and granulation tissue expressed tdTomato (<0.1%, n=6). This was further supported 
using flow cytometry to detect GFP-Cre positive fibroblasts in healthy adult skin of 
Foxd1GC/Ai14 mice, in which a mean frequency of 0.091% (±0.054%; n=7) of GFP 
positive fibroblasts was measured. Combined with the expression patterns observed 
during embryogenesis, these data suggest that the FLP cells present within the dermis 
were primarily derived from embryonic precursors that expressed Foxd1, and that de 
novo expression of Foxd1 in postnatal dermis during homeostasis and wound healing was 
minimal. 
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Figure 2.5: FLP populations in adult skin and granulation tissue were not derived 
from de novo Foxd1 expression in postnatal tissue. (A) In constitutively active 
Foxd1GC/Ai14 mice, FLP cells (tdTomato positive) are observed throughout the skin and 
granulation tissue. (B) In a tamoxifen inducible model utilizing the Foxd1GCE/Ai14 
cross, tamoxifen injection into postnatal tissue resulted in a low level of recombination, 
resulting in few tdTomato positive cells. (Scale bars are 1 mm). Postnatal injection of 
tamoxifen was performed in 6 mice. 
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2.4.3 Foxd1 lineage-positive cells contributed to diverse populations in adult skin 
To characterize the differentiated populations represented by the Foxd1 lineage, the 
constitutively active Foxd1GC line crossed to the Ai14 reporter was assessed (schematic 
shown in Figure 2.1A). Within the dorsal skin, it was evident from histological 
examination that Foxd1 derived populations were present throughout the dermis and even 
within the panniculus carnosus muscle (Figure 2.5A). To determine more specifically 
which populations these cells were contributing to within the dermis, adult mouse skin 
was labeled with several markers expressed in fibroblasts (vimentin, PDGFRα, PDGFRβ, 
and CD26), the endothelial marker CD31, and the smooth muscle and myofibroblast 
marker αSMA. All of the fibroblast markers explored overlapped with tdTomato 
expression, however tdTomato negative populations were also noted to label for these 
markers (Figure 2.6). Minimal overlap between tdTomato and CD31 was observed, 
suggesting that FLP cells were not a major contributor to the endothelial population. Co-
labelling with αSMA highlighted the contribution of FLP cells to arrector pili muscles as 
well as some of the perivascular αSMA-expressing populations. Furthermore, FLP cells 
were observed in the dermal sheath population surrounding hair follicles (Figure 2.6, 
yellow arrows).  
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Figure 2.6: Foxd1-positive progenitors gave rise to fibroblast, perivascular, and 
arrector pili populations within the adult skin. Unwounded tissue was isolated from 
mice expressing Foxd1GC and Ai14 alleles. Merged images show tdTomato (FLP) in red 
and nuclei are labelled with DAPI in blue. Scale is 100 µm. Representative images are 
shown from 3 mice. White arrows indicate representative cells with dual labeling; yellow 
arrows highlight FLP populations associated with hair follicles.  
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2.4.4 Foxd1 lineage-positive populations contributed to myofibroblasts during wound 
repair 
Next, the contribution of FLP cells to wound healing was investigated using a splinted 
wound model in constitutively active Foxd1GC/Ai14 mice (Schematic in Figure 2.1A). 
At 3 days post wounding, sparse FLP cells were evident throughout the wound bed, with 
a qualitatively higher density observed at the wound edges (Figure 2.7). The density of 
FLP cells within the wound qualitatively increased by 7 days post wounding and again at 
10 days post wounding, remaining relatively consistent up to the final time point of 21 
days post wounding. The FLP cells within the wound tissue contributed to the stromal 
population, as shown by overlap with vimentin, PDGFRα, PDGFRβ, and CD26, as well 
as contributing to the αSMA positive myofibroblast population at day 3 and 10 post 
wounding (Figure 2.8 for day 3; Figure 2.9 for day 10). However, it was evident that the 
FLP population only gave rise to a subset of these populations, with FLN cells also 
contributing. Again, overlap with CD31 was minimal, supporting that this lineage was 
not a major contributor to endothelial cells in the dermis. 
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Figure 2.7:FLP cells contributed to the myofibroblast population during wound 
repair. FLP cells (tdTomato positive) began to appear at 3 days post wounding (dpw) at 
the wound edge (indicated with arrows) and increase in density over time to 10 days post 
wounding, remaining up to 21 days post wounding. Lines indicate the granulation tissue-
epidermal junction. scale bar is 1 mm; n=3-4 mice per time point.  
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Figure 2.8: FLP cells within day-3 granulation tissue co-labelled with fibroblast 
markers. Arrows indicate points of interest, highlighting overlap with fibroblast markers 
and FLP cells (tdTomato positive). CD31 positive endothelial cells were not present 
beyond the edges of the wound at this time. Nuclei are stained with DAPI (blue). Scale 
bars are 100 µm. Representative images are shown from a sample of 3 mice. 
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Figure 2.9: FLP cells within day-10 granulation tissue co-labelled with fibroblast 
markers. FLP cells (tdTomato positive) overlap with staining for fibroblast (vimentin, 
PDGFRα, PDGFRβ, CD26) and myofibroblast (αSMA) markers within the granulation 
tissue. Nuclei are stained with DAPI (blue). Scale bars are 100 µm. Representative 
images are shown from a sample of 4 mice. 
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2.4.5 Foxd1 lineage-positive fibroblasts displayed divergent fibrosis-related gene 
expression patterns during homeostasis and wound repair 
Next, whether the Foxd1 lineage was associated with functional differences within the 
fibroblast population during homeostasis and following wounding was explored using 
gene expression arrays. Wound tissue and unwounded skin surrounding the wound was 
isolated from constitutively active Foxd1GC/Ai14 mice 10 days following wounding. 
Using FACS, a negative selection approach was taken, removing cells positive for 
EpCAM, CD45, or CD31, thereby enriching for the fibroblast population (Figure 2.10A). 
Notably, some of the cells excluded using this strategy did express tdTomato and thus 
could represent epithelial or endothelial populations that were not frequently observed 
histologically. Alternatively, these could represent bone marrow derived populations. The 
fibroblast enriched populations were then sorted into FLP and FLN populations based on 
their expression of tdTomato. No differences in distribution of FLP fibroblasts were 
evident between wounded and unwounded populations (60.0±9.7 vs. 54.1±8.5% FLP 
positive in wounded and unwounded, respectively; p > 0.05). However, a modest increase 
in FLP fibroblast number was observed in the wounded tissue when compared to naïve 
healthy dorsal skin (60.0±9.7% vs. 49.6±6.8; p < 0.05).  
From these populations, the RNA was isolated and gene expression was assessed using a 
PCR array for a pre-selected set of fibrosis related genes. The following genes were not 
consistently detected in any group and were removed from further analysis: Ccl12, Ccr2, 
Fasl, Ifng, Il13, Il4, Il5, Inhbe, Plg, and Serpina1a. Gene expression data was compared 
between lineages within tissue status (i.e. FLP wounded vs. FLN wounded) and between 
tissue status within lineages (i.e. FLP wounded vs FLP unwounded) and differentially 
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expressed genes were selected using a false discovery rate of 10% (Figure 2.10C-D, 
Figure 2.11). For a complete list of comparisons see Appendix Table A1-A4. 
Interestingly, a difference in transcripts enriched in the FLP fibroblasts versus those 
enriched in FLN fibroblasts was noted. More specifically, transcripts associated with 
matrix production and remodeling, including lox, serpinh1, col3a1, dcn, mmp3, and 
mmp14 were enriched in the FLP population. In contrast, the FLN population was 
enriched in transcripts associated with cell signaling, and matrix interaction including 
several integrins, surface receptors, and cytokines. 
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Figure 2.10: FLP fibroblasts and FLN fibroblasts contributed differentially to skin 
homeostasis and wound repair. (A) Fibroblasts were isolated from dorsal wounded and 
unwounded skin from mice 10 days post wounding (n= 8 mice) and from healthy naïve 
skin (n= 9 isolations; 4-6 mice per isolation) and enriched by FACS. Data were analyzed 
with linear mixed effects models; *p<0.05. (B) The frequency of FLP fibroblast 
populations within wounded and unwounded tissue was compared to that of fibroblasts 
isolated from naïve unwounded animals. (C and D) Isolated RNA from wounded and 
unwounded dermal fibroblasts was compared using a Qiagen RT2 Profiler array, and 
transcripts significantly enriched in either FLP or FLN populations are shown. Red bars 
represent transcripts enriched in the tdTomato-positive FLP population, and green bars 
represent those enriched in the tdTomato-negative FLN population. Data were analyzed 
by multiple t-tests and were controlled for multiple comparisons using a false discovery 
rate correction of 10%. 
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Figure 2.11: Gene expression was differentially regulated within cell lineage 
between wounded and unwounded tissue. Isolated RNA from FLP (tdTomato-positive) 
and FLN (tdTomato-negative) dermal fibroblasts was compared using a Qiagen RT2 
Profiler array, and transcripts significantly enriched in either wounded or unwounded 
populations are shown. Yellow bars represent transcripts enriched in the wound 
population, and blue bars represent those enriched in the unwounded population. Data 
were analyzed by multiple t-tests and were controlled for multiple comparisons using a 
false discovery rate correction of 10%. 
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2.4.6 Fibroblast lineage specific differences were not maintained in culture 
To determine whether these populations could be further investigated in a controlled 
culture environment, the effect of culturing on gene expression patterns in cells derived 
from healthy, naïve dermis was explored. Using a type I collagen gel as a compliant 3-
dimensional culture substrate, mRNA levels of a selection of candidate genes identified 
on the array were assessed in FACS-sorted naïve, healthy dorsal dermal fibroblasts 
directly following isolation, and again after 1 week in culture in the presence or absence 
of TGFβ1 (Figure 2.12). The data were analyzed using a linear mixed effects model to 
assess the significance of cell lineage (FLP vs. FLN) and treatment (freshly isolated; 
cultured without TGFβ1; cultured with TGFβ1) as predictors of gene expression. 
Importantly, in this model, cell lineage was determined to be a significant factor in the 
expression of col1a1, itga2, and itgb8 in the freshly-isolated cell populations (p<0.05), 
whereas cell treatment was a significant factor for the expression of all genes. Notably, 
relative expression differences were smaller in these naïve fibroblasts versus those 
isolated from the wound and unwounded tissues. Moreover, for the markers explored, no 
differences were noted between the FLP and FLN lineages following 1 week of culture 
under the conditions in the current study. 
2.4.7 Foxd1 lineage-positive fibroblasts did not mimic expression patterns of previously 
defined lineages 
In addition to assessing these genes above, the expression of a set of markers that have 
been previously shown to define subsets of fibroblasts within the skin was measured. 
Driskell et al. (2013) defined subsets of fibroblasts based on their position within the 
skin, using differential protein expression of Dlk1 and CD26 (gene: Dpp4) (Driskell et al. 
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2013). It has since been confirmed by Philippeos et al. (2018), that the gene expression of 
these markers correlates with their protein expression (Philippeos et al. 2018). 
Furthermore, the Engrailed-1 positive progenitor derived population defined by 
Rinkevich et al. (2015), was enriched in CD26 protein. In humans, expression of DPP4 
was observed to be a defining characteristic of one of two major subsets of dermal 
fibroblasts by single-cell RNA sequencing analysis (Tabib et al. 2018). PDGFRα and 
CD90 (Thy1), have been reported to be widely expressed in dermal fibroblast 
populations, and not differentially expressed in previously-investigated dermal fibroblast 
lineages (Driskell et al. 2013; Rinkevich et al. 2015; Philippeos et al. 2018). To determine 
how FLP and FLN cells related to these predefined fibroblast subsets, these genes were 
assessed in FLP and FLN fibroblast populations (Figure 2.13). Notably, cell lineage did 
not affect the expression of any of these genes in freshly isolated dermal fibroblasts or 
following 7 days in culture, but as with the functional markers assessed above, all of 
these genes were significantly affected by cell culture. Specifically, Dlk1, Pdgfra, and 
Thy1 expression were increased in culture, whereas Dpp4 expression was decreased. 
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Figure 2.12: Gene expression in FLP and FLN fibroblasts was altered in vitro. 
Quantitative PCR was used to assess gene expression in FLP and FLN fibroblasts 
isolated from naïve healthy dorsal skin and following culture on 2 mg/mL type I collagen 
gels with or without treatment with 5 ng/mL TGFβ1 for 1 week. 18S rRNA was used as a 
control. Dorsal skin was pooled from 4-6 mice for each isolation; n=6 independent cell 
isolations. Data were analyzed with linear mixed effects models; * p <0.05; ** p <0.01; 
*** p<0.001. 
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Figure 2.13: Stratification of fibroblasts by Foxd1 lineage did not directly overlap 
with previously characterized dermal fibroblast lineages. Quantitative PCR was used 
to assess gene expression in FLP and FLN fibroblasts isolated from naïve healthy dorsal 
skin and following culture on 2 mg/mL type I collagen gels with or without treatment 
with 5 ng/mL TGFβ1. 18S rRNA was used as a control. Dorsal skin was pooled from 4-6 
mice for each isolation; n=6 independent cell isolations. Data were analyzed with linear 
mixed effects models; ** p <0.01; *** p<0.001. 
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2.4.8 High expression of integrins α2 and α3 was associated with the FLN population 
Although many of the differentially expressed genes code for secreted proteins, several 
integrins were expressed at higher levels in the FLN fibroblasts. As these proteins are 
important mediators of cell-matrix interactions (Koivisto et al. 2014), it was hypothesized 
that differential expression may be at the forefront of lineage differences during 
homeostasis and wound repair. To assess whether these proteins would be useful markers 
and could provide a potential mechanism for the functional diversity of these two 
lineages, their distribution was explored histologically in excisional wounds at 10 days 
after wounding. To visualize both the FLP and FLN populations, a cross between 
Foxd1GC and mTmG reporter mice was assessed (schematic shown in Figure 2.1B). 
Labelling for integrins α2, α3, αV, β1, and β6 showed that they were widely distributed 
throughout the granulation tissue and expressed in both FLP and FLN cells (Figure 2.14 
and 2.16). Using these images, a binary threshold to show only the highest level of 
staining within the stromal tissue was set (Figure 2.15 and 2.17). Interestingly with this 
gating, low levels of overlap between FLP (GFP+) cells and high α2, α3 and β6 integrin 
expression were noted, whereas overlap was more prominent for β1, and αV integrin. 
However, it should be noted that the antibody used to detect β6 integrin has been 
described to have cross-reactivity with murine β1, β2, and β3 integrins. Therefore, the 
observed immuno-labelling may not be specific to β6 integrin, requiring further 
exploration. 
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Figure 2.14: α2, α3, and αV integrin expression in FLP and FLN cells within the 
granulation tissue at day 10 post wounding. Isolated wound tissue from 
Foxd1GC/mTmG mice was cryopreserved and sectioned to 8 µm thickness. Samples 
were fluorescently labelled for integrins (blue) and compared to endogenous fluorescent 
proteins in FLP (green) and FLN (red) populations. Scale bar is 100 µm. 
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Figure 2.15: Binary Thresholding of α2, α3, αV integrins. High expression of alpha-
integrins was observed by setting a binary threshold on staining in Figure 2.14 to select 
for pixels with the highest intensity within the granulation tissue. Thresholding of these 
integrins (blue) resulted in qualitatively low levels of overlap between integrins α2 or α3 
and FLP cells (green). FLN cells are shown in red. Representative images are shown 
from a sample of 6 mice. Scale bar is 100 µm. 
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Figure 2.16: β1 and β6 integrin expression in FLP and FLN cells within the 
granulation tissue at day 10 post wounding. Isolated wound tissue from 
Foxd1GC/mTmG mice was cryopreserved and sectioned to 8 µm thickness. Samples 
were fluorescently labelled for integrins (blue) and compared to endogenous fluorescent 
proteins in FLP (green) and FLN (red) populations. Scale bar is 100 µm. 
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Figure 2.17: Binary Thresholding of β1 and β6 integrins. High expression of beta-
integrins was observed by setting a binary threshold on staining in Figure 2.16 to select 
for pixels with the highest intensity within the granulation tissue. Thresholding of these 
integrins (blue) resulted in qualitatively low levels of overlap between integrin β6 and 
FLP cells (green). FLN cells are shown in red.  Representative images are shown from a 
sample of 6 mice. Scale bar is 100 µm. 
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2.5 Discussion 
Using a lineage tracing approach, embryonic progenitors that differentially expressed 
Foxd1 were investigated and found to give rise to fibroblasts in adult tissue that 
maintained differences. Although the hypothesis that fibroblasts differentiate into stable 
populations with divergent functions has been previously described (Phipps et al. 1989; 
McIntosh et al. 1994), these data support more recent studies showing that these different 
populations arise from unique expression patterns during development (Driskell et al. 
2013; Rinkevich et al. 2015).  
The FLP population described here does not appear to directly overlap with previously-
described embryonic lineages. The Engrailed-1 lineage described in adult mice by 
Rinkevich et al. (2015) and during development by Jiang et al. (2018), has some 
similarities with the Foxd1 lineage, but also exhibits differences. Similar to what was 
observed in the Foxd1 lineage, Jiang et al. described a developmental migratory pattern 
in which progenitors located ventral and lateral to the neural tube migrated into the 
medial dorsal dermis around E10.5, and then began to spread laterally (Jiang et al. 2018). 
However, the Foxd1 lineage represented only ~50% of the dermal fibroblasts in 
unwounded tissue, in comparison to ~70% described by Rinkevich et al. (2015). Further, 
differential gene expression of dpp4 was not detected in the Foxd1 lineage, which was 
upregulated at the protein level in the Engrailed-1 lineage. Regardless, both Foxd1 and 
Engrailed-1 derived populations display an enhanced fibrogenic potential compared to 
their lineage-negative counterparts, and thus likely share a common subset of cells 
specialized in matrix production.  
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The populations described by Driskell et al. (2013) showed distinct spatial localization 
during development and early post-natal growth, which was not identified in the Foxd1 
lineage. Moreover, differential gene expression of Dlk1 and Dpp4, which correspond 
with the reticular and papillary dermal fibroblast populations, respectively, was not 
evident in the populations sorted based on the Foxd1 lineage. Interestingly, the 
differentiation of multipotent progenitors into upper and lower dermal lineages described 
by Driskell et al. occurs around E12.5, which is much later than the patterns observed for 
the Foxd1 lineage. Further, in the inducible Cre model described here, later tamoxifen 
injection from E10.5 to E11.5 yielded recombination primarily in the deep fibroblast 
population by E14.5, whereas earlier injection resulted in a more widely distributed 
population of recombined cells, spread between deep and superficial populations. Thus, it 
is proposed that as cells migrated dorsally into the dermis during development, they 
ceased to express Foxd1.  
In this proposed model, the cells that migrate earlier in development would stop 
expressing Foxd1 earlier and become the most dorsal fibroblasts in the skin, whereas 
those migrating later would have more sustained Foxd1 expression and contribute more 
ventrally within the dermis. The significance of this is that the multipotent progenitors 
described at E12.5 by Driskell et al. could already be predetermined upper or lower 
dermal populations based on positional cues that arise from a temporal switch related to 
their initial migration into the developing dermis. Moreover, the observed stratification of 
the labelled population based on the timing of tamoxifen injection, when combined with 
the work of Driskell et al., suggests that a sub-lineage of FLP fibroblasts are reticular 
FLP fibroblasts, which may be distinct from papillary FLP fibroblasts. As the reticular 
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population was shown to be the primary contributor to granulation tissue formation and 
matrix deposition (Driskell et al. 2013), it would be expected that a reticular FLP lineage 
may be a more specific fibrogenic population of interest. Unfortunately, due to 
complications with tamoxifen injection into pregnant females, a dose that yielded high 
levels of recombination and resulted in live births was not identified, and thus this was 
not pursued further. However, it is speculated based on the tissue architecture during 
early repair, as well as from the findings of Driskell et al., that the FLP fibroblasts that 
migrated into the wound were coming from the lower dermis, and thus the repair process 
was selecting for this reticular sub-population. 
Using histological and gene expression analyses, expression of α-SMA was consistent in 
both cell lineages within the wound, suggesting that myofibroblast activation was similar 
in both groups. Conversely, the differential gene expression patterns suggest that while 
both groups can differentiate into a contractile myofibroblast phenotype, their 
complementary functional specification may be diverse. Importantly, unique expression 
signatures were noted suggesting that the expression of genes associated with matrix 
synthesis and remodeling was enhanced in FLP fibroblasts, while the expression of genes 
associated with cell signaling was enhanced in FLN fibroblasts. In general, it is notable 
that the gene expression changes, especially those upregulated in the FLP subset, were 
subtle, with both populations producing transcripts for ECM synthesis and remodeling. 
Nevertheless, assuming that gene expression would correlate directly with protein 
expression, the 2-fold increase of Col3a1 mRNA detected in the FLP fibroblasts (60% of 
wound fibroblasts) relative to FLN fibroblasts (40% of wound fibroblasts) within the 
wound tissue, would indicate that 75% of the fibroblast-produced type III collagen was 
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generated by the FLP lineage. However, whether a depletion of this population would 
result in reduced collagen production, or whether FLN cells could compensate for this 
loss, would require further investigation. Studies of the greater fibrogenic Engrailed-1 
lineage using diphtheria toxin induced depletion or selective cell transplantation, have 
shown that a reduction of this population reduced scar formation, while enrichment 
enhanced scar formation (Rinkevich et al. 2015; Jiang et al. 2018). Consequently, it 
would be interesting to explore the Foxd1 lineage in these model systems, as it would be 
postulated to have similar functional effects. 
Due to the enrichment of transcripts for cell receptors and signaling molecules present in 
the FLN population, it was proposed that these cells may act as regulators of FLP 
function. However, in order to systematically explore the interactions between the two 
populations, a robust in vitro model system would be required. It is well established that 
culture on stiff substrates results in myofibroblast activation, which can be avoided on 
soft matrices (Hinz 2007; Balestrini et al. 2012). Conversely, culture in 3D matrices 
yields a quiescent, non-proliferative cell state that more closely mimics that of native 
tissue (Erler and Weaver 2009; Rognoni et al. 2018). To first determine if gene 
expression could be maintained in vitro, a compliant collagen gel was used as a culture 
substrate and TGFβ1 was used to selectively stimulate myofibroblast activation. Naïve 
fibroblasts were used rather than the unwounded and wounded populations due to the cell 
yield required. Notably, the gene expression differences in the naïve healthy population 
appeared to be diminished relative to their potentially more activated counterparts 
isolated from unwounded tissue from mice 10 days post wounding that was included in 
the array analysis. Regardless, expression of col1a1, α2 and β8 integrins was determined 
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to be significantly affected by cell lineage in this freshly-isolated population, similar to 
the array findings.  
Using the collagen gel culture system, Col1a1, Col3a1, and Itgb8, all of which were 
expressed at higher levels in freshly isolated FLP fibroblasts compared to FLN 
fibroblasts, were expressed similarly between the groups after culturing. It is well 
established that culture on collagen gels reduces collagen synthesis (Gillery et al. 1992; 
Eckes et al. 1993), which occurs through α1β1 integrin stimulation (Langholz et al. 
1995).  However, treatment with TGFβ1 was still sufficient to upregulate col1a1 
expression in FLP fibroblasts, albeit to a level below that of freshly isolated fibroblasts. 
Thus, the cell culture method explored here resulted in a significant change in the gene 
expression patterns of these populations, inducing a reversion towards a common 
phenotype. In partial contrast to these findings, after culturing human papillary and 
reticular dermal fibroblasts on tissue culture plastic, Philippeos et al. found that while the 
populations did not retain their native differential expression of Wnt-signaling related 
genes, they maintained differences in the expression of inflammatory mediators and 
ECM-related genes including col1a1, and col1a2 (Philippeos et al. 2018). These cells 
also retained functional differences when stimulated with IFNγ. Moreover, in an 
organotypic culture system comprised of decellularized human skin seeded with a 
keratinocyte layer and cultured human fibroblasts from either the papillary or reticular 
dermal populations, both fibroblast populations maintained functional differences 
(Philippeos et al. 2018). While the papillary population migrated physically closer to the 
keratinocyte layer, and induced the formation of rete ridges and a thicker keratinocyte 
layer, the reticular population did not show preferential migration to the keratinocyte 
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layer or induce these structural changes (Philippeos et al. 2018). Thus, even though gene 
expression was altered in the culture system investigated, functional differences may be 
retained. Potentially, use of an organotypic culture system as employed by Philippeos et 
al. could be useful to study cell function in a more biologically relevant model. 
Finally, in this study the differential expression of several integrins between cell lineages 
was observed. As these proteins are pivotal for the interaction between cells and the ECM 
(Koivisto et al. 2014), they are interesting candidates for future exploration that may 
represent an integral cell intrinsic difference that mediates cell phenotype. Transcripts for 
Itga2, Itga3, Itgb6, and Itgb8 were all significantly enriched in the FLN fibroblasts in 
both wounded and unwounded tissue. Integrin α2β1 is a collagen I- and III-binding 
integrin which supports collagen fibril formation and is involved in collagen gel 
contraction (Eckes et al. 2006; Koivisto et al. 2014). Integrin α3β1, is a laminin-binding 
integrin. Interestingly, in alveolar epithelial cells α3β1 integrin was shown to mediate 
non-canonical TGFβ1 signaling via Smad-2 phosphorylation of β-catenin, a process that 
the authors linked to epithelial to mesenchymal transition (EMT) (Kim et al. 2009). 
Importantly, lineage tracing studies have suggested that resident stromal cells are the 
major contributors to myofibroblasts in lung fibrosis, while support for EMT as a source 
of myofibroblasts is not as strong (Rock et al. 2011; Bartis et al. 2014). Whether a similar 
mechanism resulting in integrin α3β1-mediated non-canonical TGFβ1 signaling takes 
place in the stromal population within the skin would be of interest.  Both integrin β6 and 
β8 dimerize with integrin αV and are strongly linked to activation of TGFβ1 signaling 
(Hinz 2015). Depletion of integrin αV in PDGFRβ-expressing cells protected against 
fibrosis in models of hepatic, renal, and pulmonary fibrosis (Henderson et al. 2013). It 
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was, however, surprising to observe expression changes in integrin β6, as it has primarily 
been reported in epidermal cells (Koivisto et al. 2014). This finding could indicate that 
there were contaminating keratinocytes within the sorted population, a potential 
limitation associated with using a negative selection-based approach for cell sorting. 
Although histological analysis supported that integrin β6 was expressed within the 
stromal population in the skin, this labelling could be associated with the described cross-
reactivity of the antibody with other integrins, including β1, β2, and β3 integrins. As 
such, the current findings regarding the expression of β6 integrin within the dermis are 
inconclusive. Alternatively, this may suggest that β6 integrin has previously 
unrecognized roles within the dermal fibroblast population, but this requires further 
exploration. 
Interestingly, as highlighted above many of the reported functions of these integrins 
support that they can modulate myofibroblast activation and function. Thus, a potential 
model for the interaction of FLP and FLN populations is one in which the FLP cells 
specialize as a matrix secreting population, whereas the FLN cells play a more supportive 
role, regulating the FLP population through growth factor secretion and activation. Future 
studies should focus on the further analysis of these integrins with techniques such as 
flow cytometry to confirm the integrin expression patterns and levels. 
2.6 Conclusions 
Using a Cre/Lox-based lineage tracing approach, an embryologically distinct fibroblast 
lineage, arising from Foxd1-expressing progenitors was characterized. This population 
migrated into the dermis during early development and contributed to the stromal 
population in adult skin. In adult skin, gene expression analysis suggested that these FLP 
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cells specialize in matrix synthesis and remodeling during homeostasis and wound repair. 
In contrast, gene expression patterns in Foxd1 lineage-negative populations suggests 
these cells may play a more supportive role associated with increased gene expression of 
cell surface receptors, integrins, and cytokines. Overall, the gene expression differences 
in the FLP and FLN populations support a functional heterogeneity between these 
populations during homeostasis and tissue repair within the skin. Further functional 
characterization of FLP and FLN fibroblasts and their interactions could provide insight 
into novel mechanisms through which to modulate wound repair in cases of impaired 
healing, such as in chronic wounds or excessive scarring. 
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Chapter 3: The role of Galectin-3 in cell 
recruitment and differentiation during wound 
healing 
A version of this chapter has been published: 
Walker, J.T., Elliott, C.G., Forbes, T.L., Hamilton, D.W. (2016) The role of Galectin-3 in 
cell recruitment and differentiation during wound healing. J Invest Dermatol. 136 (5): 
1042-1050 
3.1 Abstract: 
Galectin-3 has been linked to the regulation of several molecular processes essential for 
acute cutaneous wound healing, but a comprehensive study of the role of Galectin-3 in 
skin healing has not previously been performed. With described roles in macrophage 
polarization, myofibroblast differentiation, re-epithelialization, and angiogenesis, it was 
hypothesized that genetic deletion of Galectin-3 would significantly impair healing of 
excisional skin wounds in mice. In wild-type mice, Galectin-3 expression correlated 
temporally with the inflammatory phase of healing. Genetic deletion of Galectin-3 did 
not alter gross wound healing kinetics even though delayed re-epithelialization was 
evident. Neither inflammatory nor mesenchymal cell infiltration or cell phenotype were 
altered up to 15 days post-wounding in knockout mice in comparison with healing in wild 
type mice, and isolated dermal fibroblast function in vitro was unchanged. The 
expression of Galectin-3 was further explored spatially in human chronic wound tissue in 
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relation to the immune cell infiltrate. Decreased mRNA expression and protein 
immunoreactivity in the wound edge tissue was observed, whereas markers of 
neutrophils, M1 and M2 macrophages were expressed abundantly. Both transforming 
growth factor-β1 and tumor necrosis factor-α decreased Galectin-3 at the transcript level 
in human chronic wound edge dermal fibroblasts in vitro, providing a potential 
mechanism for this reduced expression in chronic wounds. 
3.2 Introduction: 
Impaired skin healing represents a clinically significant problem associated with vascular 
insufficiency, diabetes, and increasing age (Nelson and Bradley 2007; Sen et al. 2009). 
Although the underlying etiology of non-healing skin wounds is complex, it is 
established that the tissue remains in a proinflammatory state (Schultz and Wysocki 
2009; Widgerow 2011; Demidova-Rice et al. 2012). Gaining an understanding of the 
molecular mechanisms involved in the persistence of the inflammatory state and of the 
associated paracrine effects of prolonged inflammation on the resident cell populations 
will be central to strategies to stimulate wound closure.  
Implicated in several cellular processes associated with the inflammatory and 
proliferative phases of wound healing, Galectin-3 is a multifunctional lectin, consisting of 
a carbohydrate recognition domain, with a unique N-terminal repeat region in comparison 
to other galectins (Barondes et al. 1994). Galectin-3 has been implicated in initiating 
macrophage polarization into the anti-inflammatory wound healing related M2 phenotype 
(MacKinnon et al. 2008). In addition, it has been demonstrated to function as a 
chemotactic molecule for the recruitment of M2 macrophages in mouse tumors (Jia et al. 
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2013). Galectin-3 is highly expressed in M2 macrophages (Novak et al. 2012) and has 
been shown to play a major role in phagocytosis of opsonized cells (Sano et al. 2003; 
Karlsson et al. 2009), including neutrophils. This process is critical for terminating 
inflammation, preventing further tissue destruction (Karlsson et al. 2009). As chronic 
wounds are enriched with proteases and proinflammatory cytokines (Wiegand et al. 
2010), an improved understanding of proteins involved in regulating these responses, 
including Galectin-3, would be of significance.  
Temporally overlapping with the inflammatory phase, skin wounds progress into the 
proliferative phase of healing, where mesenchymal cells infiltrate and secrete 
extracellular matrix (Singer and Clark 1999). Several studies have implicated Galectin-3 
in fibrotic processes, including hepatic (Henderson et al. 2006; Jiang et al. 2012), renal 
(Henderson et al. 2008), and pulmonary (MacKinnon et al. 2012) fibrosis, suggesting that 
it may play a role in the pro-fibrotic proliferative phase of wound healing as well. 
Interestingly, pulmonary fibroblasts isolated from Galectin-3 knockout (KO) mice 
display impaired myofibroblast differentiation and reduced type I collagen synthesis in 
vitro (MacKinnon et al. 2012). In addition to its role in modulating the myofibroblast 
phenotype, Galectin-3 has been linked to angiogenesis, a critical process during skin 
healing (Reinke and Sorg 2012). Exogenous Galectin-3 has been shown to enhance 
endothelial cell tube formation in vitro, and a Galectin-3 null breast cancer cell line was 
only able to induce angiogenesis in vivo if the cells were transfected with Galectin-3 
cDNA (Nangia-Makker et al. 2000). Additionally, Galectin-3 loaded microbeads 
implanted into mouse corneas induced an angiogenic response (Markowska et al. 2010), 
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further demonstrating the potential role of Galectin-3 during the processes underlying the 
proliferative phase of healing.  
One study that explored the influence of Galectin-3 deletion on skin healing showed 
delayed re-epithelialization due to impaired epidermal growth factor receptor trafficking 
upon activation (Liu et al. 2012). However, evidence clearly suggests that Galectin-3 may 
play significant roles in skin repair, beyond re-epithelialization. It was hypothesized that 
alterations in the inflammatory and proliferative phases of skin healing would manifest in 
Galectin-3 KO mice. Secondarily, Galectin-3 expression was assessed in human non-
healing skin wounds and compared to the inflammatory cell infiltrate using markers of 
neutrophils and macrophages. 
 
3.3 Materials and Methods: 
3.3.1 Mice 
All animal procedures were in compliance with protocols approved by the University 
Council on Animal Care at Western University (protocol number 2008-097). Galectin-3 
KO (B6.Cg-Lgals3tm1Poi/J; 006338) mice were purchased from The Jackson Laboratory 
(Farmington, CT). These mice were crossed once with wild type (WT) C57BL/6J mice, 
also from The Jackson Laboratory (000664), to produce heterozygous offspring. 
Heterozygotes were set up into breeding pairs to generate homozygous Galectin-3 KO 
and sex-matched WT littermates. Mice were genotyped per The Jackson Laboratory’s 
instructions (Figure 3.1). 
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3.3.2 Excisional wounding experiments 
For all in vivo experiments, 6-mm full-thickness excisional wounds were created as 
previously described (Elliott et al. 2012). Mice were euthanized, and tissue was isolated 
at 1, 3, 5, and 7 days after wounding. For closure kinetics, wounds were photographed 
with a digital camera at baseline, and days 3, 5, and 7 after wounding, using a ruler to 
standardize the image dimensions. ImageJ software (Schneider et al. 2012) was used to 
calculate the wounded area. 
 
 
 
Figure 3.1: Electrophoresis following PCR of DNA isolated from Galectin-3 KO, 
wild type and heterozygous mice. Lanes from left to right: TrackIt™ 1Kb Plus DNA 
ladder (Thermo Scientific); Galectin-3 KO DNA, wild type DNA, heterozygous DNA. 
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3.3.3 Patient samples 
All tissues were collected with written, informed consent from patients under protocols 
approved by the Western University Review Board for Health Sciences Research 
Involving Human Subjects (HREB #16245E). Isolation and experimental use of dermal 
fibroblasts from human tissue were approved by the Western University Review Board 
for Health Sciences Research Involving Human Subjects and are in accordance with the 
1964 Declaration of Helsinki. Direct RNA analysis of Galectin-3 was performed on 15 
patients. Histological analysis was performed in 9 patients, and in vitro cell experiments 
were performed on cells isolated from 4 patients (see Appendix Tables A5, A6, and A7 
for relevant information). 
3.3.4 Histology 
Human and mouse tissues were fixed in 10% neutral buffered formalin and either 
processed to paraffin or into Frozen Section Compound (VWR, Mississauga, ON, 
Canada). Sections 5 µm thick were cut from paraffin blocks or 8 µm from frozen blocks. 
Colorimetric staining was performed using ImmPress HRP anti-mouse and anti-rabbit 
detection kits (Vectorlabs, Burlingame, CA), and a 3,3’-diaminobenzidine peroxidase 
substrate kit (Vectorlabs). In all cases, a minimum of three mice were used from each 
genotype. Nine human wounds were assessed for immune cell infiltration and fibrotic 
response. Blood vessel and immune cell quantification in mice were performed using 
ImageJ software (Schneider et al. 2012). Histological wound measurements were 
performed on Masson’s trichrome-stained sections from 9 WT and 8 Galectin-3 KO 
mice. Wound diameter was measured as the distance between the unwounded dermis in 
sections taken from the center of the wounds. Epithelial tongue length was measured as 
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the distance from the tip of the epithelial tongue to the unwounded dermis. Average 
epithelial tongue thickness was approximated by the equation:
area of epithelial tongue
length of epithelial tongue
 . For 
a list of antibodies used for these experiments, see Table 3.1. 
3.3.5 Hydroxyproline assay 
Mouse skin tissue was isolated from the wound bed 15 days after wounding using a 
biopsy punch, and hydroxyproline content was measured using the Hydroxyproline 
Assay Kit (Sigma-Aldrich, Oakville, ON, Canada) following protocol instructions. Tissue 
was pooled from two wounds from each animal. 
3.3.6 Human primary fibroblast culture and mouse primary fibroblast culture 
Dermal fibroblasts were isolated from humans and mice using the explant culture 
technique previously described (Rittié and Fisher 2005). Cells were grown in DMEM 
(Thermo Fisher Scientific, Burlington, ON, Canada) supplemented with 10% fetal bovine 
serum. Fibroblasts were used from passage 1 (human cells) or at passage 3 (mouse cells) 
for experiments. 
 
 
 
 
 
 
139 
 
A version of this chapter was published in the Journal of Investigative Dermatology 
Table 3.1: Primary antibodies used for immunohistochemistry and western blot. 
Staining Antibody 
used 
Supplier Dilution 
Galectin-3 (human) SC-374253 Santa Cruz Biotechnology, Dallas, 
TX 
1:400 
Galectin-3 (mouse; 
colorimetric) 
SC-20157 Santa Cruz Biotechnology, Dallas, 
TX 
1:500 
Galectin-3 (mouse; 
fluorescence) 
eBioM3/38 eBioscience, San Diego, CA 1:50 
Mannose Receptor Ab64693 Abcam, Cambridge, MA 1:1000 
Indolamine 2,3-
dioxygenase 
Ab55305 Abcam, Cambridge, MA 3:1000 
Neutrophil elastase Ab68672 Abcam, Cambridge, MA 1:2000 
αSMA (mouse) Ab5694 Abcam, Cambridge, MA 1:100 
Vimentin Ab92547 Abcam, Cambridge, MA 1:500 
CD146 Ab75769 Abcam, Cambridge, MA 1:200 
NOS2 Ab3523 Abcam, Cambridge, MA 1:50 
Arginase I SC-18354 Santa Cruz Biotechnology, Dallas, 
TX 
1:100 
GAPDH (western 
blot) 
MAB374 Millipore, Billerica, MA 1:1000 
αSMA (western 
blot) 
A5228 Sigma Aldrich, Oakville, ON 1:1000 
 
3.3.7 Cytokine treatment 
Isolated fibroblasts were seeded into a six-well plate in DMEM containing 10% fetal 
bovine serum at a density of 100,000 (human) or 50,000 (mouse) cells per well in a 6-
well plate. After 24 hours, cells were transferred into serum-free DMEM for an additional 
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24 hours. Then to the respective wells 5 ng/mL transforming growth factor β1 (TGFβ1) 
(R&D Systems, Minneapolis, MN) and 1 ng/mL TNFα (R&D Systems) were added and 
samples were incubated for 24 hours (RNA analysis) or 48 hours (protein analysis). 
Untreated controls were cultured in serum-free DMEM without cytokine treatment. All 
experiments were run in triplicate. A dose response to TGFβ1 was performed in the 
presence of 0-5 ng/mL TGFβ1 with or without the ALK5 inhibitor SB431542 (10 µM). 
3.3.8 RNA isolation and real-time quantitative PCR 
RNA was isolated with TRIzol reagent (Thermo Fisher Scientific) and purified using 
RNeasy mini kits (Qiagen, Valencia, CA). Taqman real-time PCR was performed using 
qSCRIPT XLT one-step real-time quantitative PCR ToughMix (Quanta Biosciences, 
Gaithersburg, MD) per the manufacturer’s instructions. All samples were run in triplicate 
and relative quantity measurements were determined from a standard curve. mRNA 
quantity was normalized to endogenous 18S rRNA (Thermo Fisher Scientific). See Table 
3.2 for a list of probes used. Location of non-involved, proximate, wound edge, and 
wound bed tissues in mice are demonstrated in Figure 3.2.  
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Table 3.2: Taqman® probe sets used for RT-qPCR. 
Transcript Probe identification 
LGALS3 (Human) Hs00173587_m1 
Lgals3 (Mouse) Mm00802901_m1 
Acta2 Mm00725412_s1 
Col1a2 Mm00483888_m1 
Kdr Mm01222421_m1 
Lgals1 Mm00839408_g1 
Lgals7 Mm00456135_m1 
18S rRNA 4352930E 
 
3.3.9 Protein isolation and western blot 
Protein isolation and western blots were performed as previously described (Elliott et al. 
2012). Primary antibodies were applied to the membrane overnight in 5% milk tris 
buffered saline with 0.05% tween 20. Membranes were incubated in Alexafluor 680 
conjugated goat anti-mouse (Thermo Fisher Scientific) and visualized with an Odyssey 
infrared imager (LI-COR, Lincoln, NE). 
3.3.10 In vitro scratch wound assay 
Isolated mouse fibroblasts were seeded into a six-well plate at a density of 150,000 cells 
per well in DMEM with 10% fetal bovine serum. Cells were allowed to adhere for 24 
hours before being scratched with a sterile pipette tip. Images were taken every 20 
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minutes until the scratches closed. The average distance traveled by the cell front was 
calculated every 200 minutes. All experiments were run in triplicate. 
3.3.11 Gel contraction assay 
Isolated mouse fibroblasts were seeded into 20% collagen type I solution at a density of 
50,000 cells/mL. Then 1 mL of this solution was placed into each well of a 24-well 
culture plate. After 45 minutes, a pipette tip was used to separate the polymerized gel 
from the culture plastic, and DMEM with 0.5% fetal bovine serum was added to each 
well with or without 5 ng/mL TGFβ1. After an additional 24 hours, the gels were 
removed, dabbed dry, and weighed to assess the extent of gel contraction. Each sample 
was run in triplicate. 
3.3.12 Statistical methods 
Statistical analyses were performed using R statistics software (R core team 2017), the 
“nlme” package for linear and nonlinear mixed effects models (Pinheiro et al. 2014), and 
the “multcomp” package for simultaneous inference in general parametric models 
(Hothorn et al. 2008) were used. GraphPad Prism software version 5 (GraphPad, La Jolla, 
CA) was used to produce graphs. Statistical analyses were performed using a t-test or 
linear mixed effects models as appropriate. As necessary, a Tukey post hoc test was used. 
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Figure 3.2: Location of tissue isolated for mRNA expression in mice. Red- Non-
involved, green- proximate, yellow- wound edge, blue- wound bed. 
 
3.4 Results: 
3.4.1 Galectin-3 mRNA and protein were up-regulated after excisional wounding and 
peaked 1 day after wounding 
Analysis of Galectin-3 expression profiles during cutaneous wound healing in wild-type 
(WT) mice showed Lgals3 (gene coding Galectin-3) mRNA levels were significantly 
greater in the wound bed compared to non-involved tissue at day 1 (p = 0.020), but no 
significant differences were evident 3 or 7 days after wounding (Figure 3.3a). 
Histological examination of Galectin-3 protein showed expression in both the epidermis 
and dermis of unwounded skin, and within the wound bed up to 7 days after wounding 
(Figure 3.3b). Immunohistochemical labeling at days 3 and 7 (Figure 3.3c and 3.3d, 
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respectively) displayed that at 3 days, Galectin-3 showed a high degree of overlap with 
arginase I -positive cells (M2 macrophage marker), many of which were also positive for 
NOS2 (M1 macrophage marker). However, NOS2-positive cells that were negative for 
arginase I did not co-express Galectin-3. At day 3, α-smooth muscle actin (αSMA) and 
CD146 (expressed in endothelial cells and pericytes (Li et al. 2003)) were primarily 
confined to blood vessels in the deep wound bed and edges, and little overlap with 
Galectin-3 labeling was observed. In contrast, vimentin was expressed throughout the 
wound bed and showed some overlap with Galectin-3 (Figure 3.3c). The trends at day 7 
were similar (Figure 3.3d). Galectin-3 was present primarily in arginase I-positive cells 
with lesser overlap with vimentin and αSMA noted. 
3.4.2 Genetic deletion of Galectin-3 impaired re-epithelialization but did not alter 
wound closure kinetics during excisional healing in mice 
To assess differences in the rate of wound closure between Galectin-3 KO and WT mice, 
wound size based on gross appearance was assessed up to 7 days after wounding, at 
which time the tissue was analyzed histologically. No difference in gross closure kinetics 
was evident between genotypes (p = 0.92; Figure 3.4a), nor was there a difference in 
wound diameter in day 7 wounds measured histologically (p = 0.068; Figure 3.4c). 
However, Galectin-3 KO mice displayed an impaired length of epithelial tongue (p = 
0.023; Figure 3.4b and 3.4d) and a decreased percent of re-epithelialization (p = 0.0018; 
Figure 3.4e), without any change in epithelial thickness by 7 days after wounding (p = 
0.38; Figure 3.4f). 
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Figure 3.3: Galectin-3 expression peaked in the inflammatory phase and remained 
present into the proliferative phase, primarily expressed in arginase I-positive cells. 
6-mm, full-thickness skin wounds were inflicted into the backs of WT and Galectin-3 KO 
mice. (a) Lgals3 expression was quantified in tissue from 1 to 7 days post wounding 
using quantitative PCR. Values are given as mean ± standard deviation. Four mice per 
time point. *p < 0.05; **p < 0.01. (b) Tissue isolated from unwounded skin and at 3 and 
7 days post wounding was subjected to histological analysis of Galectin-3 expression. 
Bar = 200 µm. WB, wound bed; WE, wound edge. Co-staining of tissue isolated at (c) 
day 3 and (d) day 7 after wounding shows overlap of Galectin-3 primarily in arginase I-
positive cells and in cells expressing vimentin. Bar = 50 µm. 
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Figure 3.4: Genetic deletion of Galectin-3 did not affect gross wound closure but did 
impair the rate of re-epithelialization by 7 days post wounding. (a) Wound size was 
measured up to 7 days post wounding in 6-mm wounds from 13 knockout (KO) and 12 
sex-matched wild-type (WT) littermates. Representative wounds are shown in the side 
panel in a KO mouse and its sex-matched littermate pair at 0, 3, 5, and 7 days post 
wounding (top to bottom). Bar = 5 mm. Data are expressed as mean ± standard deviation. 
(b) Masson trichrome-stained sections were examined for the epithelial tongue length and 
thickness, and wound size (bar is 1 mm). (c) KO mice displayed a similar granulation 
tissue diameter to WT mice (P=0.068). (d) KO mice displayed impaired length of the 
epithelial tongue and (e) an impaired percent of re-epithelialization at 7 days post 
wounding, but no change in the epithelial thickness was noted (f). Eight KO and nine WT 
mice were quantified from histological sections. Data are expressed as mean ± standard 
deviation. *p < 0.05; **p < 0.01. 
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3.4.3 Genetic deletion of Galectin-3 did not affect immune cell infiltration, 
myofibroblast recruitment, or vascular density during wound repair 
As impaired re-epithelialization in Galectin-3 KO mice has been previously described 
(Liu et al. 2012), whether Galectin-3 deletion influenced inflammation, fibrosis, or 
angiogenesis was explored. Using antibodies specific for NOS2 (M1 polarization), 
arginase I (M2 polarization), and neutrophil elastase (neutrophils), no significant 
differences in macrophage abundance or phenotype or in neutrophil number within the 
wound bed were evident between genotypes at day 3 (Figure 3.5). Histological analysis 
of day 7 wounds demonstrated that both genotypes showed a similar expression pattern 
for αSMA (Figure 3.6a). Using CD146 expression as a marker for neovasculature, no 
differences in vessel density or vessel size were observed (Figure 3.6a). Analysis of 
granulation tissue with Masson’s trichrome or Van Gieson stains at day 7 showed dense 
collagen within the unwounded tissue (Figure 3.6b, arrows) and areas of collagen 
deposition in the wound bed of both WT and KO animals. Analysis of tissue composition 
at day 15 showed that collagen content and αSMA levels were similar in KO and WT 
mice (Figure 3.5d). Hydroxyproline assays at 15 days after wounding confirmed similar 
levels of collagen in the wounds in both genotypes (Figure 3.6c).  
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Figure 3.5: Genetic deletion of Galectin-3 did not affect the immune cell infiltrate by 
3 days post wounding. Arginase I, NOS2, and neutrophil elastase (NE) were examined 
histologically from whole wounds, 3 days post wounding and quantified. Bar = 50 µm. 
Five wild-type (WT)/Galectin-3 knockout (Gal3KO) sex-matched littermate pairs were 
analyzed. 
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Figure 3.6: Genetic deletion of galetin-3 did not affect wound composition at 7 and 
15 days post wounding. (a) Histological staining of Galectin-3 confirmed deletion of 
Galectin-3 in KO mice, whereas there was no change in αSMA staining. Bar = 500 µm. 
The density and average size of CD146-labeled blood vessels were quantified in seven 
KO and five WT mice. Bar = 50 µm. (b) Masson’s trichrome- and Van Gieson-stained 
sections of day 7 wounds. Arrows show the edge of the wounds. Bar = 500 µm. (c) 
Masson’s trichrome and αSMA staining of day 15 wounds and relative hydroxyproline 
content measured in day 15 wounds. Bar =500 µm. Hydroxyproline content was 
measured in three sex-/age-matched WT/Gal3KO pairs. 
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3.4.4 Genetic deletion of Galectin-3 did not alter transcriptional regulation of genes 
associated with fibrotic repair or angiogenesis 
Next, quantitative PCR was performed on RNA isolated from non-involved, proximate, 
wound edge and wound bed tissues in mice 7 days after wounding (Figure 3.7a-f). 
Expression of Lgals3 was significantly lower in wound edge tissue compared to the 
proximate tissue in WT mice (p < 0.001; Figure 3.7a). Acta2 expression was up-regulated 
in the wound bed compared to all other tissues in both WT (p < 0.001) and KO (p < 
0.001) mice (Figure 3.7b). Col1a2 was not differentially expressed between genotypes, 
nor was its expression different between tissue locations (Figure 3.7c). Expression of 
Kdr, the gene for vascular endothelial growth factor receptor 2 as a marker of 
angiogenesis (Shih et al. 2002), was differentially expressed in the various tissue 
locations but was not different between genotypes (Figure 3.7d). Next, whether other 
galectin family members were upregulated to compensate for Galectin-3 deletion was 
assessed. Neither galectin-1, which shares functions with Galectin-3 (D’Haene et al. 
2013; Jin Lim et al. 2014), nor galectin-7, which is linked to wound re-epithelialization 
(Cao et al. 2002), were significantly altered between genotypes in wound tissue 7 days 
after wounding (Figure 3.7e and f). 
3.4.5 Galectin-3 was not required for the transition of dermal fibroblasts to 
myofibroblasts in vitro 
Whether Galectin-3 expression in mouse dermal fibroblasts is required for myofibroblast 
differentiation was assessed. Addition of 5 ng/mL TGFβ1 caused down-regulation of 
Galectin-3 in WT cells (p < 0.001; Figure 3.8a) but up-regulation of Acta2 in both WT (p 
< 0.001) and Galectin-3 KO (p < 0.001) dermal fibroblasts. No significant differences 
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between genotypes was evident (p = 0.74; Figure 3.8b). Both Galectin-3 KO and WT 
dermal fibroblasts contracted collagen gels after TGFβ1 treatment (Figure 3.8c), with 
αSMA stress fibers present in KO and WT cells (Figure 3.9). In vitro scratch wound 
assays identified no significant difference in migration rates between WT and Galectin-3 
KO fibroblasts (p = 0.66; Figure 3.8d). 
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Figure 3.7: Transcript abundance of genes associated with fibrotic response and 
revascularization were unchanged by Galectin-3 KO, 7 days post wounding. RNA 
was isolated from non-involved (NI), proximate (P), wound edge (WE), and wound bed 
(WB) tissues, 7 days post wounding, and quantified using quantitative PCR. Transcripts 
for fibrotic response genes Acta2 and Col1a2, and the vascular gene Kdr, were measured 
alongside Lgals3 and its related family members Lgals1 and Lgals7. Tissues were 
isolated from four sex-matched KO/WT pairs. Data are expressed as mean ± standard 
deviation. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Figure 3.8: Galectin-3 KO mouse dermal fibroblasts did not have impaired function 
in vitro. Cells from 4 independent fibroblast isolations from WT mice and their sex-
matched Galectin-3 KO littermates were treated with 5 ng/mL TGFβ1 for 24 hours prior 
to RNA isolation for RT-qPCR analysis of Lgals3 (a), and Acta2 (b). (c) A free collagen 
gel contraction assay in fibroblasts isolated from 4 wild type and 4 Galectin-3 KO mice 
was conducted with or without the addition of 5 ng/mL TGFβ1. (d) An in vitro scratch 
wound assay was set up using dermal fibroblasts isolated from 5 WT and 4 Galectin-3 
KO mice and the average distance travelled by the cell front was measured. Values 
represented as mean ± SD. ***p<0.001. Black bars indicate WT dermal fibroblasts, white 
bars indicate Galectin-3 KO dermal fibroblasts. 
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Figure 3.9: WT and Galectin-3 KO mouse dermal fibroblasts formed αSMA stress 
fibers following TGFβ1 treatment. WT and Galectin-3 KO mouse fibroblasts were 
treated with 5ng/mL TGFβ1 and stained for αSMA protein (green). Nuclei were labelled 
with DAPI (blue). Scale bar is 100µm. 
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3.4.6 Galectin-3 mRNA and protein were decreased in human non-healing skin wound 
tissue 
As human chronic wounds remain in a prolonged inflammatory state, the subsequent 
studies focused on assessing Galectin-3 expression in human nonhealing wounds (Figure 
3.10). Galectin-3 protein was observed in the epithelium in non-involved skin, but 
immunoreactivity decreased in tissue approaching the wound bed, with a lesser, variable 
immunoreactivity evident in the wound bed, as reported previously by our group (Pepe et 
al. 2014). In areas where Galectin-3 expression was low, large numbers of neutrophils 
were observed. Conversely, M1 macrophages (indolamine 2,3-dioxygenase positive 
cells) (Taylor and Feng 1991; Jaguin et al. 2013) and M2 macrophages (mannose 
receptor-positive cells) (Martinez et al. 2006; Madsen et al. 2013) were present in both 
areas of high and low Galectin-3 expression (Figure 3.10a and 3.10b). Transcript levels 
of Galectin-3 were significantly lower in the wound edge and proximate tissues than in 
non-involved tissues (30.9% of non-involved, p < 0.001, and 59.7% of non-involved, p = 
0.0027, respectively; Figure 3.9c), and expression in the wound edge was significantly 
lower than the proximate tissue (p = 0.048). 
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Figure 3.10: Galectin-3 expression was decreased in human chronic wound tissue 
and was negatively correlated with neutrophil elastase expression. (a) Histological 
analysis of Galectin-3, neutrophil elastase, mannose receptor, and indolamine 2,3-
dioxygenase in the wound edge of human chronic wounds shown for 5 of 9 total patients 
examined. Bars = 1 mm. (b) High-magnification images of staining in the wound bed of 
patient M56. Bar = 100 µm. (c) Quantification of LGALS3 gene expression in 15 patients 
after lower extremity amputation in non-involved, proximate, and wound edge tissues. *p 
< 0.05; **p < 0.01; ***p < 0.001. See Tables A6 and A7 for relevant patient information. 
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3.4.7 Galectin-3 expression in dermal fibroblasts from human wounds was modulated 
by TGFβ1 and tumor necrosis factor-α 
The human dermal fibroblast response to the M1 and M2 cytokines, tumor necrosis factor 
(TNF)-α, and TGFβ1, respectively, was subsequently investigated (Figure 3.11). 
Addition of TGFβ1 significantly decreased LGALS3 expression in chronic wound edge 
human dermal fibroblasts (p < 0.001) but did not significantly decrease expression in the 
non-involved fibroblasts of the same patients (p = 0.63). Similarly, TNFα only reduced 
LGALS3 expression in the wound edge fibroblasts (p = 0.032) but not in the non-involved 
fibroblasts (p = 0.996). A combination of both cytokines had a similar effect to TNFα 
alone (p = 0.016 wound edge; p = 1.00 non-involved). Importantly, there was also a trend 
toward an interaction effect between the tissue of origin and the treatment variables (p = 
0.051), suggesting fibroblasts from the wound edge responded differently to these 
cytokines than cells from non-involved tissue.  
The strong inhibitory effect of TGFβ1 on LGALS3 expression in wound edge fibroblasts 
was inhibited with the ALK5 inhibitor SB431542, and there was a significant interaction 
effect between the inhibitor and cytokine treatment variables (p = 0.016). To confirm that 
changes in LGALS3 transcript levels translated into decreased protein expression, western 
blot analysis for Galectin-3 protein levels showed a decrease in the presence of TGFβ1 (p 
< 0.001), TNFα (p = 0.0015), and a combination of both (p = 0.0045) at 48 hours after 
treatment. Since the change in αSMA expression of dermal fibroblasts in response to 
TGFβ1 and TNFα has been well described (Goldberg et al. 2007), its expression was 
explored to determine whether wound edge fibroblasts shared this response. As expected, 
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TGFβ1 significantly increased αSMA expression (p < 0.001), which could be blocked 
with the addition of TNFα (p = 0.020). 
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Figure 3.11: Regulation of Galectin-3 expression in human non-involved and wound 
edge dermal fibroblasts by TGFβ1 and TNFα. (a) Fibroblasts isolated from non-
involved and wound edge tissues from patients with chronic wounds were subjected to 
combinations of 5 ng/mL TGFβ1 and 1 ng/mL TNFα for 24 hours. Cells isolated from 
four patients were used. (b) Dose response of wound edge dermal fibroblasts was 
performed from 0-5 ng/mL with or without addition of 10 µM of the ALK5 receptor 
inhibitor SB431542 for 24 hours. Cells isolated from five patients were used. (c) Effect of 
TGFβ1 and TNFα on Galectin-3 and αSMA protein content within wound edge 
fibroblasts was measured by western blot after 48 hours of stimulation. Cells isolated 
from four patients were used. Data are expressed as mean ± standard deviation. *p < 
0.05; **p < 0.01; ***p < 0.001. 
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3.5 Discussion: 
In this study, Galectin-3 KO mice displayed impaired re-epithelialization 7 days after 
wounding, supporting previous work in dermal (Liu et al. 2012) and corneal healing (Cao 
et al. 2002). However, this was not concomitant with a significantly impaired rate of 
wound closure determined by gross examination. Wound closure in mice is heavily 
influenced by contraction and less so by re-epithelialization (Wong et al. 2011); thus, 
inhibition of re-epithelialization is possibly not great enough to manifest in significantly 
delayed closure in this model.  
As impaired re-epithelialization in Galectin-3 KO mice was previously characterized, 
roles of Galectin-3 in inflammation, granulation tissue synthesis, angiogenesis and wound 
contraction were investigated. In WT mice Lgals3 expression was up-regulated during 
inflammation peaking at day 1, similar to previous findings in rats (Gál et al. 2011). 
Galectin-3 was expressed primarily in arginase I-positive cells and has previously been 
linked to phagocytosis of neutrophils by macrophages (Sano et al. 2003; Karlsson et al. 
2009), M2 macrophage polarization (MacKinnon et al. 2008), and macrophage 
infiltration (Jia et al. 2013). As such, a decrease in M2 macrophage abundance in KO 
animals was expected, with increased neutrophil presence. However, similar numbers of 
arginase I-positive cells were observed within Galectin-3 KO mice compared to WT 
mice, suggesting that while Galectin-3 may help promote M2 macrophage polarization in 
vitro (MacKinnon et al. 2008), it is not necessary for M2 polarization in vivo during acute 
healing. It has also been suggested that macrophage polarization in vivo is more complex 
than findings described in vitro (Sica and Mantovani 2012), as supported by the current 
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data showing inflammatory cells simultaneously expressing NOS2 and arginase I in both 
WT and KO animals.  
It is possible that other proteins compensated for loss of Galectin-3, although assessment 
of galectin-1 and galectin-7 showed neither gene was significantly up-regulated in the 
absence of Galectin-3. However, basal expression of the proteins may be sufficient for 
compensation. Alternatively, non-family member proteins may compensate for its 
deletion. Since wound healing requires aspects associated with fibrosis (Wynn 2008; 
Johnson and Di Pietro 2013), the milder phenotype evident in Galectin-3 KO mice during 
renal (Henderson et al. 2008), hepatic (Henderson et al. 2006), or lung (MacKinnon et al. 
2012) fibrosis suggested Galectin-3 KO mice would display impaired fibrotic responses 
after wounding. However, no differences in collagen deposition nor changes in αSMA 
gene or protein expression in vivo in Galectin-3 KO mice were measured. Significantly, 
in vitro, the KO dermal fibroblasts treated with TGFβ1 showed no differences in αSMA 
gene expression, ability to contract a collagen gel, or incorporation of αSMA into stress 
fibers compared to WT cells. This is in contrast to Galectin-3 KO pulmonary fibroblasts, 
which showed impaired myofibroblast differentiation and decreased collagen expression 
in response to TGFβ1 (MacKinnon et al. 2012). These findings suggest that there are 
intrinsic differences between these two fibroblast populations. This interpretation is 
corroborated by the in vitro findings showing decreased Galectin-3 expression in 
response to TGFβ1 in WT dermal fibroblasts, again opposing results with pulmonary 
fibroblasts (MacKinnon et al. 2012). Therefore, the profibrotic role of Galectin-3 appears 
highly tissue and cell specific, which is also evident with respect to its proangiogenic 
properties (Markowska et al. 2010, 2011; Nangia-Makker et al. 2010).  
163 
 
A version of this chapter was published in the Journal of Investigative Dermatology 
Previous studies have shown that Galectin-3 increases the surface expression of vascular 
endothelial growth factor receptor 2 (VEGFR2) (Markowska et al. 2011) and levels of 
vascular endothelial growth factor (VEGF) in macrophages (Machado et al. 2014), 
stimulating angiogenesis. However, no differences were observed in gene expression for 
Kdr between the mouse genotypes included in the current study, although Kdr was up-
regulated in the wound bed and wound edge tissues at 7 days post wounding compared to 
unwounded skin. Furthermore, no significant differences in vessel density or average 
vessel size were noted within the granulation tissue at 7 days post wounding.  
Although Galectin-3 expression is involved in the development of pulmonary, renal, and 
hepatic fibrosis in mouse models (Henderson et al. 2006, 2008; Jiang et al. 2012; 
MacKinnon et al. 2012), loss of expression did not impair the pro-fibrotic proliferative 
phase of dermal wound healing. While all of these processes involve the accumulation 
and activation of myofibroblasts from their respective myofibroblast progenitor pools 
(Hinz et al. 2012), it is evident that the mechanism through which these myofibroblast 
progenitors perceive environmental signals is different. This is exemplified by the 
differences between mouse primary pulmonary fibroblast observed by MacKinnon et al. 
(2012), and mouse primary dermal fibroblasts observed here. Cultured Galectin-3 KO 
pulmonary fibroblasts were unable to upregulate αSMA or type I collagen in response to 
TGFβ1 in vitro as was observed for WT pulmonary fibroblasts, and genetic deletion of 
Galectin-3 was protective against bleomycin induced pulmonary fibrosis (MacKinnon et 
al. 2012). Conversely, dermal fibroblasts upregulated αSMA gene expression to the same 
extent as WT fibroblasts in response to TGFβ1 in culture and incorporated αSMA into 
stress fibers. Moreover, hydroxyproline content of the wound tissue at 15 days post 
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wounding was not different between WT and Galectin-3 KO mice. Thus, while both lung 
and dermal fibroblasts can differentiate into myofibroblasts, subtle intrinsic differences 
exist in the mechanism through which this differentiation occurs, highlighting a level of 
heterogeneity between these two distinct myofibroblast progenitor populations. 
Since human chronic wounds remain in a state of inflammation, the decrease in Galectin-
3 expression within the wound bed compared to non-involved tissue was unexpected, 
opposing what was observed in WT mice during initial inflammation. Importantly, in 
human chronic wound tissue, expression of M1 and M2 macrophage markers appeared to 
be independent of Galectin-3 expression, whereas neutrophil elastase was negatively 
correlated with Galectin-3 expression. Although neutrophils provide an effective 
response to eliminate invading pathogens, they are not required for cutaneous healing and 
even delay wound re-epithelialization (Dovi et al. 2003). Given that Galectin-3 mediates 
phagocytosis of neutrophils by macrophages after neutrophil apoptosis (Karlsson et al. 
2009), there may be a link between decreased Galectin-3 expression and impaired re-
epithelialization in chronic wounds. Although Galectin-3 KO mice displayed impaired 
re-epithelialization, no difference was measured in neutrophil abundance. Despite the fact 
that genetic deletion of Galectin-3 did not affect wound closure in mice, human chronic 
wounds tend to develop both in the elderly (patients ≥65 years account for 72% of 
pressure ulcers) (Sen et al. 2009) and in diabetic patients (accounting for approximately 
two-thirds of lower limb amputations) (Sen et al. 2009). Thus, in presence of underlying 
co-morbidities, it is possible that low Galectin-3 expression in the wound bed may be one 
part of the complex etiology leading to the persistence of chronic wounds in humans.  
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With respect to the regulation of Galectin-3 expression in fibroblasts, both TGFβ1 and 
TNFα were shown to reduce Galectin-3 expression in human dermal fibroblasts isolated 
from the wound edge of human chronic wounds, but not the non-involved fibroblasts. 
This fits with trends that our group has reported previously (Elliott et al. 2015), 
suggesting that chronic wound fibroblasts, although not able to function appropriately in 
vivo, respond strongly to certain stimuli in vitro. Since many fibrotic diseases correlate 
with high Galectin-3 levels (Henderson et al. 2008; Jiang et al. 2012; MacKinnon et al. 
2012) and TGFβ1 is a potent inducer of a fibrotic phenotype in fibroblasts (Desmouliere 
et al. 1993), reduced Galectin-3 expression in response to TGFβ1 was unexpected. The 
current findings confirmed that chronic wound fibroblasts still respond appropriately to 
TGFβ1, as evidenced through their up-regulation of αSMA. Moreover, the same response 
was demonstrated in WT mouse dermal fibroblasts, supporting that the response was not 
species or disease-state specific.  
Overall, the data show that the peak level of Galectin-3 mRNA associates with acute 
inflammation and that expression may be decreased after injury by the combined effects 
of TNFα and TGFβ1. It must also be mentioned that Galectin-3 is involved in the 
degradation of advanced glycation end products (AGEs) in human tissue, which is 
particularly important in diabetic individuals (Pugliese et al. 2014). Previous studies by 
our group showed that AGEs are inversely correlated with Galectin-3 expression in 
human chronic wounds (Pepe et al. 2014). Therefore, Galectin-3 expression may also be 
regulated differentially in these tissues through alternative mechanisms associated with 
advanced glycation end products.  
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3.6 Conclusions: 
Through analysis of gene expression and histological parameters, no detectable wound 
healing specific phenotype was observed in the Galectin-3 KO mice other than a reduced 
rate of re-epithelialization, as previously reported (Liu et al. 2012). Consistent with these 
findings, Galectin-3 KO fibroblasts showed no notable deficits in the in vitro assays 
performed in the current study as compared to their WT counterparts.  
In contrast to the increased expression of Galectin-3 during the inflammatory phase of 
healing relative to uninjured tissue in mice, human chronic wounds under-expressed 
Galectin-3 relative to patient-matched uninjured tissue, even though chronic wounds 
remain in a prolonged inflammatory state (Demidova-Rice et al. 2012). In isolated human 
chronic wound fibroblasts, Galectin-3 was down-regulated by both TGFβ1 and TNFα, 
both of which are expressed within human chronic wound tissue (Elliott et al. 2015), 
providing a potential mechanism for this difference. While the effects of genetic deletion 
of Galectin-3 in an acute wound model were mild, further investigation in an impaired 
model of healing, such as a diabetic mouse, could elucidate unrealized roles of this 
protein during wound repair. 
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Chapter 4: Profibrotic and pro-angiogenic 
biomaterials to induce cell recruitment and 
differentiation during skin healing  
 
4.1 Abstract: 
Chronic wounds place a major burden on the health care system and have severe 
consequences for those affected. While current advanced therapy options, including skin 
grafts and engineered skin/dermal substitutes, improve healing over standard care alone, 
they do not lead to complete healing in over half of patients treated. There is a desperate 
clinical need to improve upon existing therapeutics for the treatment of chronic wounds. 
The extracellular matrix provides not only mechanical support for cells but also contains 
many biological signals that regulate cell function. Understanding and utilizing these 
biological signals will be an important step in advancing wound care therapeutics. 
Previous experiments in the Hamilton lab identified a positive effect of biomaterials 
containing the matricellular proteins Periostin and CCN2 on wound closure in a diabetic 
mouse model; moreover, preliminary work presented here identified a similarly positive 
effect of decellularized adipose tissue-derived biomaterials on healing of wounds in 
diabetic mice. In the present study, porous foams fabricated from bovine type I collagen 
both with and without Periostin and CCN2 were investigated using an acute wound 
model in healthy pigs in comparison to similar scaffolds fabricated using human 
decellularized adipose tissue as the source material. A subset of each scaffold type was 
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also seeded with allogeneic porcine adipose-derived stem/stromal cells to assess the 
potential of the scaffolds as a cell delivery platform for wound healing. Scaffolds 
synthesized for this study could be easily customized in terms of size and shape, were 
easy to handle, and integrated well into the granulation tissue. Assessment of wound 
closure kinetics highlighted a modest delay in wounds treated with any foam biomaterial 
relative to untreated wounds, but did not alter the total time to heal. Histological 
parameters including inflammatory, mesenchymal, and vascular cell infiltration were not 
substantially altered by treatment with biomaterials in this model system. This study 
provides important baseline data for future investigation into models of impaired porcine 
wound healing. 
4.2 Introduction: 
Chronic wounds are classified based on their underlying etiology, and include pressure 
sores, venous ulcers, arterial ulcers, and diabetic ulcers (Demidova-Rice et al. 2012b; 
Frykberg and Banks 2015). Despite arising from disparate underlying pathologies, 
chronic wounds share common pathophysiological features, including a prolonged and 
excessive immune response, persistent infections, vascular insufficiency, and an inability 
to regenerate dermal and epidermal tissue (Armstrong et al. 1998; Valencia et al. 2001; 
Demidova-Rice et al. 2012b; Frykberg and Banks 2015). Combined, chronic wounds are 
a serious problem both clinically and economically (Sen et al. 2009; Frykberg and Banks 
2015). In Canada, in 2011, diabetic foot ulcers alone affected 25,597 patients, costing 
$547 M to treat (Hopkins et al. 2015).  
Chronic wounds are commonly secondary to vascular insufficiency at both the macro- 
and micro-vascular level (Li et al. 2017). Macrovascular surgeries and therapeutic 
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compression remain common practices to improve macrocirculation in affected limbs 
(Demidova-Rice et al. 2012b; Baltzis et al. 2014). Microvascular complications which 
can arise from ischemia-reperfusion injury and diabetes related complications, are more 
difficult to treat, but a highly vascularized granulation tissue is an important clinical 
target for chronic wound treatment (Mustoe et al. 2006; Demidova-Rice et al. 2012a; 
Powers et al. 2016; Li et al. 2017; Valencia and Florez 2017). In addition to poor 
microvascular circulation, human chronic wounds are also associated with a prolonged 
inflammatory state, with decreased fibroblast migration and proliferation impairing 
transition into an appropriate proliferative phase (Baltzis et al. 2014). Therefore, it is 
hypothesized that therapeutics that can improve wound microcirculation, as well as 
increasing fibroblast proliferation and activation, would be beneficial for transitioning 
from the inflammatory phase to the proliferative phase of healing.  
Previous studies in our laboratories have investigated two different approaches to 
creating biomaterials to improve the angiogenic and fibrogenic properties during tissue 
regeneration. First, biomaterials synthesized from bovine type I collagen, both with and 
without recombinant human matricellular proteins, Periostin and connective tissue 
growth factor (CCN2), were investigated. Periostin is a key regulator of myofibroblast 
differentiation (Elliott et al. 2012; Walker et al. 2016), and CCN2 has pro-fibrotic and 
pro-angiogenic effects (Hall-Glenn and Lyons 2011). Both proteins are upregulated 
during the fibrotic phase of acute wound repair in humans and mice, but are repressed in 
human chronic wounds (Elliott et al. 2015) and in wounds of diabetic mice (Elliott et al. 
2018). Previous work by our group showed that the delivery of Periostin or CCN2 
significantly increased the angiogenic and profibrotic responses during wound healing in 
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a diabetic mouse model of impaired healing (Elliott et al. 2018). While these studies were 
performed on materials synthesized through electrospinning, the present work 
investigated a foam biomaterial approach. This method enabled the fabrication of highly 
porous scaffolds designed for enhanced stability and better integration, which could be 
easily customized for shape and size, and did not require chemical cross-linking to 
maintain the biomaterial structure.  
As a comparison to the collagen-based foams, compositionally more complex porous 
foams synthesized from the extracellular matrix isolated from human adipose tissue were 
also investigated. These decellularized adipose tissue (DAT)-derived foams were 
previously found to be pro-angiogenic following subcutaneous implantation in immune-
competent rats (Yu et al. 2013). A recent proteomics study by our group has identified a 
massive array of structural and non-structural proteins present within DAT, including 
collagens, matricellular proteins, proteoglycans, glycoproteins and signaling molecules 
(Kuljanin et al. 2017). While collagen-based materials with incorporated Periostin and 
CCN2, and DAT-based scaffolds are compositionally distinct, they both hold potential as 
pro-regenerative biological wound dressings based on previous studies.  
Although the mouse is the most widely-used model to study dermal healing, the structure 
and physiology of murine skin differs significantly from human skin (Wong et al. 2011; 
Zomer and Trentin 2018). More specifically, mouse skin is thinner and more compliant, 
has an additional muscle layer (the panniculus carnosus), lacks rete ridges, and is affected 
by changes in the hair growth cycle. Unfortunately, these differences have impacted the 
translation of therapeutics from mice into humans (Sullivan et al. 2001). In contrast, 
porcine skin is more structurally similar to that of humans and studies have suggested that 
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it may be more translationally relevant (Sullivan et al. 2001). More specifically, a review 
investigating more than 180 studies across 25 different wound therapeutics showed that 
only 53% of wound healing studies in small mammals correlated with those in humans in 
terms of their effects on the rate of wound closure, whereas porcine models showed a 
stronger correlation of 78% (Sullivan et al. 2001).  
As an exploratory study to assess safety and compatibility, acute dorsal wounds in 
healthy juvenile pigs were treated with the biomaterials described above and the tissue 
response was assessed during the early proliferative stage at 7 days post-wounding, and 
during the remodelling phase at 28 days post-wounding. In addition to their potential as 
off-the-shelf pro-regenerative biological wound dressings, the foam biomaterials tested 
could be applied as carriers for cell therapies. In particular, mesenchymal stem/stromal 
cell (MSC) treatment is a promising therapeutic strategy for the treatment of human 
wounds (Falanga et al. 2007). Adipose-derived MSCs (ASCs) are an abundant population 
that can be harvested from tissues that would otherwise be discarded as medical waste. 
Supporting the selection of ASCs, novel lineage tracing data has suggested that 
adipogenic fibroblast lineages contribute to myofibroblast populations that play a role 
during wound healing, and in fibrotic disease (Driskell et al. 2013; Marangoni et al. 2015; 
El Agha et al. 2017). Furthermore, perivascular populations, a major source of MSCs 
across organs (Crisan et al. 2008), have been shown to naturally contribute to 
myofibroblasts during fibrotic injury in many organs including kidney, liver, lungs, heart, 
and bone marrow (Kramann et al. 2015; Schneider et al. 2017). Whether exogenous 
ASCs would contribute to wound closure through differentiation into myofibroblasts is 
unknown; however, much of the promise of ASCs lies in their paracrine capacity 
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including the potential to modulate the immune response towards a more pro-
regenerative state, and induce angiogenesis (Nuschke 2014; Bateman et al. 2018).Within 
the context of this study, ASCs can be obtained in abundance from pigs (Williams et al. 
2011), allowing for a clinically relevant allogeneic transplant model. As such, the 
potential of the foam biomaterials as an allogeneic cell delivery platform was probed at 7 
days post-wounding.  
The biomaterials investigated in this study have been reported to display pro-angiogenic 
and pro-fibrotic potential during tissue regeneration. In this study, we hypothesized that 
treatment with these biomaterials would improve the rate of wound closure and 
correspond with increased myofibroblast activation and enhanced angiogenesis within the 
granulation tissue compared to untreated wounds. Furthermore, we hypothesized that 
seeding these biomaterials with ASCs would be an effective strategy to deliver cells into 
the granulation tissue. 
 
4.3 Materials and methods: 
4.3.1 Synthesis of bovine type I collagen and DAT foams 
Bovine type I collagen, purified from tendon (BTC) was purchased from Advanced 
Biomatrix and was minced in-house prior to further processing. Human decellularized 
adipose tissue was isolated from discarded tissue samples collected with informed 
consent from elective lipo-reduction procedures (HREB #105426) and pooled from 5 
donors, as previously described (Flynn 2010). Lyophilized forms of these materials were 
rehydrated, treated with α-amylase to improve solubility and suspended in acetic acid, as 
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previously described (Yu et al. 2013). Foams used for the mouse pilot study were 
synthesized using 200 µL of 25 mg/mL suspended DAT or BTC loaded into a 48-well 
plate. For foams used in the porcine study, 1.5 mL of 15 mg/mL suspended DAT or BTC 
was transferred into a circular mold of 2 cm diameter. Loaded molds were frozen at -
20ºC prior to lyophilization. Representative images of the final rehydrated foams used in 
the porcine study are shown below in Figure 4.1. For the addition of Periostin and CCN2, 
following rehydration, BTC foams were soaked in a solution of 500 µL phosphate 
buffered saline (PBS) containing 2.6 µg/mL of Periostin (Human; R&D Systems) and 2.6 
µg/mL CCN2 (Human; R&D Systems) overnight at 4ºC. For treatment, foams were 
warmed prior to implantation. 
4.3.2 db/db mouse model 
As DAT foams had not previously been tested in a wound application, an initial pilot 
study was designed to explore their potential efficacy and physical suitability in a db/db 
mouse model of type II diabetes. All animal work was performed in accordance with 
protocols approved by the University Council on Animal Care at the University of 
Western Ontario, following the guidelines of the Canadian Council on Animal Care 
(protocol # 2016-085). The dorsal skin of 8 db/db mice (B6.BKS(D)Leprdb/J, 000697, 
JAX) was wounded using a 6 mm biopsy punch. Wounds were filled with electrospun 
collagen scaffolds, DAT foams (cut to an 8 mm diameter) or were left untreated. Closure 
was monitored over time and wound size was measured from photographs using ImageJ 
software (Schneider et al. 2012). Four of the animals were euthanized at 3 days post 
wounding, and the remaining 4 euthanized at 7 days post wounding. 
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Figure 4.1: DAT and BTC foams. Scale bar in the top frame is 5 mm; scale bar in the 
bottom frame is 1 cm. 
 
4.3.3 Porcine wound model 
Nine 3-month-old male farm pigs (Landrace and Yorkshire backgrounds) from two 
different cohorts, were observed up to either 7 days post wounding (n=3) or 28 days post 
wounding (n=6), at which time the animals were euthanized, and the tissue collected for 
analysis (animal use protocol # 2017-082). Eight (day 7 cohort), or five (day 28 cohort) 2 
cm diameter, circular full thickness excisional wounds were made in the dorsal skin using 
a custom punch biopsy. These wounds were either left untreated (2 untreated controls in 
the 28-day cohort), or treated with 2 stacked 2 cm diameter foam biomaterials from each 
treatment group: (i) purified type I collagen isolated from bovine tendon (BTC), (ii) BTC 
loaded with Periostin and CCN2 (PN/CCN2), or (iii) human DAT.  The four remaining 
wounds in the 7-day cohort were used to assess porcine ASC-seeded BTC, 
BTC+PN/CCN2, and DAT foams relative to an additional untreated control. Only five of 
the six pigs in the 28-day cohort were treated with BTC+PN/CCN2 foams; all six pigs 
received each other treatment. Wounds were covered in a semi-occlusive dressing 
(Tegaderm™; 3M) and bandaged. Bandages were replaced as required. For the 7-day 
cohort, wounds were photographed starting at day 3, whereas those in the 28-day cohort 
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were first photographed for assessment of closure on day 7-12. Wound size was 
normalized to a ruler and measured using ImageJ software (Schneider et al. 2012).  
4.3.4 Histological assessment 
Immediately after euthanasia, tissue samples were collected. One quarter of the wound 
was frozen on dry ice for assessment of hydroxyproline content, and the remaining tissue 
was fixed in neutral buffered formalin. Tissues were dehydrated for cryopreservation 
using a sucrose gradient and embedded in Frozen Section Compound (Leica). 
Cryosections were cut to a thickness of 8 µm. Antigen retrieval was performed in all 
samples using 1% SDS in PBS for 5 minutes. Blocking was performed with horse serum 
and primary antibodies used are shown with dilutions in Table 4.1. Coverslips were 
mounted with VectaShield mounting media with DAPI (Vectorlabs).  
For all measurements, only the viable granulation tissue was quantified, and not the 
eschar or the undegraded biomaterials. Quantification of staining was performed using 
macros in ImageJ software. For fluorescence quantification, 2-5 full depth vertical 
regions of interest with a width of one field of view (~1.4 mm) were measured for each 
wound. For blood vessel quantification, a minimum size threshold was set to 100 pixels 
(~100 µm2) to prevent quantitation of non-vascular structures. CD68 and CD163 staining 
were each thresholded for a minimum size of 10 pixels and a maximum size of 500 pixels 
(~10-500 µm2). Cross-sectional wound diameter was measured from the junction of the 
unwounded dermis, the hypodermis, and the granulation tissue as a clear landmark. For 
all staining performed large vertical regions of interest are shown in the body of this 
chapter. For higher magnification images of each staining performed, please see 
Appendix Figure A3-A7. 
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Table 4.1: Antibodies for histological assessment 
Target Antibody Dilution 
CD146 Ab75769 (Abcam) 1:500 
αSMA A5228 (Sigma-Aldrich) 1:1000 
Vimentin Ab92547 (Abcam) 1:500 
CD68 Ab125212 (Abcam) 1:100 
CD163 MCA2311GA (Bio-rad) 1:100 
 
4.3.5 Hydroxyproline assay 
From each frozen wound and unwounded tissue sample, a section of tissue spanning the 
entire depth of the wound was removed (20-70 mg wet weight). These pieces were 
lyophilized prior to acid hydrolysis in 6 M HCl at 120ºC for 3 hours. Measurement of 
hydroxyproline content was performed using the Hydroxyproline Assay Kit (Sigma-
Aldrich) following the protocol instructions. Measured hydroxyproline content was 
normalized to tissue wet weight.  
4.3.6 Porcine ASC isolation and tri-lineage differentiation 
Dorsal, subcutaneous adipose tissue was harvested from four male donor pigs at ~3 
months of age. The tissue was minced in a sterile environment, and then digested with 2 
mg/mL collagenase type I (Sigma). The digested suspension was filtered through a 250 
µm pore size stainless steel mesh and allowed to gravity settle to allow removal of the 
floating adipocyte layer through aspiration. Red blood cells were removed using an 
ammonium chloride lysis buffer. The resultant cell population was seeded onto culture 
flasks and cultured at 39ºC, 5% CO2, in DMEM/Ham’s F-12 media (Sigma) with 10% 
fetal bovine serum (FBS; VWR) and 1% penicillin/streptomycin (PS; Gibco). Media was 
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changed every 2-3 days, and cells were cultured for 3 passages at which time they were 
frozen and stored in liquid nitrogen. Assessment of tri-lineage differentiation and scaffold 
seeding was performed using passage 4 cells. For differentiation, control populations 
were cultured in non-inductive proliferation media consisting of the base media plus 10% 
FBS and 1% PS. In all cases, cells were cultured at 39ºC with 5% CO2. 
Adipogenic differentiation was carried with slight modifications to that described by 
Hauner et al. and as previously published by Dr. Flynn (Hauner et al. 2001; Flynn 2010). 
Cells seeded at a density of 50,000 cells/cm2 were treated with DMEM/Ham’s F-12 
media with 3% FBS, supplemented with 33 µM biotin, 17 µM pantothenate, 66 nM 
human insulin, 1 nM triiodothyronine, 10 µg/mL transferrin, 100 nM hydrocortisone, 1 
µg/mL Troglitazone, 250 µM 3-isobutyl-1-methylxanthine (IBMX), and 1% PS. After 3 
days, the troglitazone and IBMX were excluded from the formulation. Cells were 
cultured for 14 days, with media changes every 2 days. Staining with oil red O dye was 
used to assess the formation of intracellular lipid droplets at 14 days.  
Chondrogenic differentiation was carried out on 250,000 cells, pelleted by centrifugation 
(5 minutes; 400 g) in the bottom of 15 mL conical tubes. These pellets were cultured in 
DMEM (Gibco), supplemented with 10% FBS, 50 µg/mL ascorbate-2-phosphate, 10 
ng/mL TGFβ1, 6.25 µg/mL insulin, 100 nM dexamethasone and 1% PS. Media was 
changed every 2 days, and differentiation was assessed after 28 days. Cell pellets were 
frozen, cryosectioned, and collagen types I and II were observed by immunofluorescence 
(Ab90395, Ab34712; Abcam).  
Osteogenic differentiation was carried out at a seeding density of 20,000 cells/cm2 using 
αMEM (Gibco) supplemented with 10% FBS, 50 µM ascorbate-2-phosphate, 10 mM β-
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glycerophosphate, 10 nM dexamethasone, and 1% PS. Matrix mineralization was 
assessed with von Kossa staining at 28 days. 
4.3.7 ASC labelling and seeding 
Passage 4 ASCs were labelled with PKH26 (Sigma-Aldrich) as per the manufacturer’s 
instructions. Hydrated, sterilized 2 cm diameter foam biomaterials were placed 
individually into a 50 mL vented conical tube (Corning), and seeded with 1.5 x 106 ASCs 
in 3 mL DMEM/Ham’s F-12 culture media with 10% FBS, and 1% PS at 39ºC with 5% 
CO2. The tubes were angled at 20-30º and placed on a rotating table set at 100 rpm, for 
16 hours at 39ºC. The scaffolds were then removed and placed in a 12-well plate for 
static culture for 2 additional days of static culture. All scaffolds were then transferred 
into DMEM/Ham’s F-12 with 1% FBS on the evening prior to implantation. 
Matricellular proteins were added, at the concentrations described above, to seeded 
scaffolds in this final solution, to allow infiltration into the scaffold overnight. The 
following day, the seeded foam biomaterials were implanted into wounds, 2 scaffolds per 
wound as described for the unseeded scaffolds. Untreated wounds were left empty, and 
did not receive biomaterials or ASCs. 
 
4.3.8 Statistical methods 
Statistical analyses were performed using R statistics software (R core team 2017). Db/db 
mouse wound closure, all histological analyses, and hydroxyproline content were 
assessed using linear mixed effects models with the “nlme” (Pinheiro et al. 2014), and the 
“multcomp” package for simultaneous inference in general parametric models (Hothorn 
et al. 2008). Statistical comparisons were made within each treatment group between day 
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7 and day 28, and at both the 7- and 28-day time points, comparisons were made between 
each treatment group and the untreated control as the standard of care but were not made 
between different biomaterials groups due to the limited sample size. The values for the 
unwounded tissue were plotted for comparative purposes but were excluded from 
statistical analyses. Wound size measurements were estimated linearly at non-measured 
intervals for each pig, and this complete data set was used to fit the data to a regression 
model. Specifically, a basis spline function was used to fit the data to a regression curve, 
allowing estimation of wound size and variability between measured data. This was 
performed in R using the Companion to Applied Regression, “car” (Fox and Weisberg 
2011), and Functional Data Analysis in R, “fda” (Ramsay et al. 2017) packages. 
Comparisons of these data were made with a 2-way ANOVA, and multiple comparisons 
were assessed using Dunnett’s test comparing to untreated wounds as the control. The 
raw size measurements used in the regression analysis are included in Appendix Figure 
A8. 
 
4.4 Results: 
4.4.1 DAT foams increased the rate of wound closure in db/db mice 
Initial testing of the DAT foams was performed in a pilot study investigating wound 
closure up to 7 days post-wounding in a db/db mouse model of impaired wound healing. 
Treatment with 25 mg/mL DAT foams resulted in improved wound closure in 
comparison to untreated wounds, as well as those treated with electrospun bovine type I 
collagen scaffolds (Figure 4.2). Importantly, further investigation in wild-type mice 
revealed that the DAT foams fabricated at this concentration could be excluded from the 
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wounds over time by the cellular infiltrate. To address this issue, more porous 15 mg/mL 
foams were selected for future testing in the porcine model, following confirmation of 
improved integration through pilot testing in wild-type mice.    
4.4.2 Addition of foam biomaterials into 2 cm diameter wounds in the dorsal skin of 
pigs induced a delay to the rate of healing, but did not alter the time to complete 
closure 
Following the pilot study in mice, influence of each biomaterials on wound closure was 
assessed in a porcine model. The treatment of a wound with any biomaterial significantly 
delayed wound closure relative to untreated wounds (Figure 4.3). Notably, in the 7-day 
cohort, where wound size was measured more frequently within the first week compared 
to the 28-day cohort, the wound size was similar between days 3 and 7 in the wounds 
treated with each of the biomaterials (Figure 4.4). In contrast, the untreated wounds 
showed a more linear pattern of wound closure, with a significant reduction in size from 
day 3 to 7 (p < 0.05). However, the total time to heal did not change, with all wounds 
being completely closed by the day 28 end-point (Figure 4.3B).  
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Figure 4.2: DAT foams improved healing in diabetic mice compared to untreated 
wounds and electrospun collagen scaffold control treatment. 6 mm diameter punch 
biopsies were taken from the dorsal skin of db/db mice. Photographs were taken to 
monitor wound size over time and measured using ImageJ software. (n=8, days 0 & 3; 
n=4, days 5 & 7); data were analyzed with linear mixed effects models; * p<0.05; ** 
p<0.01, *** p<0.001. 
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Figure 4.3: Addition of foam biomaterials into excisional wounds in the dorsal skin 
of pigs decreased the rate of wound closure. Foam biomaterials were added to fill 2 cm 
diameter excisional wounds in the dorsal skin for each treatment group (1 wound per 
treatment per pig; n=5-6 pigs for each treatment group) or were left untreated (untreated; 
2 wounds per pig; n=6 pigs). (A) Photographs were taken over the course of the healing 
process. Scale bar is 1 cm. (B) Wound size was measured and then fit using a basis-spline 
function to compare closure kinetics of each treatment group to that of untreated wounds 
(solid lines indicate means; dashed lines indicate standard deviation; n=4 pigs for 
PN/CCN2 treated wounds; n=5 for all other groups). The range in which each treatment 
significantly differed from the untreated group was determined with a two-way ANOVA 
using the fitted data and each treatment group was compared to the untreated control 
group with a Dunnett’s post hoc test.  
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Figure 4.4: The rate of wound closure within the first week of healing was reduced 
in wounds treated with biomaterials. Wound size was measured and then fit using a 
basis-spline function to compare closure kinetics of each treatment group to that of 
untreated wounds (solid lines indicate means; dashed lines indicate standard deviation; 
n=3 pigs). Scale bar is 1 cm. The range in which each treatment significantly differed 
from the untreated group was determined with a two-way ANOVA using the fitted data 
and each treatment group was compared to the untreated control group with a Dunnett’s 
post hoc test.  
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4.4.3 Foam biomaterials did not alter the contractile or fibrotic phenotypes of the 
wounds 
To assess whether the delayed closure of the wounds treated with biomaterials resulted in 
decreased wound contraction, the wound diameter was measured in histological cross-
sections in the middle of the wounds after 7 and 28 days (Figure 4.5A). All wounds, 
regardless of treatment, contracted to approximately 60% of their 2 cm original diameter 
by 28 days without any differences noted between treatment groups and untreated 
controls. Furthermore, the collagen content in the granulation tissue was similar as 
assessed through measurement of hydroxyproline content (Figure 4.5B) and visualized 
with Masson’s trichrome staining in histological sections at 7 days (Figure 4.5C) and 28 
days (Figure 4.5D; Appendix Figure A3).  
It is noteworthy that the foam biomaterials remained within the wound throughout the 
experiment, and were infiltrated by cells; however, by day 7 variable amounts of scaffold 
remained intact and were not incorporated into the viable granulation tissue, likely to be 
removed with the eschar. Conversely, there was no evidence of the biomaterials coming 
out of the wound, and thus the scaffold materials not present in the eschar were assumed 
to have been remodeled with the granulation tissue at day 7. Staining of vimentin and 
αSMA by day 7 showed there was already an abundant infiltration of stromal cells and 
differentiated myofibroblasts within the wound at this time (Figure 4.5E; Appendix 
Figure A4). αSMA staining was highly variable, even across different areas of the same 
wound, notably detected more strongly at the base of the granulation tissue at day 7, but 
more uniformly expressed by day 28. Vimentin expressing cells were abundant 
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throughout the wound at both 7- and 28-days post wounding (Appendix Figure A4). No 
consistent differences were noted between treatment groups.  
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Figure 4.5: Wound contraction and matrix production were not affected by 
treatment with the biomaterials. (A) Full thickness skin samples, isolated from 
wounded and unwounded tissue, were sectioned along the midline of the wound and the 
granulation tissue diameter was measured in these cross sections (measurements taken 
from 2 cross sections per wound; n= 5-6 pigs at day 28; n= 3 pigs at day 7). (B) 
Hydroxyproline content was measured in fresh frozen samples from the wound 
(measured once per wound; n= 5-6 pigs at day 28; n= 3 pigs at day 7). Masson's 
trichrome staining of histological sections was used to qualitatively assess matrix 
deposition at day 7 (C) and day 28 (D); arrows indicate wound edge; performed twice per 
wound; n=5-6 pigs at day 28; n= 3 pigs at day 7. Scale is 5 mm. (E, F) αSMA staining of 
day 7 (n= 3) and day 28 (n=5-6) wound tissue. Nuclei are stained with DAPI. For co-
staining with vimentin, see Appendix Figure A4.  Scale bar is 1 mm. Data were analyzed 
using a linear mixed effects model; * p < 0.05; *** p < 0.001. 
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4.4.4 Foam biomaterials did not alter the vascular density of the wounds 
Histological sections were stained for CD146 to assess the vascular density and average 
vessel size (Figure 4.6; Appendix Figure A5). CD146 is widely expressed on endothelial 
cells as well as perivascular cells, labelling similar structures as CD31 (Li et al. 2003). 
Quantification of the staining showed a significant decrease in vessel density between 
day 7 and 28 post wounding in all treatment groups, as expected through vascular 
regression; however, no differences were noted between treatment groups and the 
untreated control (Figure 4.6B). The average cross-sectional projection of vascular 
structures was also not different between treatment groups and the untreated control. 
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Figure 4.6: Treatment with foam biomaterials did not alter the vascular density of 
the wound bed. (A) Histological assessment of CD146 positive (red; shown at 28 days) 
vasculature showed that there were no differences in vessel density between treatment 
groups and the untreated control (B; n= 3 pigs at 7 days; n= 5-6 pigs at 28 days; 2-5 full 
depth vertical regions of interest were quantified per wound). Nuclei are stained with 
DAPI. Scale bar is 1 mm. Data were analyzed with a linear mixed effects model; *** p 
<0.001. 
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4.4.5 CD68- and CD163-positive cell infiltrate within the wound bed was not 
significantly altered by the addition of biomaterials 
Histological sections were stained for macrophages with the markers CD68 and CD163 
(Figure 4.7A; Appendix Figure A6). CD68 is often considered to label both inflammatory 
M1, and regenerative M2 macrophages, whereas CD163 has been linked towards M2 
polarization (Buechler et al. 2000; Hesketh et al. 2017). CD68 has also been detected in 
cultured, non-myeloid lineages including endothelial cells and fibroblasts, although with 
a lower measured mean fluorescence intensity (Gottfried et al. 2008). Compared to the 
αSMA and vimentin staining performed here, it is evident that CD68 is not labelling the 
bulk fibroblast population, yet smaller subsets of CD68+ fibroblasts may be present. 
Conversely some staining is evident in and around vascular structures, identified by tight 
clusters of cell nuclei labelled with DAPI (examples can be seen in day 28 images of 
Appendix Figure A6). However, it is not clear whether this is extravasating CD68+ 
macrophages or endothelial cells. Interestingly, we noted similar staining in apparent 
vascular structures within unwounded tissue, but the extent of this was greater in tissue 
isolated at 7 days post wounding as compared to 28 days post wounding. These findings 
suggest that the inflammatory response in the unwounded tissues may be altered to some 
extent due to their proximity to the wounds. However, the reduction by day 28 suggests 
that the detected signal was not primarily due to the vasculature, which is similarly 
abundant in the unwounded tissues between the two time points. Within the porcine 
tissue assessed here, no difference in total CD68+ or CD163+ cell density was measured 
at either day 7 or day 28. However, a significant increase in dual-labelled CD68+CD163+ 
cells was noted at day 7 between the DAT and untreated groups. (Figure 4.7).  
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4.4.6 Porcine ASCs displayed tri-lineage differentiation potential 
As a first step in the pilot study to assess the potential of the foams as cell delivery 
platforms for ASCs, the tri-lineage differentiation capacity of the isolated porcine ASCs 
was verified through histological analysis (Figure 4.8). Control cells cultured in non-
inductive proliferation media, did not display markers of differentiation.  
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Figure 4.7: Foam biomaterials did not alter macrophage infiltration. Day 7 (A) and 
day 28 (B) wound tissue was stained for CD68 (red) and CD163 (green); nuclei are 
stained with DAPI (blue). Quantification was performed on each marker independently, 
as well as on dual labelled cells. n= 3 pigs at 7 days; n= 5-6 pigs at 28 days; 2-5 full 
depth vertical regions of interest were quantified per wound. Scale bar is 1 mm. Data 
were analyzed with linear mixed effects models; * p < 0.05 compared to the untreated 
control. 
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Figure 4.8: Porcine ASCs differentiated towards the adipogenic, osteogenic, and 
chondrogenic lineages. Adipogenic differentiation yielded cells with large fat vacuoles 
after 14 days of differentiation, as visualized with oil red O staining (A). Osteogenic 
differentiation resulted in calcium deposits, visualized with von Kossa staining, at 28 
days of differentiation (B). Differentiation towards the chondrogenic lineage resulted in 
increased expression of both type I and type II collagens in ASC cell pellets by 28 days 
of differentiation (C). Scale bars are 500 µm. 
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4.4.7 ASC seeding affected closure differentially depending on the biomaterial carrier 
To investigate ASC delivery, PKH26 labelled ASCs were seeded onto foam biomaterials 
and implanted into dorsal wounds in the porcine model. Seeding scaffolds with porcine 
ASCs resulted in the qualitative contraction of the scaffolds prior to implantation, which 
was noted to a greater extent in the type I collagen-based foams and occurring to a lesser 
extent in the DAT foams. Assessment of gross wound closure showed a significantly 
increased wound size in both DAT and PN/CCN2 containing groups as compared to the 
untreated wounds, but not in the BTC group (Figure 4.9). PKH26 positive cells were 
detected within the viable granulation tissue of all wounds treated with ASCs (Figure 
4.10). 
4.4.8 ASC delivery on foam biomaterials did not alter histological parameters or 
hydroxyproline content of the granulation tissue 
Wound closure in wounds treated with ASC-seeded biomaterials was further assessed 
histologically, as previously performed in the unseeded scaffolds (Figure 4.11). Both 
seeded BTC and PN/CCN2 treatments resulted in a larger cross-sectional granulation 
tissue diameter compared to the untreated wounds, although none of the other parameters 
measured were different between the treatment groups and untreated wounds. 
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Figure 4.9: Closure kinetics of wounds treated with ASC-seeded biomaterials. 
Wound size was measured, and closure kinetics were fit using a basis-spline function to 
compare each treatment group to untreated wounds (solid lines indicate means; dashed 
lines indicate standard deviation; n=3 pigs). Scale bar is 1 cm. The range in which each 
treatment significantly differed from the untreated group was determined with a two-way 
ANOVA using the fitted data and each treatment group was compared to the untreated 
control group with a Dunnett’s post hoc test. Seeded BTC foams were not significantly 
different in size than untreated wounds.  
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Figure 4.10: PKH labelled porcine ASCs were detectable within the granulation 
tissue at 7 days post wounding. PKH26 was detected within the granulation tissue of 
treated wounds. Nuclei are labelled with DAPI. Scale is 500 µm. 
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Figure 4.11: ASC-seeded biomaterials did not alter the histological parameters or 
hydroxyproline content of treated wounds. (A) Granulation tissue diameter was 
measured from wound cross-sections processed with Masson’s trichrome stain (shown in 
E; measured twice per wound; * p < 0.05; *** p < 0.001). (B) Hydroxyproline content 
was measured in fresh frozen samples from the wound (measured once per wound). 
Relative vessel density was determined through immunofluorescence of CD146 (C), and 
macrophage counts were measured through quantification of CD68 and CD163 (D). 
Wounds from 3 pigs were assessed in all analyses; for C and D 3-5 full depth vertical 
regions of interest were quantified. (E) Masson’s trichrome stain the full wound diameter. 
Arrows indicate wound edges; scale bar is 5 mm. For high magnification images of the 
staining performed see Appendix Figure A3 and A7. Data were analyzed using linear 
mixed effects models. 
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4.5 Discussion 
Using a porcine acute wound model, treatment with either Periostin and CCN2 
containing type I collagen foam biomaterials, or decellularized adipose tissue foam 
biomaterials, was shown to have relatively minor effects on wound healing parameters 
compared to wounds that were left untreated at both 7 and 28 days. Importantly, relative 
to untreated wounds, treatment with any biomaterial resulted in a delay in the gross 
wound closure rate. This difference was evident in early repair, but diminished over time, 
resulting in the same total time to heal in all groups. Based on the timing and normal 
appearance of the granulation tissue, it is postulated that the delayed wound closure is the 
result of the biomaterials providing mechanical resistance to contraction, rather than an 
alteration in the wound biology. It is hypothesized that the resistance provided by the 
foams would be less consequential in chronic wounds of the extremities, where skin is 
tightly anchored, and wound contraction has a smaller role in healing (Levinson 2013). 
This is supported by the improved rate of healing noted with DAT-based foams in db/db 
mice, which naturally contract less, and display impaired and delayed granulation tissue 
synthesis compared to wild-type mice (Tkalĉević et al. 2009). 
The histological and biochemical analyses showed similar levels of cell infiltration, 
matrix production, and the same final granulation tissue diameter. However, it is 
important to consider the limited sample size of this study, especially in day 7 tissue for 
which three pigs were assessed. Consequently, the effect size required to be able to detect 
statistically significant differences with high power is potentially larger than what might 
be biologically significant. Although few statistically significant differences were noted 
between treatment groups and the control group, some of these measurements warrant 
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further exploration in future studies. One such parameter of importance is the immune 
cell infiltrate. A significant increase in CD68+CD163+ double-labelled macrophages was 
noted in the DAT treatment group at 7 days post wounding, and a trend towards increased 
CD163+ cell infiltration was noted in all treatment groups at day 7, including those 
treated with ASCs, compared to the untreated controls. CD163 itself is a scavenger 
receptor with affinity for hemoglobin-haptoglobin complexes and both gram-positive and 
gram-negative bacteria (Buechler et al. 2000; Fabriek et al. 2011). In previous reports, 
CD163+ macrophages have been shown to accumulate at tissue-biomaterial interfaces and 
were associated with a reduction in total inflammation over time following biomaterial 
implantation in a rat model (Badylak et al. 2008; Bullers et al. 2014). Generally, CD163 
is associated with an M2 phenotype due to its positive regulation by IL-6 and IL-10, and 
negative regulation by pro-inflammatory stimuli including LPS, TNFα, and IFNγ 
(Buechler et al. 2000). However, it is well established that macrophage phenotypes 
represent a large spectrum, and therefore single markers are insufficient to describe their 
function (Mosser and Edwards 2008). The results provided here, suggest a potentially 
more regenerative phenotype in all biomaterial treated wounds, supporting the need for a 
more complete assessment in future studies. 
The findings in this study support that the tested biomaterials are promising carriers for 
cell therapy. Although limited by the small sample size, this preliminary study found that 
allogeneic porcine ASCs could be delivered into the viable granulation tissue via scaffold 
seeding. Early clinical trials using MSCs suggest that they are safe (Lalu et al. 2012), and 
that they are potentially beneficial as a chronic wound therapy, with roles in 
immunomodulation postulated to be a major influencing factor (Falanga et al. 2007; 
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Nuschke 2014; Otero-Viñas and Falanga 2016). Additionally, MSCs have previously 
been genetically modified to produce and deliver bioactive factors, including antibodies 
and signaling proteins, in animal models (Loebinger et al. 2009; Braid et al. 2016), 
opening up a range of possibilities for this technology by combining their innate 
immunomodulatory and angiogenic functionality with an engineering approach to tissue 
repair. Such a system could even be used to modify the scaffold production as performed 
here, by inducing cells to produce the matricellular proteins investigated, or by providing 
alternative biological cues. 
Compared to rodent skin, porcine skin is anatomically more similar to that of humans and 
is a more translationally relevant model of wound closure (Sullivan et al. 2001; Seaton et 
al. 2015). Regardless, how well the findings in an acute wound model will translate to an 
impaired model is difficult to assess. In fact, strategies that would be beneficial for acute 
wounds, such as reducing matrix deposition, would be detrimental for chronic wounds 
(Levinson 2013). Similarly, approaches that would be favorable for chronic wounds, such 
as enhancing fibroblast function or inducing angiogenesis, could have negative 
consequences during acute wound healing.  While enhanced fibroblast function is 
associated with fibrotic repair, evidence supports that excessive angiogenesis plays a 
supporting role in this process (DiPietro 2016). Importantly, an investigation of five 
approved acellular dermal substitutes in a porcine full thickness model reported similar 
findings to those here (Philandrianos et al. 2012). More specifically, reduced contraction 
at 21 days post-wounding was noted for three of the five dermal substitutes relative to an 
untreated control, and no differences in clinical wound parameters, including wound 
contraction, were detected at 2- and 6-month endpoints. Thus, while pig skin is more 
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similar to that of humans as compared to rodent skin (Sullivan et al. 2001), it is apparent 
that beyond an assessment of basic parameters such as cell infiltration and matrix 
degradation, an acute model in young, healthy animals is likely not an appropriate pre-
clinical model of human chronic wounds as they do not recapitulate the underlying 
pathophysiology.  
Impaired healing models in pigs are more complex than in rodents. However, such 
models are capable of reproducing some aspects of human chronic wounds (Seaton et al. 
2015). Bipedicle flaps, which disconnect the skin from the underlying vascular supply, 
have been used to recreate chronic ischemia, leading to impaired rates of closure, and 
histological parameters mimicking those of ischemic wounds in humans (Roy et al. 
2009). Additionally, streptozotocin induced type I diabetes has been used as a model for 
diabetic wounds, with pigs displaying impaired re-epithelialization, and reduced TGFβ 
and insulin-like growth factor-1 (IGF-1) expression (Velander et al. 2008). However, in 
our hands, a pilot study to explore the use of streptozotocin-induced diabetes resulted in 
the mortality of one of two pigs directly following the initial streptozotocin injection, 
which precluded continuation of this approach. Such discrepancy could be due to the 
animal background and breeding practices, or a dosing consideration. Streptozotocin has 
a low circulating half-life of 5-15 minutes (Eleazu et al. 2013), and thus the rate at which 
it is administered can greatly affect its efficacy and toxicity. Nevertheless, these models 
of impaired wound healing could represent important pre-clinical models of human 
chronic wounds and constitute a critical next step in testing the efficacy of these foam 
biomaterials. 
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4.6 Conclusions 
Periostin and CCN2 containing type I collagen foam biomaterials and DAT foam 
biomaterials were assessed in a porcine model of acute wound repair in healthy juvenile 
pigs. Treatment with the biomaterials resulted in a delay in wound closure during early 
repair, related to delayed contraction. Other wound healing parameters explored were 
similar between treatment groups at both 7 and 28 days. The biomaterial strategy utilized 
in this study offers a straightforward and customizable method to synthesize foam 
biomaterials that are easy to handle and integrate into the wound. Moreover, these 
biomaterials offer a platform for delivering therapeutic cell populations, supporting 
allogeneic ASC integration within the granulation tissue at 7 days. Further investigation 
in a clinically-relevant impaired wound healing model is warranted to more fully assess 
the potential of these scaffold-based approaches for the treatment of chronic wounds. 
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Chapter 5: Discussion 
5.1 General Discussion 
In this thesis, research into cell-intrinsic and cell-extrinsic factors that regulate wound 
repair was presented with the goal of guiding future therapeutic development. To this 
end, progress was made in 1) developing a better understanding of the basic biology of 
key cell populations and extracellular matrix (ECM) constituents involved in wound 
repair, and 2) initial analysis of the wound healing response to novel ECM-derived 
biomaterials in a porcine model. 
5.1.1 Lineage tracing of Foxd1-expressing embryonic progenitors to assess the role of 
divergent embryonic lineages on adult dermal fibroblast function 
The first aim of this thesis focused on examining fibroblast lineage as a determinant of 
cell function during skin homeostasis and in wound repair. Based on previous lineage 
tracing studies in kidney (Humphreys et al. 2010) and lung (Hung et al. 2013) fibrosis, 
the Foxd1-lineage as a marker of myofibroblast progenitors was investigated in the dorsal 
dermis through lineage tracing. Embryonic Foxd1-expressing progenitors migrated into 
the dorsal skin during development and contributed to Foxd1 lineage-positive populations 
in adult tissue, including a subset of dermal fibroblasts. Furthermore, the Foxd1 lineage 
was a source of myofibroblast during cutaneous wound repair. Notably, the binary 
expression of Foxd1 during development correlated with differential fibrosis-related gene 
expression patterns in the fibroblast progeny in adult tissue. Specifically, during wound 
repair, the lineage-positive fibroblast population maintained higher levels of expression 
for matrix synthesis associated genes, including type III collagen, and decorin, whereas 
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the lineage-negative population maintained higher gene expression of several integrins, 
and signaling proteins including PDGF-A, PDGF-B, TNFα, and Endothelin-1. These 
findings support a level of functional heterogeneity between these two fibroblast 
populations.  
While the findings of this work are not immediately applicable to biomaterials 
development, there are several directions in which a contribution to therapeutic design 
are potentially foreseeable. An exceptional study by Rinkevich et al. utilized a relatively 
broad lineage tracing strategy in dermal fibroblasts to focus in on a specific, druggable 
target, Dpp4 (CD26), which could be inhibited to reduce scarring during acute wound 
repair in mice (Rinkevich et al. 2015).  Whether a similar strategy could be used to 
identify targets to promote ECM synthesis and skin repair in a model of impaired healing, 
is unknown. The work presented in this thesis contributes to a growing understanding of 
fibroblast heterogeneity and provides insight into how divergent populations might 
cooperate during wound repair.  
Whereas most organs undergo fibrotic repair following acute or chronic injury, chronic 
wounds represent a unique challenge in that they are characterized by impaired ECM 
synthesis (Hinz 2016). Accordingly, it is natural that studies investigating fibroblast 
lineages outside of the skin focus on strategies to reduce matrix production. Even within 
the skin, much of the work to date has focused on inhibition of fibrosis and scarring. This 
emphasis on fibrosis may be related to the translational interests of the broader 
myofibroblast progenitor community, or that fibrotic repair is the natural end-point of 
cutaneous wound healing in healthy wild-type mice, making it a simpler initial point of 
study. Several studies, including those by Dulauroy et al., Rinkevich et al., and 
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Marangoni et al., have identified specific populations of myofibroblast progenitors with 
fibrogenic potential (Dulauroy et al. 2012; Marangoni et al. 2015; Rinkevich et al. 2015). 
An investigation by Driskell et al. highlighted two spatially distinct lineages that 
contributed either to granulation tissue synthesis or hair follicle formation during wound 
repair (Driskell et al. 2013). Interestingly, interaction between activated myofibroblasts 
and hair follicles has been observed to induce myofibroblast differentiation into 
adipocytes during wound resolution, a mechanism which could be exploited to reduce 
scarring (Plikus et al. 2017). It is evident that within the last 7 years, an immense amount 
of knowledge regarding skin fibroblast functional heterogeneity has been established, but 
whether this work can be translated into models of impaired healing remains unknown. 
Potential strategies to explore in models of impaired healing could include cell delivery 
by enriching for fibroblast subsets with the greatest fibrogenic potential, or targeting the 
molecular mechanisms involved in fibroblast subset-specific activation and deactivation. 
Jiang et al. (2018) performed cell transplantation studies in immune deficient Rag2 
knockout recipient mice, which resulted in fibrotic repair when wounds were enriched 
with the more fibrogenic Engrailed-1 lineage and more regenerative when enriched with 
their less fibrogenic lineage-negative counterparts (Jiang et al. 2018). Such findings could 
have important implications for cell therapy. However, testing in models of impaired 
healing would be required to fully assess their potential effects.  
A further question of interest that warrants more in-depth investigation is what the roles 
are of fibroblast populations that contribute less to matrix synthesis during wound repair. 
The presence of these populations in such an evolutionarily-conserved process suggests 
that they may have alternative functional roles, which have not yet been fully elucidated. 
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Jiang et al. highlighted that lesser fibrogenic Engrailed-1 lineage-negative fibroblasts are 
involved in fibronectin deposition during development (Jiang et al. 2018), and it is 
perceivable that they may maintain this functionality during healing in adult mice. 
Furthermore, fibroblast populations that do not contribute to early granulation tissue 
formation can play an influential role in hair follicle regeneration (Driskell et al. 2013). 
However, in this thesis, Foxd1 lineage-negative fibroblasts (PDGFRα+/ Vimentin+/ 
Foxd1 lineage-negative) were observed within the wound at 3 days post wounding, 
suggesting that there are fibroblasts with lesser fibrotic potential present even during 
early stages of skin repair. Further, the work presented in this thesis identified that a 
number of integrins, cell receptors, and growth factors were enriched in the Foxd1 
lineage-negative population during wound repair, while type III collagen mRNA was 
relatively under-expressed compared to the Foxd1 lineage-positive fibroblasts. At the 
present time, the consequences of these differential expression patterns are difficult to 
predict, but it is hypothesized that this cell population may play a more supportive role 
during skin repair, influencing matrix deposition by the more fibrogenic Foxd1 lineage-
positive fibroblast population.  
 
5.1.2 The role of Galectin-3 in cell recruitment and differentiation during wound 
healing 
In the second aim of this thesis, the matricellular protein Galectin-3 was investigated as a 
potential extrinsic mediator of cell behavior in wound repair. Matricellular proteins are 
temporally regulated throughout the wound repair process, and their expression has been 
linked to a range of important functional outcomes, including the regulation of 
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inflammation, angiogenesis, and fibrogenesis (Walker et al. 2015). This, in combination 
with their extracellular localization, makes them potential candidates for incorporation 
into ECM-mimetic biomaterials. Galectin-3 is considered a member of the matricellular 
protein family, but does not act exclusively in the ECM (Midwood et al. 2004). In fact, its 
role within keratinocytes during dermal wound repair is associated with intracellular 
protein trafficking after receptor-ligand binding (Liu et al. 2012). However, Galectin-3 
can also modify receptor activation and trafficking extracellularly. Receptor clustering 
resulting from the binding of Galectin-3 homopentamers to cell surface receptors has 
been shown to activate focal adhesion kinase (FAK) through αVβ3 integrin clustering, 
prevent endocytosis of vascular endothelial growth factor receptor 2 (VEGFR2) and 
transforming growth factor receptor 2 (TGFR2), and can activate regenerative 
macrophage polarization through binding and activation of CD98 (MacKinnon et al. 
2008, 2012, Markowska et al. 2010, 2011).  
Recognizing these extracellular roles that result in enhanced signaling in pro-regenerative 
pathways motivated the investigation of Galectin-3 in wound healing. Surprisingly, 
genetic deletion of Galectin-3 in a murine model resulted in no major defects during 
acute wound repair. Specifically, in relation to fibroblast activation, Galectin-3 knockout 
mice did not display impairments within the skin as has been observed in other organs 
(Henderson et al. 2006, 2008; Jiang et al. 2012; MacKinnon et al. 2012). Further, 
characterization of primary dermal fibroblasts in vitro supported intrinsic differences 
compared to primary pulmonary fibroblasts studied by MacKinnon et al. (2012). 
Whereas Galectin-3 knockout pulmonary fibroblasts displayed impaired fibroblast 
activation in vitro, Galectin-3 knockout dermal fibroblasts were similar to wild-type. 
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Although both sources of fibroblast are responsible for fibrotic repair, it is evident that 
there might be subtle differences in the mechanisms that result in an activated state in 
order to do so. 
The findings in this chapter do not imply that treatment with exogenous Galectin-3 would 
not be beneficial in an impaired wound model. In this thesis, it was shown that Galectin-3 
gene expression is highest in the wound one day post excisional wounding in a mouse 
model, corresponding with inflammatory cell infiltration. However, human chronic 
wounds, which are characterized by an unresolved inflammatory phase (Demidova-Rice 
et al. 2012; Frykberg and Banks 2015), have a significantly decreased level of Galectin-3 
in the tissue at the wound edge. Whether this decrease contributes to the pathophysiology 
of chronic wounds or is protective is not currently known. This question should be 
assessed in models of impaired wound healing through exploration of its expression 
profile and through treatment with exogenous protein. 
5.1.3 Profibrotic and pro-angiogenic biomaterials to induce cell recruitment and 
differentiation during skin healing 
The final aim of this thesis was to investigate the effects of ECM-based biomaterials in a 
porcine wound model. Although a specific role for Galectin-3 in acute dermal wound 
repair was not determined, previous work from the Hamilton laboratory identified a key 
role of the matricellular protein periostin in myofibroblast differentiation (Elliott et al. 
2012). Continuation of this work identified the therapeutic potential of exogenous 
periostin through an improved rate of wound closure in a db/db model of impaired wound 
healing when delivered in an electrospun type I collagen scaffold (Elliott et al. 2018). 
Similarly, exploration of the pro-fibrotic matricellular protein CCN2, which shares a 
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similar expression profile with periostin during acute wound repair, identified a positive 
effect on the rate of closure in db/db mice (Elliott et al. 2018). Micro-array analysis of 
gene expression in whole wound tissue following treatment with either exogenous 
periostin or CCN2 resulted in distinct expression patterns, suggesting that these 
matricellular proteins function through different pathways (Elliott et al. 2018). Moreover, 
treatment with both periostin and CCN2 resulted in novel genes being regulated 
compared to each individually. Overall, in this work, the rate of healing was improved in 
all matricellular protein treated groups, but granulation tissue thickness was significantly 
greater in the combined group, and thus, this approach was chosen for future 
investigation. These promising findings using periostin and CCN2 served as the rationale 
to explore their delivery further in the porcine wound model.  
To continue this work in the present thesis, a combination treatment including both 
periostin and CCN2 was applied using an alternative foam biomaterial format, and acute 
healing was assessed in 3-month-old healthy pigs. Switching to a foam design offered 
several benefits over the electrospinning process including greater uniformity, ease of 
synthesis and customization, scaffold stability without chemical cross-linking, and larger 
scaffold pore sizes to enhance cell infiltration. Furthermore, healing was assessed in a 
porcine wound model, which has greater anatomical similarity to human skin as 
compared to rodents and has been suggested to be a more appropriate model for 
translation of wound therapeutics (Sullivan et al. 2001). 
In addition to the modifications made to the previous research design investigating 
matricellular protein-based therapies, similar foam scaffolds derived from human 
decellularized adipose tissue (DAT) were explored as a novel wound healing therapeutic. 
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The exploration of the DAT foams provides insight relevant to future scaffold design, not 
only in terms of applying these materials as stand-alone biological dermal substitutes, but 
also as a potential platform for further modification with other pro-regenerative factors 
such as matricellular proteins. Numerous components of the ECM are suggested to be 
beneficial for skin repair including structural proteins, glycoproteins, 
glycosaminoglycans, proteoglycans, and matricellular proteins (Turner and Badylak 
2015), all of which are present in DAT (Kuljanin et al. 2017). The DAT foam 
biomaterials were not excluded from the wounds during repair and were assumed to 
integrate into the granulation tissue and to be remodeled by the cellular infiltrate in an 
acute wound setting.  
Lastly, the application of the foams as delivery platforms for allogeneic adipose-derived 
stem/stromal cells (ASCs) was explored. While the studies performed were preliminary 
in nature, it is promising that the ASCs delivered on the various scaffolding platforms 
could be visualized within the viable granulation tissue in all treated wounds at 7 days 
post wounding. Adding a cellular component to the therapeutic design opens a range of 
possibilities for future exploration. While the innate immunomodulatory properties of 
mesenchymal stem/stromal cells (MSCs) are promising independently (Falanga et al. 
2007; Nuschke 2014; Otero-Viñas and Falanga 2016),  previous work has shown that 
MSCs can also be genetically modified to deliver proteins of interest upon in vivo 
implantation (Braid et al. 2016). This approach could be investigated in the future as an 
alternative strategy to deliver matricellular proteins. In conclusion, previous work from 
our research groups was combined and modified to make progress towards improving 
biomaterial design and assessing therapeutic efficacy for wound healing applications. The 
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findings of this work demonstrate the need to explore models of impaired healing in 
future studies to bridge the gap between bench and bedside. 
 
5.1.4 Conclusion 
Work in this thesis has contributed to the present state of knowledge in diverse areas of 
wound healing research. Contributions have been made to the broader wound healing 
field to better understand the cell-intrinsic and -extrinsic properties that regulate wound 
repair. Moreover, within our laboratories new techniques have been introduced and pre-
existing techniques have been advanced to expand upon the expertise available. 
Specifically, lineage tracing studies have been introduced into our lab, and fibroblast 
isolation through fluorescence activated cell sorting has been explored; expertise in a 
splinted murine wound model has been established; scaffold synthesis has been adapted 
for better infiltration and easier handling; an acute porcine wound model has been 
established; isolation and characterization of porcine ASCs has been performed, and an 
effective method for allogeneic transplantation of ASCs was developed. An exploration 
of future directions for near-term continuation of this work will be provided below. 
 
 
 
 
 
227 
 
 
 
5.2 Future directions 
5.2.1 Investigating the functional relevance of divergent gene expression in Foxd1 
lineage-positive fibroblasts 
Foxd1 lineage-positive and lineage-negative dermal fibroblasts were identified to have 
divergent gene expression patterns. Future studies should focus on further probing how 
these genetic differences impact cell function. Most importantly, the differential 
expression of surface markers, including those identified in the PCR array such as 
integrins α2, α3, β6, and β8 as well as dermal fibroblast markers characterized in 
previous lineage studies including CD90, PDGFRα, and PDGFRβ (Rinkevich et al. 2015; 
Philippeos et al. 2018), should be assessed through flow cytometry. Determining markers 
to stratify the different lineages is an important step towards translation away from the 
lineage tracing model, making these findings more relevant to the broader research 
community. Proteins expressed on the cell surface are critical mediators of cellular 
interactions with their immediate environment, and thus, differential expression of these 
surface markers can give clues towards the mechanisms driving divergent expression 
patterns and overall cell phenotypes. Furthermore, differential surface marker expression 
could be useful in identifying these distinct fibroblast sub-populations in human skin. 
Such findings could be helpful in understanding the etiology of human chronic wounds. 
Specifically, identification of fibroblast sub-populations in human chronic wounds would 
help to determine the relationship between cell-intrinsic and -extrinsic factors in 
determining wound chronicity. Theoretically, if sub-populations exist in skin, depletion 
of certain populations could result in an inability to heal, leading to wound chronicity.  
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Moving forward, functional differences between lineages should be assessed in vitro and 
in vivo. An effective strategy to assess cell function in vivo is through transplantation 
studies using FACS-sorted populations. Using this strategy, Driskell et al. identified a 
role of papillary fibroblasts in hair follicle formation (Driskell et al. 2013). Additionally, 
Rinkevich et al. and Jiang et al. provided evidence of scarring potential in the engrailed-1 
lineage of fibroblasts over the lineage-negative population using transplantation studies 
(Rinkevich et al. 2015; Jiang et al. 2018). However, with cell transplantation studies, the 
lineages are not assessed in isolation of each other due to the contribution of cells 
endogenous to the recipient. Regardless, these experiments can provide important 
information on cell function. Another method that allows for the assessment of specific 
lineages in vivo is cell ablation using a diphtheria toxin (DT)/ DT receptor (DTR) 
approach (Dulauroy et al. 2012; Rinkevich et al. 2015). This method results in the 
selective ablation of cells, controlled by Cre/Lox recombination or cell-specific 
promoters, inducing cell death through inhibition of protein synthesis (Saito et al. 2001). 
However, because the Foxd1 lineage is not specific to the fibroblast population, using 
this approach could have severe health consequences for the animal if not controlled by 
additional cell-type specific promoters, or localized DT delivery. Another ablation 
method, Herpes simplex virus thymidine kinase (HSV-TK)/ ganciclovir, is toxic 
primarily to replicating cells by inhibiting DNA elongation (Heyman et al. 1989; Tieng et 
al. 2016), and thus may be more appropriate for targeting wound fibroblasts more 
selectively. However, ablation strategies have been used to target only the fibroblast 
population tracked through lineage tracing, but not the reciprocal non-lineage fibroblasts 
(Dulauroy et al. 2012; Rinkevich et al. 2015). Thus, the effects of ablation could simply 
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be due to a loss in total fibroblast number and not specifically the cells of interest. While 
the reciprocal experiment is theoretically possible (potentially a Col1a1 or PDGFRα 
promoter controlling loxP-DTR-loxP/ loxP-HSV-TK-loxP), how well this would work in 
practice is uncertain. To my knowledge, such an approach has not been explored. 
Overall, with the current state of available methods, cell transplantation studies offer a 
more robust model for in vivo exploration of functional differences between fibroblast 
lineages. 
In vitro approaches to investigate cell function are required to allow greater control over 
experimental parameters, but normal cell culture conditions alter cell phenotype. Few 
studies to date have explored different fibroblast lineages in culture. Similar to our 
findings in collagen gels, Philippeos et al. reported altered expression in a selection of 
markers explored after culturing human dermal fibroblasts sorted into papillary and 
reticular populations. Specifically, the human papillary dermal fibroblast specific markers 
CD39 and Col6A5 were lost upon culturing. However, the other markers monitored, 
CD36, Lumican, and CD90, were expressed at similar levels in the freshly isolated and 
cultured populations (Philippeos et al. 2018). The group also found that FACS-enriched 
papillary or reticular human dermal fibroblasts maintained important functional 
differences in vitro on tissue culture plastic. More specifically, expression differences 
were maintained in culture for genes relating to ECM synthesis, and differences in their 
responsiveness to interferon γ (IFNγ) were noted. However, while papillary dermal 
fibroblasts displayed upregulated Wnt signaling genes in vivo, some of these were higher 
in the reticular population in vitro, including Wnt5a and Lef1 (Philippeos et al. 2018). 
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Overall, these findings suggest that specific properties of disparate fibroblast populations 
are retained on tissue culture plastic while others are not. 
More promising for the development of relevant in vitro models to assess dermal 
fibroblast function, Philippeos et al. found that cultured human papillary and reticular 
dermal fibroblasts maintained functional differences when transplanted into an 
organotypic culture model that consisted of human decellularized dermal tissue and a 
seeded keratinocyte layer (Philippeos et al. 2018). The papillary fibroblasts integrated 
with the epidermis, while increased epidermal thickness and formation of rete ridges 
were evident. In contrast, implanted reticular fibroblasts were more evenly spread 
throughout the tissue and negatively affected epidermal thickness. Using this human 
decellularized dermis model, the fibroblasts entered a state of quiescence with minimal 
cell proliferation similar to native tissue. However, the fibroblasts were shown to become 
activated upon localized injection of collagenase as a model for tissue injury, supporting 
the utility of this system for exploration of diverse tissue states (Rognoni et al. 2018). 
These findings highlight the relevance of this organotypic model, which could potentially 
be utilized to assess functional differences in the Foxd1 lineage. However, it is unknown 
whether murine fibroblasts will behave similarly on human-derived decellularized dermis 
or whether murine sources would be required. Nevertheless, use of a compositionally-
relevant organotypic culture model could be a useful tool to provide valuable insight into 
the functional diversity of fibroblast populations. 
To conclude, further characterization of protein expression in the Foxd1 lineage should 
be performed to verify changes in gene expression and assist in the translation of this 
work. Further exploration of functional differences could help to identify underlying cell-
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intrinsic mechanisms that regulate skin repair. Moreover, a better understanding of how 
diverse fibroblast populations interact, and the major mechanisms coordinating their 
interactions could potentially identify important targets for future investigation in the 
context of cutaneous wound healing. 
5.2.2 Galectin-3 as a therapeutic for impaired wound healing 
Galectin-3 is a matricellular protein with diverse roles in processes involved in wound 
repair. Our group recently published a review article discussing these roles with a focus 
on the potential use of exogenous Galectin-3 in a chronic wound setting (McLeod et al. 
2018). Overall, Galectin-3 has roles in both pro- and anti- inflammatory processes, 
fibrosis, angiogenesis, and wound re-epithelialization, all of which could be beneficial 
when applied to chronic wounds (McLeod et al. 2018). However, a distinct 
pathophysiological feature associated with human chronic wounds, advanced glycation 
end-products (AGEs), could affect translation of Galectin-3 research from culture 
systems and animal models into human chronic wounds. This will be discussed in more 
detail below. 
Like all lectins, Galectin-3 recognizes specific sugar moieties through its carbohydrate 
recognition domain based on a tightly controlled glycosylation state. This “sugar code” is 
normally tightly regulated by post-translational modification by enzymatic means 
(Murphy et al. 2013). One of these enzymes, Mgat5, modifies proteins with β1,6-
GlcNAc-branched N-glycans, which are high affinity ligands of Galectin-3 (Lagana et al. 
2006; Markowska et al. 2011). However, in diabetic patients, glycosylation begins to 
occur randomly, through non-enzymatic means in the presence of excessive amounts of 
reducing sugars over prolonged periods of time (Singh et al. 2014). Notably, the resultant 
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AGE modifications are particularly apparent at sites of diabetic complications, including 
within chronic wounds (Pepe et al. 2014), and have been reported to have roles in 
diabetic pathology, including altered immune function and impaired vascular function 
(Stirban et al. 2014). Importantly, AGE modifications have been reported to be ligands 
for the carbohydrate recognition domain of Galectin-3 (Vlassara et al. 1995), with 
Galectin-3 itself acting in a larger AGE-receptor complex (Pricci et al. 2000). Ligand 
binding with the AGE-receptor complex results in endocytosis and degradation of AGE-
modified proteins, and has also been shown to be protective against oxidative stress, 
counteracting the pro-inflammatory effects of the other major AGE receptor, receptor for 
advanced glycation end-products (RAGE) (Torreggiani et al. 2009; Ott et al. 2014). 
Although the role of endogenous Galectin-3 is protective against AGE accumulation, 
further investigation is required to assess the effect of the exogenous protein delivered as 
a therapeutic agent in impaired healings environments.  
Unfortunately, there is no standard animal model for AGE accumulation, with 
combinations of time, high AGE diets, diabetes, and/or delivery of AGE-modified 
compounds or precursors being used experimentally (Peppa et al. 2003; Sandu et al. 
2005; Berlanga et al. 2005; Liao et al. 2009), and are rarely assessed for the extent of 
glycation. However, one exemplary study investigated AGE accumulation in wild-type 
and diabetic (db/db) mice fed a high- or low-AGE diet (Peppa et al. 2003). The diets were 
controlled for protein, fat, carbohydrate, and caloric content, differing only in AGE 
content.  Importantly, db/db mouse skin on its own did not show increased AGE content, 
but this was increased when combined with a high AGE diet for three months. Thus, to 
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assess the effect of exogenous Galectin-3 in a translational model, a db/db mouse 
combined with a high-AGE diet should be considered.  
5.2.3 Assessment of biomaterial scaffolds in a porcine model of impaired wound 
healing 
As highlighted previously in this thesis, a logical continuation of the work on the 
developed foam biomaterials would be to assess their effects on healing using a relevant 
impaired wound model. It is important to note that no animal model will recapitulate 
every aspect of a human disease state, and thus it is necessary to select a subset of 
parameters that can be mimicked to provide a more representative and translational 
model system.  
Chronic wound pathophysiology includes excessive inflammation, chronic infection, and 
an impaired response of resident populations to injury (Demidova-Rice et al. 2012; 
Frykberg and Banks 2015). Moreover, chronic wounds of vascular or diabetic ulcer 
etiology are associated with vascular insufficiency leading to tissue ischemia. As such, 
several different models of impaired wound healing have been developed, each 
replicating some of these aspects (Seaton et al. 2015). Unfortunately, there is no gold-
standard porcine model used to quantitatively assess diverse therapeutics for specific 
indications. In fact, even clinically, the selection of therapeutics for chronic wounds from 
wound dressings to skin substitutes is not strongly based on evidence (Snyder et al. 2012; 
Frykberg and Banks 2015; Santema et al. 2016; Norman et al. 2017). Although the use of 
approved therapies leads to better outcomes than standard care alone, the level of 
evidence to choose one therapeutic over another for a specific indication is poor (Snyder 
et al. 2012; Santema et al. 2016; Norman et al. 2017).  
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More robust and standardized pre-clinical models of impaired healing are critically 
needed to allow for better assessment of outcomes of novel materials in a highly 
controlled environment, as well as to validate and compare current therapeutics. A similar 
approach to the one undertaken in this thesis using an acute porcine wound model 
showed no benefit of currently approved dermal substitutes over untreated controls 
(Philandrianos et al. 2012). However, an acute porcine wound model, while useful for 
assessing integration and the host tissue response to implanted biomaterials, does not 
reproduce any of the pathophysiological features of human chronic wounds.  
Induced-diabetic porcine models have been explored, but the overall level of impairment 
in terms of the rate of closure is small compared to closure in non-diabetic pigs (Velander 
et al. 2008; O’Brien et al. 2014). This is consistent with the fact that in humans, diabetic 
complications, including micro- and macro-vascular complications and all-cause 
mortality, are positively associated with both age and duration of disease (Zoungas et al. 
2014). Even in pigs, increasing the duration of induced-diabetes and resultant 
hyperglycemia from 20 to 90 days prior to wounding, was shown to negatively impact 
the rate of healing (O’Brien et al. 2014). In our hands, a pilot investigation exploring the 
induction of diabetes via administration of streptozotocin resulted in mortality for one of 
two pigs tested (unpublished data). Still, others have reported much lower mortality 
associated with streptozotocin (Velander et al. 2008; O’Brien et al. 2014), suggesting that 
further in-house optimization may be sufficient to overcome this hurdle. However, it is 
important to note that in our pilot investigation, while the surviving pig maintained a 
hyperglycemic state over three weeks, the wounds that were inflicted one-week post 
streptozotocin administration healed similarly to those in a non-diabetic control pig over 
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a two-week period of assessment. These findings further support that short-term 
induction of diabetes may not be sufficient to impair wound closure. Overall, due to the 
cost, time, ethical considerations, and limited impairment associated with this model, it is 
not recommended for future investigation. 
Another porcine model that has been shown to have a more drastic effect on the rate of 
closure relies on surgically-induced ischemia (Roy et al. 2009). In this model, a bipedicle 
flap was created in the dorsal skin, and a silicone sheet placed below and sutured into 
place. With this approach, the flap was disconnected from the underlying circulation and 
the overlying skin became ischemic, as measured by laser Doppler imaging, and the level 
of tissue oxygen content via spectroscopic techniques. Importantly, by 3 weeks, ischemic 
wounds only closed to ~80% of their initial size, whereas those in non-ischemic tissue 
were fully closed. These findings were further supported with histological analyses 
showing delayed macrophage recruitment into the wound, and fewer von Willebrand 
Factor (vWF)-positive endothelial cells within the granulation tissue. Whether outcomes 
in this porcine ischemic wound model accurately reflect those in human chronic wound 
patients would require further testing. However, due to the extent of impairment 
displayed, this model system is intriguing and warrants further investigation. One 
potential concern is how well this model can be replicated. During study optimization in 
a single pig, a recent study using this approach cited problems with fluid build-up and 
dehiscence along the incision associated with the underlying silicone sheet (Patil et al. 
2017). To remedy this, the flap was disconnected from the underlying tissue, without 
placement of the silicone sheet for the remaining three pigs tested. The study reported 
equivalent blood flow within the ischemic and non-ischemic wounds based on laser 
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Doppler imaging by 8 days. Unfortunately, no wound size or oxygenation measurements 
were reported, and untreated control wounds within the ischemic tissue were not 
performed, making it difficult to assess the level of impairment. Regardless, potential 
problems associated with this surgical model should not be discounted, and whether it 
can be reproduced would require further exploration. Moreover, whether the ischemic 
model with the adaptations made by Patil et al. is sufficient to impair wound closure in a 
reproducible manner, would require investigation. 
Overall, it is evident that there is a need to develop and test relevant animal models of 
impaired wound healing. There is already a vast array of skin substitutes approved for 
use, with few randomized controlled trials systematically comparing their efficacy 
(Snyder et al. 2012). Moreover, meta-analyses to compare wound therapeutics are 
hindered by a lack of quality clinical data (Santema et al. 2016; Norman et al. 2017). 
Consequently, the current approach to selection of wound therapeutics is not evidence-
based, and patient outcomes may be compromised. No animal model will replace the 
need for high quality clinical trials, however, standardized, predictive, and reproducible 
pre-clinical models would be extremely valuable for screening and comparing therapeutic 
options. 
5.2.4 Exploring the interplay between cell-intrinsic and -extrinsic properties governing 
wound repair 
As a longer-term goal of this work it would be interesting to explore the interplay 
between cell lineage and the microenvironment. A key finding from the lineage tracing of 
Foxd1 lineage-positive and lineage-negative fibroblasts was the dichotomy in their 
expression profiles. Specifically, lineage-negative populations expressed higher levels of 
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genes associated with cell signaling, including integrins which act as cellular receptors 
for numerous ECM components (Koivisto et al. 2014). Using the biomaterial foams 
explored in this thesis as a culture substrate, the response of lineage-positive and lineage-
negative fibroblasts to diverse ECM components including the matricellular proteins 
periostin, CCN2, and galectin-3 could be explored systematically. Findings from such an 
experiment would provide further insight into the functional differences in fibroblast sub-
populations. Furthermore, differences in the fibroblast response to specific ECM 
components have not previously been linked to specific fibroblast lineages or 
populations. Such findings would point to novel mechanisms of tissue level control over 
the response to specific stimuli. If fibroblast subsets respond differently to external cues, 
then differences in their distribution between regions of the skin could be a useful 
predictor of how each region will respond following tissue injury. 
As mentioned above, transplantation studies offer a potential strategy to investigate 
functional differences between fibroblast subsets. Alternatively, in models of impaired 
healing such as db/db mice or impaired porcine wound models, it would be valuable to 
explore how divergent fibroblast subsets modify the healing response. The expression 
data collected from Foxd1 lineage-positive and lineage-negative fibroblasts suggested 
that while the lineage-positive cells may be more synthetic, the lineage-negative 
population may be more modulatory in nature. However, it is unknown how delivery of 
these populations into an impaired wound would affect the healing outcome. Again, this 
would provide valuable information regarding the interplay between cell lineage and 
external cues which would be useful for the development of novel cell-based therapies 
for wound healing applications. 
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Continuation of the studies provided in this thesis will offer a wide range of opportunities 
to further explore the relationship between cells and their environment. In addition to 
enhancing the understanding of the fundamental mechanisms involved in wound repair 
and tissue homeostasis, future exploration in this direction would be impactful for 
regenerative medicine applications. 
5.3 Summary 
The overall focus of this thesis was to expand upon the understanding of fundamental 
mechanisms involved in wound repair, with the goal of applying the findings to future 
therapeutics for chronic wounds. First, a cell lineage tracing strategy previously used to 
identify profibrotic populations in the kidney and lung was determined to label a 
fibroblast population with similar potential within the skin. Next, the matricellular protein 
Galectin-3 was determined to be dispensable during acute wound repair, however further 
investigation into impaired models is warranted. Finally, progress was made in 
developing a flexible platform to deliver functionally relevant proteins and cells into a 
wound, using a porcine model. Through these diverse studies, insights into functional 
heterogeneity of fibroblasts and effects of the ECM microenvironment in the context of 
cutaneous repair have been made that could be exploited in the future to develop 
innovative strategies for the treatment of chronic wounds.  
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Figure A–1: Negative staining controls (no-primary controls) for staining. Nuclei are 
stained with DAPI in all samples. Scale bar is 100 µm. Colors are as indicated (black text 
is shown in white). 
246 
 
 
 
Figure A–2: FLP cells contribute to populations within the heart (A), lungs (B), and 
kidney (C) in mice at embryonic day 14.5. A cross between Foxd1GC and Ai14 mice 
results in tdTomato expression in FLP cells (shown in red). Cells are counterstained with 
DAPI. Scale bars are 500 µm. 
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Figure A–3: High magnification images of porcine granulation tissue stained with 
Masson’s trichrome stain. Scale bars are 500 µm.  
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Figure A–4: High magnification images of αSMA (red) and vimentin (green) stained 
porcine wound tissue at Day 7 (top) and Day 28 (bottom). Nuclei are stained with 
DAPI (blue); scale bars are 500 µm. 
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Figure A–5: High magnification images of CD146 (red) stained porcine wound 
tissue at Day 7 (top) and Day 28 (bottom). Nuclei are stained with DAPI (blue); scale 
bars are 500 µm. 
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Figure A–6: High magnification images of CD68 (red) and CD163 (green) stained 
porcine wound tissue at Day 7 (top) and Day 28 (bottom). Nuclei are stained with 
DAPI (blue); scale bars are 500 µm. 
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Figure A–7: High magnification images of wounds treated with ASC seeded 
biomaterials at 7 days. Top panel: αSMA (red); vimentin (green). Middle panel: CD146 
(red). Bottom panel: CD68 (red); CD163 (green). Nuclei are stained with DAPI (blue); 
scale bars are 500 µm. 
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Figure A–8: Individual wound size measurements used to complete the regression 
analyses highlighted in Figures 3.2 and 3.3. 
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Table A–1: Normalized Gene expression data relative to housekeeping panel from 
Qiagen RT2 Profiler array for fibrosis related genes; unwounded tissue comparison. 
Gene Discovery? P value Mean 
unwounded 
FLN 
Mean 
unwounded 
FLP 
Difference SE of 
difference 
t ratio df 
Acta2 
 
0.634914 0.616963 0.735142 -0.118179 0.243064 0.486207 13 
Agt 
 
0.971656 0.00362571 0.003575 5.07143E-05 0.0014001 0.0362219 13 
Akt1 
 
0.0909378 0.198106 0.270086 -0.0719805 0.0394252 1.82575 13 
Bcl2 
 
0.104419 0.00410571 0.003105 0.00100071 0.000573213 1.7458 13 
Bmp7 
 
0.356914 0.107879 0.0863737 0.0215048 0.022514 0.955176 13 
Cav1 
 
0.321783 1.17691 1.47905 -0.302136 0.293329 1.03002 13 
Ccl11 
 
0.152835 0.540463 0.710196 -0.169733 0.111779 1.51847 13 
Ccl3 
 
0.0322879 0.00235571 0.00078 0.00157571 0.00065747 2.39663 13 
Cebpb 
 
0.0269476 1.67512 2.40513 -0.730015 0.289778 2.51922 12 
Col1a2 
 
0.182805 83.1964 125.028 -41.8311 29.5855 1.41391 12 
Col3a1 
 
0.26553 35.3815 44.9769 -9.59532 8.24679 1.16352 13 
Ctgf 
 
0.451333 0.375689 0.451394 -0.0757052 0.0974914 0.776532 13 
Cxcr4 * 0.00831787 0.00738143 0.00324375 0.00413768 0.0013313 3.10799 13 
Dcn 
 
0.52726 14.3297 16.1474 -1.81772 2.7982 0.649604 13 
Edn1 
 
0.206692 0.05198 0.0401825 0.0117975 0.00887675 1.32903 13 
Egf 
 
0.46395 0.00192857 0.00249 -
0.000561429 
0.000744024 0.754584 13 
Eng 
 
0.0248758 0.188467 0.302794 -0.114327 0.0446113 2.56274 12 
Grem1 
 
0.563756 0.177119 0.20666 -0.0295414 0.0498687 0.592384 13 
Hgf 
 
0.0640165 0.0541014 0.0866513 -0.0325498 0.0160814 2.02407 13 
Il10 
 
0.775462 0.00476143 0.00519 -
0.000428571 
0.00147154 0.291241 13 
Il13ra2 
 
0.355287 0.00304286 0.00244333 0.000599524 0.000621276 0.964988 11 
Il1a * < 0.0001 0.00390714 0.000180143 0.003727 0.000605922 6.15096 12 
Il1b 
 
0.121834 0.00267286 0.00106125 0.00161161 0.000973727 1.65509 13 
Ilk 
 
0.167775 0.259764 0.354564 -0.0947995 0.0648889 1.46095 13 
Itga1 
 
0.919285 0.0566343 0.0578725 -0.00123821 0.0119841 0.103322 13 
Itga2 * 0.00159188 0.0375957 0.0167513 0.0208445 0.00524692 3.9727 13 
Itga3 * 0.0146205 0.0863186 0.0049175 0.0814011 0.0289229 2.81442 13 
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Itgav 
 
0.343393 0.550541 0.68055 -0.130009 0.132213 0.983329 13 
Itgb1 
 
0.0816699 1.56866 2.1692 -0.600534 0.318224 1.88715 13 
Itgb3 
 
0.110607 0.214646 0.362486 -0.147841 0.0863487 1.71213 13 
Itgb5 
 
0.106998 0.634389 1.13882 -0.504436 0.29132 1.73155 13 
Itgb6 * < 0.0001 0.0184014 0.00266375 0.0157377 0.00281452 5.5916 13 
Itgb8 * 0.00689869 0.0269571 0.0069975 0.0199596 0.00622734 3.20516 13 
Jun 
 
0.284225 1.3148 1.12377 0.19103 0.171024 1.11697 13 
Lox * 0.0033334 2.09645 3.59958 -1.50312 0.419418 3.58383 13 
Ltbp1 
 
0.134205 0.438347 0.544015 -0.105668 0.0661529 1.59733 13 
Mmp13 
 
0.161662 0.0404843 0.015715 0.0247693 0.0165087 1.50038 11 
Mmp14 
 
0.162952 1.54771 1.9581 -0.410397 0.277478 1.47903 13 
Mmp1a 
 
0.142321 0.000568571 0.0009025 -
0.000333929 
0.000213798 1.56189 13 
Mmp2 
 
0.0682244 3.64687 5.99811 -2.35124 1.18239 1.98854 13 
Mmp3 * 0.00924985 1.62256 2.8758 -1.25324 0.410521 3.05281 13 
Mmp8 
 
0.0935178 0.00661 0.0163625 -0.0097525 0.00538912 1.80966 13 
Mmp9 
 
0.691412 0.01167 0.00981429 0.00185571 0.00456323 0.406666 12 
Myc 
 
0.189024 0.319444 0.268455 0.0509893 0.0367854 1.38613 13 
Nfkb1 
 
0.337063 0.527876 0.408602 0.119273 0.119658 0.996782 13 
Pdgfa 
 
0.0445869 0.0386833 0.024515 0.0141683 0.00631778 2.24261 12 
Pdgfb 
 
0.0166271 0.03108 0.0077225 0.0233575 0.00850235 2.74718 13 
Plat 
 
0.752836 1.04266 1.08533 -0.0426684 0.132657 0.321644 13 
Plau 
 
0.0393458 0.465539 0.345875 0.119664 0.0522434 2.2905 13 
Serpine1 
 
0.0742413 0.938399 1.36976 -0.43136 0.222225 1.9411 13 
Serpinh1 * 0.00471221 2.65042 4.95482 -2.3044 0.677104 3.40332 13 
Smad2 
 
0.159925 0.197391 0.277326 -0.0799348 0.0536257 1.49061 13 
Smad3 
 
0.291228 0.124423 0.1757 -0.0512771 0.0466098 1.10014 13 
Smad4 
 
0.0375703 0.132441 0.0986275 0.0338139 0.014604 2.31538 13 
Smad6 
 
0.305899 0.0710129 0.0976725 -0.0266596 0.0250132 1.06582 13 
Smad7 
 
0.190027 0.05723 0.068545 -0.011315 0.00818283 1.38277 13 
Snai1 
 
0.170862 0.0115429 0.0176667 -0.00612381 0.00417956 1.46518 11 
Sp1 
 
0.280726 0.268163 0.375519 -0.107356 0.0953848 1.1255 13 
Stat1 
 
0.114802 0.127681 0.177174 -0.0494923 0.0292811 1.69025 13 
Stat6 
 
0.345663 0.00200286 0.00120833 0.000794524 0.000806394 0.98528 11 
256 
 
 
Tgfb1 
 
0.244665 0.357791 0.44903 -0.0912386 0.0748743 1.21856 13 
Tgfb2 
 
0.368076 0.0491729 0.0546562 -0.00548339 0.00588033 0.932498 13 
Tgfb3 
 
0.38087 0.0245386 0.0266925 -0.00215393 0.00237457 0.907082 13 
Tgfbr1 
 
0.110569 0.129563 0.167615 -0.0380521 0.0222224 1.71233 13 
Tgfbr2 
 
0.760386 0.35422 0.371194 -0.0169738 0.0544965 0.311465 13 
Tgif1 * 0.000309042 0.0142457 0.0072325 0.00701321 0.00144171 4.86451 13 
Thbs1 
 
0.135883 3.80892 5.9654 -2.15648 1.3564 1.58985 13 
Thbs2 
 
0.251963 1.30932 1.6862 -0.376875 0.314349 1.19891 13 
Timp1 
 
0.108444 0.266021 0.474925 -0.208904 0.121195 1.7237 13 
Timp2 
 
0.151351 2.39077 3.34708 -0.956306 0.627316 1.52444 13 
Timp3 
 
0.23345 1.35835 1.95398 -0.59563 0.476629 1.24967 13 
Timp4 
 
0.0559856 0.00242143 0.0011025 0.00131893 0.000628572 2.09829 13 
Tnf * 0.00367252 0.00431667 0.0008525 0.00346417 0.000963329 3.59604 12 
Vegfa 
 
0.201713 0.638917 0.88731 -0.248393 0.184719 1.34471 13 
 
 
Table A–2: Normalized Gene expression data relative to housekeeping panel from 
Qiagen RT2 Profiler array for fibrosis related genes; wounded tissue comparison. 
Gene Discovery? P value Mean 
wounded 
FLN 
Mean 
wounded 
FLP 
Difference SE of 
difference 
t ratio df 
Acta2 
 
0.0737829 1.55205 0.857998 0.694052 0.356914 1.94459 13 
Agt 
 
0.278323 0.00132286 0.0018675 -0.000544643 0.000481385 1.13141 13 
Akt1 
 
0.467398 0.198116 0.212149 -0.014033 0.0187445 0.74865 13 
Bcl2 
 
0.603073 0.00192857 0.00221875 -0.000290179 0.000544496 0.53293 13 
Bmp7 * 0.0121957 0.148619 0.0403487 0.10827 0.0372191 2.90899 13 
Cav1 
 
0.057228 1.67892 0.886535 0.792388 0.379825 2.08619 13 
Ccl11 
 
0.484319 0.627933 0.548415 0.0795179 0.110454 0.719917 13 
Ccl3 
 
0.0422429 0.0235633 0.001885 0.0216783 0.00953921 2.27255 12 
Cebpb 
 
0.0513599 2.07708 1.17703 0.90005 0.419471 2.14568 13 
Col1a2 
 
0.736434 97.8863 87.3718 10.5145 30.5759 0.343882 13 
Col3a1 * 0.0050077 31.3666 62.3805 -31.014 9.19841 3.37167 13 
Ctgf * 0.00411083 0.160476 0.354964 -0.194488 0.055977 3.47443 13 
257 
 
 
Cxcr4 
 
0.224537 0.00730571 0.004675 0.00263071 0.00206289 1.27526 13 
Dcn * 0.00124996 7.23182 13.2328 -6.00101 1.46318 4.10136 13 
Edn1 * 0.0035927 0.0847214 0.0158325 0.0688889 0.0194343 3.5447 13 
Egf 
 
0.149429 0.00148429 0.00078375 0.000700536 0.000457194 1.53225 13 
Eng 
 
0.447562 0.174737 0.153231 0.0215059 0.0274602 0.783167 13 
Grem1 
 
0.055317 0.0521657 0.105287 -0.0531218 0.025237 2.10491 13 
Hgf 
 
0.920767 0.0699157 0.0726537 -0.00273804 0.0269979 0.101417 13 
Il10 
 
0.064421 0.0107086 0.00584375 0.00486482 0.00240766 2.02056 13 
Il13ra2 
 
0.730462 0.0108157 0.00946375 0.00135196 0.00384055 0.352023 13 
Il1a * 0.00122348 0.00491 0.00127375 0.00363625 0.000864979 4.20386 12 
Il1b 
 
0.0448307 0.0304243 0.0011275 0.0292968 0.0131976 2.21986 13 
Ilk 
 
0.0521942 0.294146 0.230043 0.0641032 0.029999 2.13685 13 
Itga1 
 
0.0485497 0.201064 0.084105 0.116959 0.0537385 2.17645 13 
Itga2 * 0.00473543 0.0723686 0.0171275 0.0552411 0.0162438 3.40076 13 
Itga3 * 0.000317166 0.07782 0.003265 0.074555 0.0149558 4.98503 12 
Itgav 
 
0.0545087 0.973169 0.512201 0.460967 0.218156 2.11301 13 
Itgb1 
 
0.176021 2.47284 1.82993 0.642912 0.449266 1.43103 13 
Itgb3 
 
0.0828145 0.307753 0.1863 0.121453 0.064629 1.87923 13 
Itgb5 
 
0.854017 0.749311 0.719936 0.0293752 0.156509 0.18769 13 
Itgb6 * < 0.0001 0.0239486 0.0031575 0.0207911 0.00326654 6.36486 13 
Itgb8 * 0.00621946 0.0720033 0.0135 0.0585033 0.0176724 3.31043 12 
Jun 
 
0.076934 0.643719 1.08833 -0.444615 0.23145 1.921 13 
Lox 
 
0.466655 3.24312 3.85222 -0.609097 0.81221 0.749926 13 
Ltbp1 
 
0.417644 0.26 0.29501 -0.03501 0.0418215 0.83713 13 
Mmp13 
 
0.24039 0.174983 0.239025 -0.0640421 0.0520548 1.23028 13 
Mmp14 * 0.00943269 1.24578 2.02525 -0.779463 0.25618 3.04264 13 
Mmp1a 
 
0.0782242 0.00170714 0.00082625 0.000880893 0.000460816 1.91159 13 
Mmp2 
 
0.780116 5.26942 4.91861 0.350807 1.2308 0.285024 13 
Mmp3 
 
0.320594 3.54759 4.69702 -1.14943 1.10941 1.03608 12 
Mmp8 
 
0.0639558 0.00832833 0.0321 -0.0237717 0.0115442 2.05918 11 
Mmp9 
 
0.9492 0.0792629 0.0810262 -0.00176339 0.0271491 0.0649521 13 
Myc * 0.00396502 0.24814 0.398999 -0.150859 0.0431857 3.49325 13 
Nfkb1 
 
0.347686 0.72009 0.597936 0.122154 0.125375 0.974306 13 
Pdgfa * 0.0225694 0.12113 0.04529 0.07584 0.0293195 2.58667 13 
258 
 
 
Pdgfb * 0.0198367 0.0610757 0.00817625 0.0528995 0.0199273 2.65462 13 
Plat 
 
0.490702 1.74946 1.51876 0.230696 0.325273 0.709237 13 
Plau * 0.00724158 0.853203 0.389811 0.463392 0.145722 3.17997 13 
Serpine1 
 
0.214839 1.41411 1.71148 -0.29737 0.228038 1.30404 13 
Serpinh1 
 
0.454056 3.01872 3.52037 -0.501647 0.650002 0.771763 13 
Smad2 
 
0.0464625 0.358286 0.174952 0.183333 0.0833178 2.20041 13 
Smad3 
 
0.0360272 0.138274 0.0870188 0.0512555 0.0219235 2.33793 13 
Smad4 
 
0.161781 0.0985243 0.113199 -0.0146745 0.00989189 1.48348 13 
Smad6 * 0.0278754 0.0782729 0.0302075 0.0480654 0.019421 2.47492 13 
Smad7 
 
0.126746 0.0434771 0.0519112 -0.00843411 0.00516933 1.63157 13 
Snai1 * 0.0022331 0.00495 0.00960375 -0.00465375 0.00122664 3.79389 13 
Sp1 * 0.0193868 0.383954 0.163284 0.220671 0.0827513 2.66667 13 
Stat1 * 0.0192642 0.195503 0.111524 0.0839791 0.0314528 2.67 13 
Stat6 
 
0.560539 0.00129857 0.00114375 0.000154821 0.000259183 0.597343 13 
Tgfb1 
 
0.126836 0.530799 0.337012 0.193786 0.118804 1.63115 13 
Tgfb2 * 0.0038915 0.03945 0.0709912 -0.0315413 0.00900404 3.50301 13 
Tgfb3 * 0.000329841 0.0155671 0.037375 -0.0218079 0.0045169 4.82806 13 
Tgfbr1 
 
0.0939911 0.17235 0.120681 0.0516688 0.0285975 1.80676 13 
Tgfbr2 * 0.0102387 0.194876 0.357994 -0.163118 0.0543725 3.00001 13 
Tgif1 
 
0.479628 0.0109886 0.0124037 -0.00141518 0.0019444 0.727821 13 
Thbs1 
 
0.726903 3.46332 3.69149 -0.228177 0.638198 0.357532 12 
Thbs2 * < 0.0001 1.1126 2.29054 -1.17795 0.211382 5.57261 13 
Timp1 
 
0.951707 0.732224 0.719904 0.0123205 0.199549 0.061742 13 
Timp2 
 
0.132944 1.85864 2.46326 -0.604612 0.377176 1.603 13 
Timp3 * 0.0229377 2.07066 0.955054 1.1156 0.432717 2.57813 13 
Timp4 
 
0.055868 0.00106429 0.000618 0.000446286 0.000212572 2.09945 13 
Tnf * 0.0208898 0.00780286 0.0012875 0.00651536 0.00247976 2.62741 13 
Vegfa 
 
0.144233 1.00906 0.611171 0.397887 0.256075 1.55379 13 
 
 
 
 
259 
 
 
Table A–3: Normalized Gene expression data relative to housekeeping panel from 
Qiagen RT2 Profiler array for fibrosis related genes; FLN lineage comparison. 
Gene Discovery? P value Mean 
unwounded 
FLN 
Mean 
wounded 
FLN 
Difference SE of 
difference 
t ratio df 
Acta2 
 
0.0229857 0.616963 1.55205 -0.935086 0.35887 2.60564 12 
Agt 
 
0.0399098 0.00362571 0.00132286 0.00230286 0.000999518 2.30397 12 
Akt1 
 
0.999707 0.198106 0.198116 -1.00008E-05 0.0266856 0.00037476 12 
Bcl2 
 
0.0145119 0.00410571 0.00192857 0.00217714 0.000762812 2.8541 12 
Bmp7 
 
0.362094 0.107879 0.148619 -0.04074 0.0429991 0.947461 12 
Cav1 
 
0.253405 1.17691 1.67892 -0.50201 0.418444 1.19971 12 
Ccl11 
 
0.489743 0.540463 0.627933 -0.08747 0.122755 0.712559 12 
Ccl3 
 
0.0626594 0.00235571 0.0235633 -0.0212076 0.01024 2.07105 11 
Cebpb 
 
0.413279 1.67512 2.07708 -0.40196 0.472723 0.850309 11 
Col1a2 
 
0.699921 83.1964 97.8863 -14.6899 37.2089 0.394795 12 
Col3a1 
 
0.595047 35.3815 31.3666 4.01499 7.35298 0.546036 12 
Ctgf * 0.00321674 0.375689 0.160476 0.215213 0.0586677 3.66834 12 
Cxcr4 
 
0.973288 0.00738143 0.00730571 7.57145E-05 0.00221452 0.0341899 12 
Dcn * 0.00356825 14.3297 7.23182 7.09787 1.96522 3.61173 12 
Edn1 
 
0.159278 0.05198 0.0847214 -0.0327414 0.0218174 1.5007 12 
Egf 
 
0.472273 0.00192857 0.00148429 0.000444286 0.000598646 0.74215 12 
Eng 
 
0.635456 0.188467 0.174737 0.0137295 0.0281616 0.487527 11 
Grem1 * 0.00878206 0.177119 0.0521657 0.124953 0.0399921 3.12444 12 
Hgf 
 
0.523854 0.0541014 0.0699157 -0.0158143 0.0240865 0.656563 12 
Il10 
 
0.0361815 0.00476143 0.0107086 -0.00594714 0.00252209 2.35802 12 
Il13ra2 
 
0.0142448 0.00304286 0.0108157 -0.00777286 0.00271389 2.86411 12 
Il1a 
 
0.374625 0.00390714 0.00491 -0.00100286 0.00108373 0.925377 11 
Il1b 
 
0.0745538 0.00267286 0.0304243 -0.0277514 0.0142106 1.95287 12 
Ilk 
 
0.423366 0.259764 0.294146 -0.0343814 0.0414805 0.828857 12 
Itga1 
 
0.0250286 0.0566343 0.201064 -0.14443 0.0564309 2.55941 12 
Itga2 
 
0.0749278 0.0375957 0.0723686 -0.0347729 0.0178322 1.95 12 
Itga3 
 
0.824353 0.0863186 0.07782 0.00849857 0.0373877 0.227309 11 
Itgav 
 
0.0944573 0.550541 0.973169 -0.422627 0.232753 1.81577 12 
Itgb1 
 
0.0726774 1.56866 2.47284 -0.904179 0.459562 1.96748 12 
260 
 
 
Itgb3 
 
0.244939 0.214646 0.307753 -0.0931071 0.076153 1.22263 12 
Itgb5 
 
0.520412 0.634389 0.749311 -0.114923 0.17357 0.662113 12 
Itgb6 
 
0.246049 0.0184014 0.0239486 -0.00554714 0.00454836 1.21959 12 
Itgb8 
 
0.0461313 0.0269571 0.0720033 -0.0450462 0.0200472 2.24701 11 
Jun * 0.000718908 1.3148 0.643719 0.67108 0.148925 4.50616 12 
Lox 
 
0.136153 2.09645 3.24312 -1.14667 0.717821 1.59743 12 
Ltbp1 
 
0.0167216 0.438347 0.26 0.178347 0.0642068 2.7777 12 
Mmp13 * 0.00219976 0.0404843 0.174983 -0.134499 0.0346913 3.87701 12 
Mmp14 
 
0.231362 1.54771 1.24578 0.301923 0.239479 1.26075 12 
Mmp1a 
 
0.0360844 0.000568571 0.00170714 -0.00113857 0.000482549 2.3595 12 
Mmp2 
 
0.255766 3.64687 5.26942 -1.62255 1.35958 1.19342 12 
Mmp3 
 
0.0534178 1.62256 3.54759 -1.92502 0.889948 2.16307 11 
Mmp8 
 
0.564482 0.00661 0.00832833 -0.00171833 0.00289247 0.594071 11 
Mmp9 * 0.00236377 0.01167 0.0792629 -0.0675929 0.0176144 3.83736 12 
Myc 
 
0.0650901 0.319444 0.24814 0.0713043 0.0351195 2.03033 12 
Nfkb1 
 
0.190004 0.527876 0.72009 -0.192214 0.138361 1.38923 12 
Pdgfa 
 
0.032526 0.0386833 0.12113 -0.0824467 0.0337188 2.44512 11 
Pdgfb 
 
0.219393 0.03108 0.0610757 -0.0299957 0.0231473 1.29586 12 
Plat 
 
0.0204154 1.04266 1.74946 -0.706794 0.264729 2.66988 12 
Plau 
 
0.0205235 0.465539 0.853203 -0.387664 0.145355 2.66702 12 
Serpine1 
 
0.0547285 0.938399 1.41411 -0.475714 0.223527 2.12822 12 
Serpinh1 
 
0.593875 2.65042 3.01872 -0.3683 0.672331 0.547796 12 
Smad2 
 
0.0958676 0.197391 0.358286 -0.160894 0.0890351 1.80709 12 
Smad3 
 
0.623617 0.124423 0.138274 -0.0138514 0.0275014 0.503662 12 
Smad4 
 
0.0570055 0.132441 0.0985243 0.0339171 0.0161103 2.1053 12 
Smad6 
 
0.769308 0.0710129 0.0782729 -0.00726 0.0241997 0.300004 12 
Smad7 
 
0.113668 0.05723 0.0434771 0.0137529 0.00805989 1.70633 12 
Snai1 
 
0.112265 0.0115429 0.00495 0.00659286 0.00384705 1.71375 12 
Sp1 
 
0.244814 0.268163 0.383954 -0.115791 0.09468 1.22298 12 
Stat1 
 
0.0741897 0.127681 0.195503 -0.0678214 0.0346792 1.95568 12 
Stat6 
 
0.376754 0.00200286 0.00129857 0.000704286 0.000767284 0.917895 12 
Tgfb1 
 
0.196637 0.357791 0.530799 -0.173007 0.126544 1.36717 12 
Tgfb2 
 
0.109447 0.0491729 0.03945 0.00972286 0.0056238 1.72888 12 
Tgfb3 * 0.00293544 0.0245386 0.0155671 0.00897143 0.00241271 3.7184 12 
261 
 
 
Tgfbr1 
 
0.187628 0.129563 0.17235 -0.0427871 0.0306217 1.39728 12 
Tgfbr2 
 
0.0368598 0.35422 0.194876 0.159344 0.0678697 2.3478 12 
Tgif1 
 
0.0726173 0.0142457 0.0109886 0.00325714 0.00165509 1.96795 12 
Thbs1 
 
0.635934 3.80892 3.46332 0.345602 0.709903 0.48683 11 
Thbs2 
 
0.320503 1.30932 1.1126 0.196721 0.189834 1.03628 12 
Timp1 
 
0.0270113 0.266021 0.732224 -0.466203 0.185153 2.51794 12 
Timp2 
 
0.339169 2.39077 1.85864 0.53213 0.534564 0.995446 12 
Timp3 
 
0.145134 1.35835 2.07066 -0.712309 0.457109 1.55829 12 
Timp4 
 
0.0546326 0.00242143 0.00106429 0.00135714 0.000637395 2.1292 12 
Tnf 
 
0.277412 0.00431667 0.00780286 -0.00348619 0.00305075 1.14273 11 
Vegfa 
 
0.215573 0.638917 1.00906 -0.370141 0.283113 1.3074 12 
 
 
Table A–4: Normalized Gene expression data relative to housekeeping panel from 
Qiagen RT2 Profiler array for fibrosis related genes; FLP lineage comparison. 
Gene Discovery? P value Mean 
wounded 
FLP 
Mean 
unwounded 
FLP 
Difference SE of 
difference 
t ratio df 
Acta2 
 
0.637374 0.857998 0.735142 0.122856 0.254979 0.481826 14 
Agt 
 
0.133722 0.0018675 0.003575 -0.0017075 0.0010726 1.59193 14 
Akt1 
 
0.10503 0.212149 0.270086 -0.0579375 0.0334293 1.73314 14 
Bcl2 * 0.0162345 0.00221875 0.003105 -0.00088625 0.000324497 2.73115 14 
Bmp7 * 0.0118122 0.0403487 0.0863737 -0.046025 0.015911 2.89266 14 
Cav1 
 
0.0397179 0.886535 1.47905 -0.592514 0.261304 2.26753 14 
Ccl11 
 
0.129764 0.548415 0.710196 -0.161781 0.100501 1.60974 14 
Ccl3 
 
0.202964 0.001885 0.00078 0.001105 0.000827296 1.33568 14 
Cebpb * 0.00044084 1.17703 2.40513 -1.22811 0.269022 4.56507 14 
Col1a2 
 
0.114109 87.3718 125.028 -37.6557 22.2313 1.69381 13 
Col3a1 
 
0.090647 62.3805 44.9769 17.4037 9.57712 1.81721 14 
Ctgf 
 
0.309767 0.354964 0.451394 -0.09643 0.0914959 1.05393 14 
Cxcr4 
 
0.268985 0.004675 0.00324375 0.00143125 0.00124341 1.15107 14 
Dcn 
 
0.244086 13.2328 16.1474 -2.91457 2.39683 1.21601 14 
Edn1 * 0.00154609 0.0158325 0.0401825 -0.02435 0.00621494 3.91798 14 
262 
 
 
Egf * 0.0164401 0.00078375 0.00249 -0.00170625 0.000626207 2.72474 14 
Eng * 0.002264 0.153231 0.302794 -0.149563 0.0401545 3.72468 14 
Grem1 * 0.0205459 0.105287 0.20666 -0.101372 0.03883 2.61067 14 
Hgf 
 
0.506103 0.0726537 0.0866513 -0.0139975 0.0205113 0.682429 14 
Il10 
 
0.661041 0.00584375 0.00519 0.00065375 0.00145942 0.447953 14 
Il13ra2 
 
0.0484265 0.00946375 0.00244333 0.00702042 0.00319596 2.19666 12 
Il1a * 0.00319474 0.00127375 0.000180143 0.00109361 0.000303271 3.60604 13 
Il1b 
 
0.908365 0.0011275 0.00106125 0.00006625 0.000565266 0.117201 14 
Ilk 
 
0.0432222 0.230043 0.354564 -0.124521 0.0560235 2.22266 14 
Itga1 
 
0.111777 0.084105 0.0578725 0.0262325 0.0154568 1.69715 14 
Itga2 
 
0.921457 0.0171275 0.0167513 0.00037625 0.00374784 0.100391 14 
Itga3 
 
0.287907 0.003265 0.0049175 -0.0016525 0.00149586 1.10472 14 
Itgav 
 
0.201344 0.512201 0.68055 -0.168349 0.125561 1.34078 14 
Itgb1 
 
0.311267 1.82993 2.1692 -0.339268 0.322946 1.05054 14 
Itgb3 
 
0.0354821 0.1863 0.362486 -0.176186 0.0757132 2.32702 14 
Itgb5 
 
0.141288 0.719936 1.13882 -0.418889 0.268674 1.55909 14 
Itgb6 
 
0.533186 0.0031575 0.00266375 0.00049375 0.000772782 0.638925 14 
Itgb8 
 
0.0376227 0.0135 0.0069975 0.0065025 0.00283189 2.29617 14 
Jun 
 
0.882207 1.08833 1.12377 -0.035435 0.234823 0.150901 14 
Lox 
 
0.670385 3.85222 3.59958 0.252642 0.581149 0.434729 14 
Ltbp1 * 0.000114472 0.29501 0.544015 -0.249005 0.0470815 5.28881 14 
Mmp13 * 0.000466178 0.239025 0.015715 0.22331 0.0469394 4.75741 12 
Mmp14 
 
0.816459 2.02525 1.9581 0.0671438 0.283889 0.236514 14 
Mmp1a 
 
0.735652 0.00082625 0.0009025 -7.625E-05 0.000221389 0.344416 14 
Mmp2 
 
0.32878 4.91861 5.99811 -1.0795 1.06686 1.01185 14 
Mmp3 * 0.0274615 4.69702 2.8758 1.82121 0.74006 2.4609 14 
Mmp8 
 
0.17529 0.0321 0.0163625 0.0157375 0.0109774 1.43363 13 
Mmp9 * 0.00659856 0.0810262 0.00981429 0.071212 0.0220589 3.22827 13 
Myc * 0.00911454 0.398999 0.268455 0.130544 0.0431747 3.02362 14 
Nfkb1 
 
0.101583 0.597936 0.408602 0.189334 0.108048 1.75231 14 
Pdgfa * 0.0126286 0.04529 0.024515 0.020775 0.00726701 2.85881 14 
Pdgfb 
 
0.841424 0.00817625 0.0077225 0.00045375 0.00222619 0.203824 14 
Plat 
 
0.0842404 1.51876 1.08533 0.43343 0.233208 1.85855 14 
Plau 
 
0.541266 0.389811 0.345875 0.0439362 0.0701644 0.62619 14 
263 
 
 
Serpine1 
 
0.150209 1.71148 1.36976 0.341724 0.224485 1.52225 14 
Serpinh1 
 
0.0449587 3.52037 4.95482 -1.43445 0.651527 2.20168 14 
Smad2 
 
0.0627051 0.174952 0.277326 -0.102374 0.0506273 2.0221 14 
Smad3 
 
0.0513175 0.0870188 0.1757 -0.0886813 0.0416187 2.1308 14 
Smad4 
 
0.114593 0.113199 0.0986275 0.0145712 0.00865946 1.6827 14 
Smad6 * 0.00576878 0.0302075 0.0976725 -0.067465 0.0207341 3.25381 14 
Smad7 * 0.0112093 0.0519112 0.068545 -0.0166338 0.00569812 2.91916 14 
Snai1 * < 0.0001 0.00960375 0.0176667 -0.00806292 0.00132515 6.08454 12 
Sp1 * 0.0245312 0.163284 0.375519 -0.212235 0.0842418 2.51936 14 
Stat1 * 0.0262614 0.111524 0.177174 -0.06565 0.0264283 2.48408 14 
Stat6 
 
0.752153 0.00114375 0.00120833 -6.45833E-05 0.000199864 0.323137 12 
Tgfb1 
 
0.138391 0.337012 0.44903 -0.112018 0.0712813 1.57148 14 
Tgfb2 
 
0.0829096 0.0709912 0.0546562 0.016335 0.00874702 1.86749 14 
Tgfb3 * 0.0252797 0.037375 0.0266925 0.0106825 0.00426649 2.50381 14 
Tgfbr1 
 
0.040731 0.120681 0.167615 -0.0469337 0.0208207 2.25419 14 
Tgfbr2 
 
0.752272 0.357994 0.371194 -0.0132 0.0410043 0.321917 14 
Tgif1 * 0.0100566 0.0124037 0.0072325 0.00517125 0.00173882 2.97399 14 
Thbs1 
 
0.0914036 3.69149 5.9654 -2.2739 1.25456 1.8125 14 
Thbs2 
 
0.0731793 2.29054 1.6862 0.60435 0.311989 1.93709 14 
Timp1 
 
0.117194 0.719904 0.474925 0.244979 0.146728 1.66961 14 
Timp2 
 
0.0989167 2.46326 3.34708 -0.883824 0.50003 1.76754 14 
Timp3 
 
0.0434315 0.955054 1.95398 -0.998924 0.449947 2.22009 14 
Timp4 
 
0.102459 0.000618 0.0011025 -0.0004845 0.000277272 1.74738 14 
Tnf 
 
0.200243 0.0012875 0.0008525 0.000435 0.000323599 1.34426 14 
Vegfa 
 
0.110631 0.611171 0.88731 -0.276139 0.162136 1.70313 14 
 
Table A–5: Information on patient cells examined in vitro. 
Sex Age Diabetic (Type 1, Type 2, No) Wound Site 
M 60 No Toe 
F 64 No Toe 
F 87 2 Toe 
M 88 2 Heel 
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Table A–6: Information on patients used for histological analysis. 
Sex Age Diabetic (Type 1, Type 2, No) Wound Site 
F 46 2 Toe 
F 64 No Toe 
F 79 No Foot 
F 87 2 Toe 
M 56 2 Forefoot 
M 60 No Toe 
M 70 2 Toe 
M 74 No Heel 
M 88 2 Heel 
 
Table A–7: Information on patients included in direct RNA analysis. 
Sex Age Diabetic (Type 1, Type 2, No) Wound site 
M 34 1 Heel 
F 46 2 Toe 
M 47 2 Plantar flap 
M 55 2 Not available 
M 56 2 Forefoot 
M 58 2 Toe 
M 65 2 Not available 
M 66 2 Toe 
M 70 2 Toe 
M 73 2 Heel and plantar region 
M 78 2 Non-healing wound from 
previous foot amputation 
F 79 No Not available 
M 79 2 Toe 
F 83 2 Toe 
M 86 2 Foot 
265 
 
 
Appendix B: Human Ethics Approval 
 
266 
267 
Appendix C: Animal Ethics Approval 
268 
269 
Curriculum Vitae 
John T. Walker 
Education: 
Bachelor of Health Sciences (Honours) (2008-2012) 
Major in biomedical sciences; Minor in Nanoscience 
University of Calgary, Calgary, AB 
Ph.D. Candidate (2012-Present) 
Department of Anatomy and Cell Biology 
Western University, London, ON 
Honours and Awards: 
1. NSERC Canada Graduate Scholarship – Master’s, CGSM (2012-2013)
2. Western Graduate Research Scholarship (2012-2018)
3. Ontario Graduate Scholarship (declined; 2014-2015)
4. NSERC Alexander Graham Bell Canada Graduate Scholarship – Doctoral,
CGSD (2014-2018)
5. Western University Doctoral Excellence Research Award (2016-2017)
6. European Tissue Repair Society Young Investigator Award, 2nd place
(2017)
Related Work Experience: 
Teaching Assistantships 
1. Medical Sciences 4900F/G – Medical Sciences Laboratory (2013-2017)
2. Medical Sciences 3900F/G – Medical Sciences Laboratory (2017-2018)
Internships 
1. Tissue Regeneration Therapeutics, Toronto, ON (May 2015- August 2015)
2. Tissue Regeneration Therapeutics, Toronto, ON (May 2016- August 2016)
270 
Publications: 
1. McLeod K, Walker JT, Hamilton DW. Galectin-3 regulation of wound
healing and fibrotic processes: insights for chronic skin wound
therapeutics. J Cell Commun Signal. 2018; 12(1):281-287
2. Davies JE, Walker JT, Keating AK. Wharton’s jelly: the rich, but
enigmatic, source of MSCs. Stem Cells Transl Med. 2017;6:1620-1630
3. Walker JT, Keating AK, Davies JE. Stem Cells: Umbilical
Cord/Wharton’s Jelly Derived. In: Tissue Engineering and Regeneration:
Cell Engineering and Regeneration. Springer; In Press.
4. Walker JT, Elliott CG, Forbes TL, Hamilton DW. Genetic Deletion of
Galectin-3 Does Not Impair Full-Thickness Excisional Skin Healing. J
Invest Dermatol. 2016;136(5):1042–50
5. Walker JT, McLeod K, Kim S, Conway SJ, Hamilton DW. Periostin as a
multifunctional modulator of the wound healing response. Cell Tissue
Res. Cell and Tissue Research; 2016; 1-13
6. Walker JT, Kim S, Michelsons S, Creber K, Elliott C, Leask A, et al.
Cell–matrix interactions governing skin repair: matricellular proteins as
diverse modulators of cell function. Res Reports Biochem. 2015;5:73
7. Arnold CR, Lamont RE, Walker JT, Spice PJ, Chan C, Ho C, et al.
Comparative analysis of genes regulated by Dzip1/iguana and hedgehog in
zebrafish. Dev Dyn. 2015;211–23.
8. Yaehne K, Tekrony A, Clancy A, Gregoriou Y, Walker JT, Dean K, et al.
Nanoparticle accumulation in angiogenic tissues: Towards predictable
pharmacokinetics. Small. 2013;9(18):3118–27.
9. Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A,
Liu Y, Walker JT, et al. High incidence of post transplant
lymphoproliferative disorder after antithymocyte globulin-based
conditioning and ineffective prediction by day 28 EBV-specific T
lymphocyte counts. Bone Marrow Transplant. 2011;46(8):1104–12
271 
Presentations 
1. Walker JT, Flynn LE, Hamilton DW; FoxD1 lineage derived fibroblasts
as contributors to skin development, homeostasis, and wound healing
(Poster); Canadian Connective Tissue Conference (2018); Toronto,
Canada
2. Walker JT, Flynn LE, Hamilton DW; FoxD1 lineage derived fibroblasts
as contributors to skin development and wound healing (Oral); European
Tissue Repair Society (2017); Brussels, Belgium
3. Walker JT, Flynn LE, Hamilton DW; Biomaterials for Cell Recruitment
and Differentiation in Wound Repair (Poster); Toronto Fibrosis
Conference (2017); Toronto, Canada
4. Walker JT, Elliott CG, Li X, Dunmore-Buyze J, Drangova M, Forbes T,
Guan J, Leask A, Hamilton D; 2014; Granulation-Tissue Biomimetic
Scaffolds Induce the Proliferative/Profibrotic Phase of Skin healing (Oral);
Canadian Biomaterials Society.
